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at 1, 10 or 20ng/ml.  Light grey bars: IL-6 + LPS.  Dark grey bars:  IL-6 + LPS + 
sIL6R (100ng/ml). 216 
Figure 75 - TNFα production in HMDM on culture for 2 hours ascending 
concentrations of LPS (ng/ml).   Donor n = 1 217 
Figure 76 – TNF-α production in HMDM on culture for 24 hours with LPS with or 
without IL-6, as percentage of response seen with cells exposed to LPS alone.   
Mean±SD; analysed by t-test, donor n=6.  Black bar = LPS alone.   White bars (not 
visible due to TNF-α production being below limit of detection): IL-6 alone at 1, 
10 or 20ng/ml.    Grey bars: IL-6 + LPS + sIL-6R (100ng/ml). 217 
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Figure 77 - Oil red O staining of THP-1 macrophage foam cells cultured for 48 
hours with oxLDL at (A) 1mcg/ml, (B) 10mcg/ml and (C) 50mcg/ml.  10x 
magnification   Images representative of two experiments. 218 
Figure 78 - Oil red O staining of THP-1 macrophage foam cells cultured for 48 
hours with 50 mcg/ml oxLDL and (A) RPMI alone (B) 10ng/ml IL-6 (C) IL-6 + 
100ng/ml tocilizumab.  20x magnification.   Images representative of one 
experiment. 220 
Figure 79 - Oil red O staining of THP-1 macrophage foam cells cultured for 48 
hours with (A) RPMI alone (B) 50mcg/ml oxLDL, (C) oxLDL + 10ng/ml IL-6 (D) 
oxLDL + IL-6 + 100ng/ml tocilizumab.   Images obtained from the same 
experiment. 221 
Figure 80 - Fluorescence of DiI-oxLDL at increasing concentrations in a 96-well 
plate.  Bars represent mean±SD of three wells for each condition in one 
experiment. 221 
Figure 81 - Fluoresence of THP-1 macrophages following culture with DiI-labelled 
oxLDL at varying times and concentrations.   Points represent mean±SD of three 
wells for each condition in one experiment. 222 
Figure 82 - Fluorescence of THP-1 macrophages following culture for varying 
times with (A) 10mgc/ml or (B) 50mcg/ml DiI-labelled oxLDL.   Points represent 
mean±SD of three wells for each condition in one experiment. 222 
Figure 83 - Fluorescence of macrophages following culture with DiI-oxLDL, 
expressed as % of fluorescence of cells cultured with DiI-oxLDL and RPMI alone.   
Bars represent mean ± 95% C.I. of three wells for each condition in three or five 
experiments. 223 
Figure 84 – Oil red O staining of THP-1 macrophage foam cells. (A) unstained (B) 
unstimulated (C) IL-6 10ng/ml (D) IL-6 + Tocilizumab 100µg/ml.   Images 
obtained from one experiment. 224 
Figure 85 - Oil red O staining of HMDM foam cells. (A) unstained (B) unstimulated 
(C) IL-6 10ng/ml (D) IL-6 + Tocilizumab 100µg/ml.   Images obtained from one 
experiment. 224 
Figure 86 - Cell surface staining for membrane-bound IL-6R in (A) THP-1 
monocytes, (B) "original" THP-1 macrophages and (C) "alternative" THP-1 
macrophages.   Red: unstained.   Blue: IL-6R.   Orange - isotype. 226 
Figure 87 - Intracellular staining for phosphorylated STAT3 in (A) THP-1 
monocytes, (B) "original" THP-1 macrophages and (C) "alternative" THP-1 
macrophages.   Green: unstained.   Orange: unstimulated.   Blue: IL-6 10ng/ml.   
Red:  IL-6 10ng/ml plus tocilzumab 10µg/ml. 227 
Figure 88 - Cell surface staining for membrane-bound IL-6R in (A) human primary 
CD14+ monocytes and (B) human monocyte-derived macrophages (HMDM).   Red: 
unstained.   Blue: IL-6R.   Orange: isotype. 228 
Figure 89 - Fold change in gene expression for lipid receptors in IL-6-exposed 
HMDM compared to unstimulated cells from same donor.  N of donors=6 230 
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Figure 90 - Fold change in gene expression for cholesterol export proteins in IL-
6-exposed HMDM compared to unstimulated cells from same donor.  N of 
donors=6 231 
Figure 91 - Fold change in gene expression for intracellular mediators of lipid 
metabolism in IL-6-exposed HMDM compared to unstimulated cells from same 
donor.  N of donors=6 232 
Figure 92 - Change in expression of LOX-1 and MARCO as determined by (a) mean 
fluorescence intensity of primary antibody minus that of isotype; (b) ratio of 
mean fluorescence intensity of primary antibody / isotype.   Analysis by 
Wilcoxon matched-pairs test. 233 
Figure 93 - Flow cytometric analysis of MARCO expression on HMDM from one 
donor. (A) FACS plot of selected cells. (B) MARCO present in detectable levels on 
cell surface. (C) MARCO expression increased on this donor following IL-6 
stimulation. 234 
Figure 94  - Flow cytometric analysis of LOX-1 expression on HMDM from one 
donor. (A) FACS plot of selected cells. (B) LOX-1 present in detectable levels on 
cell surface. (C) No change in LOX-1 expression on this donor following IL-6 
stimulation. 235 
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Summary 
Background 
Patients with rheumatoid arthritis (RA) carry an increased risk of cardiovascular 
disease and cardiovascular death compared to age- and sex-matched controls.   
This risk appears to be related to cumulative inflammatory burden, and can be 
at least partially ameliorated by successful treatment of the disease with 
conventional or biologic disease-modifying anti-rheumatic drugs (DMARDS).   
However, RA patients typically exhibit reduced serum levels of cholesterol, 
which can be increased following DMARD therapy; this is in contrast to the 
general population, where serum cholesterol is directly proportional to 
cardiovascular risk.   The magnitude and nature of this increase varies between 
therapeutic agents.   Blockade of interleukin-6 (IL-6) signalling with the drug 
tocilizumab conveys perhaps the most profound lipid changes, leading to average 
increases in LDL-cholesterol (LDL-c) of around 20% as well as changes in HDL-
cholesterol (HDL-c) and triglycerides.    
The mechanisms behind this so-called “lipid paradox”, and its impact on 
cardiovascular outcomes following RA therapy, are not fully understood.   Animal 
studies have shown that hypercatabolism of LDL can lead to reduced circulating 
LDL-c, possibly due to increased consumption by the reticulo-endothelial system.   
A deeper understanding of the lipid paradox, and its implications for 
cardiovascular risk, is vital to allow physicians to provide optimal management 
of both articular RA and its cardiovascular manifestations.   Using IL-6 blockade 
as a molecular tool, I attempted to unravel the physiological processes 
underlying the lipid changes observed in RA, and to understand what these 
changes might mean in term of cardiovascular risk for patients. 
Objectives 
1) To investigate lipid changes in patients treated with tocilizumab as 
assessed by nuclear magnetic resonance (NMR) spectroscopy 
2) To determine whether increased LDL-c  following IL-6 blockade is due to 
increased production or reduced catabolism of LDL 
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3) To explore the lipid-handling behaviour of macrophages in response to IL-
6 
Methods: The MEASURE study was a placebo-controlled, randomised controlled 
trial evaluating NMR lipid profiles in patients with severe active RA following 
treatment with tocilizumab or placebo, with the placebo group switching to 
open-label tocilizumab after 24 weeks.   Results to week 12 have been published 
previously.   Data on all patients to 52 weeks using an updated NMR platform 
were evaluated, and changes in lipid values were correlated with markers of 
disease activity, including the acute phase markers C-reactive protein (CRP) and 
erythrocyte sedimentation rate (ESR), and the composite clinical score DAS28.   
NMR analysis also yielded the novel marker GlycA, a composite NMR signal 
reflecting a measure of the acute phase response.   GlycA levels were compared 
to other markers of disease activity, and GlycA’s utility as a marker of future 
response to therapy and of persistent disease activity in those with normal ESR 
or CRP was assessed. 
The KALIBRA study analysed the kinetics of the apoB-containing lipoproteins 
before and after IL-6 blockade.   Patients with severe active RA (defined as 
DAS28 ≥5.1) and who were eligible for tocilizumab therapy underwent kinetic 
modelling of VLDL, IDL and LDL at baseline and again following at least three 
months’ treatment with tocilizumab.   The primary outcome measure was the 
fractional catabolic rate of LDL, though LDL production rate was also assessed as 
well as a variety of other lipid parameters.   Changes in LDL production and 
catabolic rates were correlated with serum LDL-cholesterol ester content and 
with measures of disease activity. 
To provide information on the cellular processes underlying kinetic changes, 
macrophages were generated in vitro from the THP-1 monocyte cell line or from 
healthy human donor monocytes.   These cells were then exposed to IL-6 and 
assessed for signs of response, including phosphorylation of STAT3 and 
production of TNF-α.   Macrophage lipid loading (and subsequent foam cell 
formation) following stimulation with 10ng/ml IL-6 for 24 hours was assessed by 
staining with oil red O and fluorimetry following culture with fluorescently-
labelled oxidised LDL.   Altered expression of genes involved in lipid metabolism, 
including surface receptors for both native and oxidised LDL, was assessed at the 
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RNA level using quantitiative polymerase chain reaction (qPCR) and Taqman 
Low-Density Array (TLDA) plates, with fold change of ≥2 considered significant.   
Outcomes from these experiments were then validated at the protein level by 
flow cytometry. 
Results 
The MEASURE study showed no change in small LDL particles with tocilizumab 
therapy.  Increases were seen in large LDL, small HDL and some VLDL particles in 
the tocilizumab group, with change seen by the earliest assessment timepoint of 
2 weeks.   At 52 weeks follow-up, the same changes were observed in placebo 
patients who had switched to open-label tocilizumab.   Greater increases in 
large LDL and small HDL tended to associate with falls in CRP, but less so with 
disease activity as measures by CDAI. 
GlycA levels correlated significantly at baseline with CRP (r=0.70, p<0.001) and 
ESR (r=0.44, p<0.001) but not with CDAI, and fell in a similarly precipitous 
manner following IL-6 blockade.   Neither baseline (area under curve =0.60) or 
week 2 (AUC=0.53) GlycA levels were effective at predicting response at week 
24 as measured by CDAI.   In treated patients, with CRP<5mg/l, GlycA did not 
associate with persistent clinical disease activity. 
In KALIBRA, 12 patients were recruited of whom complete data was available for 
11.   As expected, significant increases in mean serum LDL-c (2.90 v 
3.40mmol/L, p=0.014) and HDL-c (1.23 v 1.52 mmol/L, p=0.006) were observed 
after treatment.   IL-6 blockade led to a reduction in median LDL fractional 
catabolic rate (FCR) from 0.53 to 0.27 pools/day, (p=0.006) with median 
reduction of 30%, and the change in LDL FCR correlated tightly with that of 
serum LDL cholesterol ester content (r=-0.74, p=0.011).   LDL FCR correlated at 
baseline with CRP (r=0.74 p=0.012) but not CDAI (r=0.04, p=0.91).   The degree 
of change in CRP with treatment showed a trend to association with change in 
FCR (r=0.46, p=0.15) and LDL cholesterol ester (r=-0.43, p=0.18).   LDL 
production rate did not increase, and in fact fell (median 763.8 v 442 
mg/kg/day, p=0.002).   No changes were seen in the activity of lipoprotein 
lipase (LPL), hepatic lipase (HL), cholesterol-ester transfer protein (CETP) or 
PCSK9. 
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Human monocyte-derived macrophages (HMDM) displayed altered TNF-α 
production and increased STAT3 phosphorylation in response to IL-6; THP-1 
macrophages did not, and appeared to lose their IL-6 receptor in the process of 
differentiation from monocytes.   Neither cell type displayed increased uptake 
of oxidised LDL following culture with IL-6.   TLDA analysis showed altered 
expression of scavenger receptors with an increase in the “macrophage receptor 
with collagenous structure” (MARCO) and a reduction in LOX-1 in HMDM, though 
this was not observed at the protein level on flow cytometry. 
Conclusions 
 IL-6 blockade in RA elevates numbers of large LDL and small HDL particles, but 
not the most pro-atherogenic small LDL particles.   These changes are 
maintained up to 52 weeks follow-up, and seem to be more prominent in 
subjects with greater reductions in the acute phase response.   The KALIBRA 
study showed that the elevation in LDL is almost entirely due to a reduction in 
LDL fractional catabolic rate, from a baseline state of hypercatabolism in severe 
active disease to values approximating the population average after treatment.   
Greater changes in FCR were associated with greater reductions in acute phase 
reactants, regardless of RA activity as assessed clinically by CDAI.  Lipid changes 
did not appear to be explicable by changes in activity of lipolytic enzymes, CETP 
or PCSK9.   IL-6 does not appear to exert its lipidaemic effects via augmented 
macrophage lipid metabolism or increased foam cell formation.   These findings 
are consistent with a normalisation of a pathological, IL-6 driven state of 
hypercatabolism leading to LDL-c increases following IL-6 blockade, with 
hepatocytes as the possible main effector cell type.   This suggests that LDL-c 
elevations observed during treatment for RA may not be pro-atherogenic or 
contribute to increased CVD risk, though confirmation of this hypothesis is 
required with trials reporting clinical cardiovascular outcomes. 
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1.1 Rheumatoid arthritis 
Rheumatoid arthritis is a chronic autoimmune disease of unknown aetiology 
which manifests primarily as an inflammatory polyarthritis.  Over the course of 
the disease, the initial symptoms of joint pain, stiffness and swelling are 
succeeded by the accumulation of irreversible joint damage and deformity.   The 
resultant disability of this common disease imposes a considerable burden on 
both the individual and society as a whole.   This burden can, however, be 
reduced by effective use of medications such as corticosteroids and disease-
modifying anti-rheumatic drugs, and by attention to relevant co-morbidity. 
1.1.1 Epidemiology 
A 2002 primary care-based study in Norfolk using the 1987 American College of 
Rheumatology (ACR) criteria for RA reported prevalence of 0.81%, with around 
two thirds of patients female (1).   If this figure were extrapolated to the rest of 
the country, this would give a total RA population in the year 2000 of 386,600 
across the United Kingdom.   Prevalence seems to have fallen somewhat through 
the 20th century (2, 3).   Disease onset is most common in the 6th-7th decades (4), 
though can occur at any age over 16 (before this point, a seropositive 
inflammatory arthritis would by convention be diagnosed as juvenile idiopathic 
arthritis).   Similar figures have been found in the USA (5), again with a 
reduction in prevalence since the 1960s (2, 6), although one recent study from 
Minnesota reported an increase in prevalence (0.62% v 0.72%) from 1995 to 2005 
(7).   This last study reported incidence of 40.9 cases per 100,000 population 
annually.   Whilst these figures are derived from Caucasian populations, 
prevalence in other ethnic groups can be significantly higher (6.8% in Chippewa 
native Americans (8)) or lower (0.2% in Japan (9), 0.26% in China (10) and 0.3% in 
British Afro-Caribbeans (11)). 
1.1.2 Clinical Features 
Rheumatoid arthritis classically presents as a symmetrical, small joint 
polyarthritis, most commonly affecting the metacarpophalangeal (MCP) and 
proximal interphalangeal (PIP) joints.  Most other synovial joints can also be 
affected.   Inflammation in joints causes pain and stiffness, sometimes with 
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erythema, heat and swelling (this latter due to effusion or synovial hyperplasia), 
and ultimately loss of function.   Symptoms tend to be worst after inactivity or 
on waking, receding to some degree with activity.   RA can run a somewhat 
relapsing-remitting course, but symptoms are often persistent.   Over time, 
irreversible damage will result in the form of cartilage loss and bony erosions; 
accumulation of structural damage leads to deformities such as ulnar deviation 
of the fingers, MCP subluxation, and swan-neck or boutonniere deformities.     
Loss or limitation of employment is common in RA, and the total cost of RA in 
the UK (including work-related disability) is estimated at between £3.8 and £4.8 
billion per year in the UK (12). 
 Extra-articular manifestations may affect varied tissues including skin 
(rheumatoid nodules, vasculitis), lung (bronchiolitis obliterans, pleural effusion), 
nerve (peripheral and compression neuropathies, fatigue), bone (osteoporosis), 
eye (sicca symptoms, scleritis), kidney (AA amyloidosis), blood (anaemia, 
neutropenia and Felty’s syndrome), heart (pericarditis, myocarditis, and nodules 
causing conduction defects) and vasculature (atheromatous disease and deep 
vein thrombosis) (13).   RA is associated with increased rates of malignancy, 
including lymphoma (over three-fold compared to the non-RA population) as well 
as some solid tumours such as lung cancer (14).   Perhaps most profoundly for 
the physician, RA is associated with increased mortality, a concept which will be 
explored in later sections. 
1.1.3 Diagnosis 
There is no single diagnostic test for RA.   Plain radiographs can identify 
erosions, though these typically require years of inflammation to become 
apparent.   Ultrasound scanning (USS) and magnetic resonance imaging (MRI) are 
able to illustrate active synovitis long before erosive damage has accrued, and 
are especially helpful in detecting “subclinical” synovitis (15).   Importantly, 
they can also exclude inflammation as a cause of arthralgia, thus avoiding futile 
and potentially harmful drug therapy (16).   Blood may be tested for elevated 
acute phase reactants such as C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) but these are normal in up to half of patients at 
presentation.   Autoantibodies, particularly rheumatoid factor (RF) and anti-
citrullinated peptide antibodies (ACPA), are more useful.   Rheumatoid factor 
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refers to a variety of immunoglobulin molecules directed against the Fc 
component of human IgG; IgM rheumatoid factors are most common, but they 
may also exist in IgG and IgA forms.   These were first identified in RA in the 
1940s, and are present in around two-thirds of RA patients as well as other 
conditions such as Sjogren’s syndrome and cryoglobulinaemias, and about 5% of 
healthy over-70s.  RF is associated with the presence of extra-articular features 
and more severe arthritis.   ACPA are present in 70-90% of patients, and, like RF, 
confer a worse prognosis.   Modern assays, however, carry sensitivities of around 
95% (17).   ACPAs are raised against citrullinated proteins such as fibrinogen and 
vimentin, and are potentially pathogenic (17).  
The 2010 American College of Rheumatology (ACR) diagnostic criteria for RA are 
outlined in Table 1.   These can be used in day-to-day practice but are more 
commonly used for research purposes.   The target population for these criteria 
are patients who have at least one joint with definite clinical synovitis (swelling) 
without a better alternative explanation; the criteria for RA are met if the sum 
of the scores from categories A-D is ≥6. 
 
  
  29 
 
 
 
 Score 
A.   Joint involvement*  
   1 large joint 0 
   2-10 large joints 1 
   1-3 small joints (with or without involvement of large joints) 2 
   4-10 small joints (with or without involvement of large joints) 3 
   >10 joints (at least 1 small joint) 5 
B.   Serology (at least 1 test result is needed for classification)  
   Negative RF and negative ACPA 0 
   Low-positive RF or low-positive ACPA 2 
   High-positive RF or high-positive ACPA 3 
C.   Acute phase reactants (at least 1 test result is needed for classification)  
   Normal CRP and normal ESR 0 
   Abnormal CRP or abnormal ESR 1 
D.   Duration of symptoms  
   <6 weeks 0 
   ≥6 weeks 1 
 
Table 1 - ACR/EULAR classification criteria for rheumatoid arthritis.      
‘Large joints’ refers to shoulders, elbows, knees, hips, and ankles.   ‘Small 
joints’ refers to MCP joints, PIP joints, 2nd-5th MTP joints, thumb 
interphalangeal joints and wrists. 
 
1.1.4 Aetiology  
The underlying cause of RA remains unknown, but is thought to be due to an 
environmental “trigger” in a genetically susceptible individual.   Twin studies 
demonstrate a genetic component to the disease, with concordance rates of 
around 10-15% in monozygotic twins and 3-7% in dizygotic twins (18, 19).   These 
studies conclude that genetic factors account for roughly 60% of disease risk 
(19).   Genome-wide association studies (GWAS) implicate numerous genes 
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involved in different branches of immune regulation, especially pathways 
related to T-cell activation and nuclear factor κB (NFκB) (20).   The best 
understood genetic association is with the HLA-DRB1 locus.   Possession of the 
DRB1 allele on its own increases disease risk, but susceptibility is particularly 
increased with certain haplotypes which share a common five amino-acid 
sequence termed the “shared epitope”.   HLA genes code for the major 
histocompatibility complex II (MHC-II) molecule which presents antigen to T-
cells, and the shared epitope can bind citrullinated peptides more strongly than 
native sequences (21).   This has led to the hypothesis that altered antigen 
binding, antigen presentation or T-cell selection may cause the initial “breach of 
tolerance” that leads to chronic inflammation.  Notably, whilst most shared 
epitope patients are ACPA positive, ACPA-negative RA seems to involve different 
HLA alleles, suggesting that ACPA positive and negative RA should perhaps be 
treated as separate disease entities (22).   Risk may also be modulated by 
epigenetic factors, including histone modification and DNA methylation (23). 
Environmental risk factors are also recognised.   The most prominent is tobacco 
smoking: this was first observed in the 1980s (24), and subsequently shown to 
increase the risk of seropositive RA in several observational studies (25).   This 
increased risk may persist for over 10 years after smoking cessation (26).   
Interestingly, smoking can act synergistically with the shared epitope to 
markedly increase ACPA production (27) and RA risk (28, 29), though smoking 
also seems to increase risk in seronegative patients with the shared epitope (30).   
It has been suggested that smoking may increase severity of RA, but this may 
simply be a result of confounding by ACPA status (31).    
Various infectious agents, including parvovirus, Epstein-Barr virus, 
cytomegalovirus, Escherichia coli and Porphyromonas gingivalis, have been 
posited as having a causative role in RA.   P. gingivalis is a common cause of 
chronic inflammatory periodontitis (32), and expresses peptidyl argenine 
deaminase IV (PAD4) enzymes which can promote protein citrullination (33).   
Molecular mimicry has been suggested as a possible mechanism of disease, but 
this is controversial (34).   Discrete infectious agents aside, it is also increasingly 
recognised that the microbiome as a whole can alter the host’s systemic 
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inflammatory response, and research is ongoing into the roles of microbiota in 
gut, mouth and lung (35).    
1.1.5 Pathophysiology 
Synovitis, the signature lesion of inflammatory arthritis, occurs when leukocytes 
migrate into the synovial membrane and fluid.   A variety of immune and 
inflammatory pathways have been identified in the joint which may contribute 
to the initiation or perpetuation of synovitis and joint destruction. 
1.1.5.1 Cell migration 
Infiltration of leukocytes into the joint depends on the activation of endothelial 
cells in synovial capillaries, where expression of adhesion molecules and 
chemokines is increased.   Actively inflamed synovium in both early and 
established disease demonstrates increased vascularity on ultrasound or 
magnetic resonance imaging.   This is reflected histologically by increased 
angiogenesis (36) and inadequate lymphangiogenesis (37) which may be induced 
by local cytokines or hypoxia. 
1.1.5.2 Adaptive immunity 
Evidence of a role for adaptive immunity in RA is seen in the contribution of 
autoantibodies and genes including HLA to disease risk, and the clinical efficacy 
of B-cell depletion and T-cell co-stimulatory blockade (discussed later).   T-cells, 
including autoreactive T-cells against citrullinated peptides, abound in the 
synovitic joint, as do B-cells and their plasma-cell descendents.   Indeed, 
synovial T-cell-B-cell aggregates are common, with lymphoid follicle and 
germinal centre development occasionally seen within the joint (38).   An array 
of factors that may drive this process are also detectable in the joint, including 
a proliferation-inducing ligand (APRIL), B-lymphocyte stimulator (BLyS)(38), IL-
12, IL-15, IL-23, and various chemokines (39).   The success of anti-CD20 
therapy, which depletes B cells but spares plasma cells, implies a pathogenic 
role for humoral immunity beyond autoantibody production alone, possibly 
involving cytokine production or antigen presentation. 
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Despite these factors, therapies aimed specifically at targeting T-cells (such as 
cyclosporine-A or monoclonal antibodies against CD4) have shown little or no 
clinical efficacy (40).   More recently, the role of Th-17 cells, which can produce 
IL-17 family members as well as cytokines such as TNF-α, has been explored.   
IL-17 can synergise with TNF-α to activate fibroblasts.   However, whilst IL-17 
blockade is efficacious in ankylosing spondylitis and psoriatic arthritis (41, 42), 
results in RA have been disappointing (43, 44).   An alternative target may be 
CD25 and Foxp3-expressing “regulatory” T cells (“T-regs”).   These cells are 
capable of suppressing inflammation and re-establishing homeostasis via 
cytokines including TGF-β and IL-10, and are functionally impaired in RA (45). 
1.1.5.3 Innate immunity 
Several innate immune cells are present in the inflamed joint.   Macrophages, 
the archetypal cell of chronic inflammation, are derived from circulating 
monocytes which rely on macrophage colony-stimulating factor (M-CSF) or 
macrophage-granulocyte colony-stimulating factor (GM-CSF) for migration into 
and maturation in the synovium.   They are primarily activated by receptors 
which recognise pathogen- and damage-associated molecular patterns (PAMPs 
and DAMPS, respectively) which are commonly present on bacteria and viruses, 
but can also be affected by cytokines, immune complexes, oxidised lipoproteins 
and direct interaction with T-cells.   Macrophages are highly capable of 
phagocytosis, ingesting and destroying pathogens, toxic particles or waste 
materials.   Other cells present include neutrophils (short-lived cells which 
produce prostaglandins and reactive oxygen species) and mast cells (which can 
synthesise vasoactive peptides as well as cytokines and chemokines).    These 
cells produce a variety of pro-inflammatory cytokines which drive leukocyte 
recruitment and survival, endothelial activation, angiogenesis and pain; the 
most significant of these are discussed later in the context of therapeutic 
targeting. 
1.1.5.4 Bone Erosion 
The influx of leukocytes and their behaviour described above has a profound 
impact on fibroblast-like synoviocytes (FLS), the endogenous stromal cell that 
constitutes the local tissue cellular phenotype.   The healthy synovial membrane 
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is composed of a thin layer of these cells on a basement membrane, secreting 
small amounts of viscous synovial fluid to lubricate the joint.   In RA, these cells 
demonstrate both proliferation and resistance to apoptosis, resulting in a 
massively enlarged membrane, often generating large quantities of fluid 
(detectable clinically as an effusion).   Pro-inflammatory cytokines, amongst 
other pathways, probably support this behaviour; the recruitment of new 
mesenchymal cells may also contribute (46). 
The resulting volume of tissue containing leukocyte-rich synovium is known as 
pannus, which manifests as an advancing tissue front which invades and erodes 
cartilage and bone.   FLS synthesise matrix metalloproteinases (MMPs) and other 
enzymes, which degrade collagen and alter its biomechanical properties.   IL-1, 
TNF and IL-17A drive chondrocytes to apoptosis, retarding the ability of cartilage 
to regenerate.   A variety of other cytokines, including receptor activator of Nf-
κB ligand (RANKL), TNF-α, IL-1 and IL-6, promote osteoclast differentiation and 
invasion into bone beside the articular cartilage (47); osteoclasts enzymatically 
destroy mineralised bone in discrete pits which are visible on plain radiography 
as erosions.   Bone marrow inflammation may also occur, forming a focus of 
tissue promoting immune dysfunction (48).   Unlike synovitis, these bone and 
cartilage changes are essentially irreversible, and lead to lifelong loss of joint 
function and disability. 
1.1.6 Drug treatments for rheumatoid arthritis 
Most current treatments in RA are aimed at suppressing the inflammatory 
response to reduce synovitis, improve symptoms and prevent erosions.   These 
can be broadly divided into steroid therapy, conventional disease-modifying 
anti-rheumatic drugs (DMARDS), biologic drugs and JAK inhibitors. 
1.1.6.1 Corticosteroids 
Corticosteroids were identified in the 1940s as agents which could profoundly 
and rapidly improve joint inflammation; a cine-film of a previously bedridden RA 
patient walking independently was hailed as a “modern miracle” and landed 
Kendall, Reichstein and Hench the 1950 Nobel Prize in Physiology or Medicine.   
More recently, the Utrecht (49) and CAMERA II (50) trials demonstrated the 
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ability of 10mg/day prednisolone to both reduce disease activity and reduce 
radiological disease progression.   This relatively low dose is important, as long-
term corticosteroid use carries a litany of potential side effects, including 
osteoporosis, infection, insulin resistance, weight gain, and cardiovascular 
disease.   These effects appear to be dose-dependent (51, 52), though the 
possibility of confounding by indication is hotly debated (53).    Some centres 
(including my own) attempt to minimise these risks by using intra-muscular (IM) 
depot or intra-articular (IA) delivery.    
1.1.6.2 DMARDS 
Conventional DMARDS also aim to reduce inflammation and disability, without 
corticosteroid-related harms.   Methotrexate (MTX), a dihydrofolate reductase 
inhibitor, is perhaps the most commonly used.   Its mode of action in RA is 
unclear but probably involves reduced availability of intracellular adenosine to 
leukocytes; folate supplementation improves adherence without reducing 
efficacy (54).   Oral administration of 10-20mg weekly is usual but IM or 
subcutaneous (SC) preparations can have increased efficacy and tolerance, and 
may avert unnecessary and expensive switch to biologic drugs in some patients 
(55).   Common side effects include nausea, headache, mouth ulcers and 
infection; neutropenia, marrow suppression, transaminitis and pneumonitis are 
rarer.    MTX is highly teratogenic and must be avoided during pregnancy or 
breastfeeding.   Monthly blood monitoring is recommended for the first year of 
treatment (56). 
Sulfasalazine (SSZ) was the first DMARD synthesised specifically for treatment of 
RA by the addition of a sulfapyridine group to 5-aminosalicylic acid, and was 
shown in controlled trials to be as effective as gold (57) and penicillamine (58).   
The side effect profile may be slightly better than MTX, with headache and GI 
disturbance the most common, and the drug may cause transient oligospermia 
and therefore reduced fertility in men.   Monthly monitoring of full blood count, 
renal and liver function is recommended initially, and quarterly thereafter (56).  
A third agent is the antimalarial hydroxychloroquine (HCQ).   HCQ tends to be 
well tolerated, though retinopathy is a rare but serious complication; annual 
review by an optician is recommended.  Both SSZ and HCQ have multiple anti-
inflammatory and possibly antimicrobial effects, though their exact mechanisms 
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of action in RA are unknown.   Other DMARDS used less frequently include 
leflunomide, penicillamine and gold salts.   A systematic review has shown these 
agents to have roughly equivalent efficacy (59) but methotrexate remains the 
most commonly used first-line agent in our centre.  
1.1.6.3 “Biologics” 
Biologic medications are so names as they mimic naturally-occurring substances 
in the human body.   Most biologics are monoclonal antibodies, and can be 
divided into several categories. 
Cytokine blockade:  Tumour necrosis factor alpha (TNFα) is a potent pro-
inflammatory cytokine produced by macrophages, dendritic cells and T-cells in 
response to an assortment of molecular patterns on microbes – for example, 
bacterial lipopolysaccharide (LPS) binding to toll-like receptor (TLR4) and 
signalling via the NFκB pathway.   TNFα can drive inflammation by activating 
endothelial cells and neutrophils, and has other systemic effects such as fever 
via the hypothalamus.    In vitro work in the 1980s implicated TNFα in cartilage 
destruction (60), and inhibition of TNFα in mouse models improved joint swelling 
and erosive progression (61).   These results were replicated in several large 
human studies with Infliximab, a chimeric monoclonal antibody (Mab) against 
TNFα (62).   Today, five TNF blockers are licensed for use in RA: infliximab; the 
fully human Mabs adalimumab and golimumab; certulizumab pegol, a humanised 
antigen-binding fragment of antibody conjugated to polyethylene glycol; and 
etanercept, a soluble TNF-receptor fusion protein.   These drugs are efficacious 
in many patients but must be given with methotrexate for full benefit.   Risks of 
therapy include infection (particularly tuberculosis), cardiac failure, allergic 
reactions and possibly melanoma (63), though other malignancies do not seem to 
be increased (64).   Other attempts at cytokine blockade, including IL-1 (65) and 
IL-17 (43), have been less successful and are not recommended for use in clinical 
practice (66); targeting of GM-CSF may hold more promise (67).   IL-6 blockade 
will be discussed in depth later in the manuscript. 
B-cell depletion: Rituximab is a chimeric antibody which binds to the CD20 
molecule on B cells.   This induces depletion of B cells in peripheral blood (68) 
but allows reconstitution as CD20 is not present on pro-B cells.   Administration 
  36 
 
 
 
of two infusions two weeks apart improves disease activity, with results still 
apparent after 48 weeks in some patients (69).   Efficacy seems significantly 
better in rheumatoid factor-positive patients (70).  Infusion reactions are 
common, and hypogammaglobulinaemia with repeat infusions may lead to 
opportunistic infection(70).   An alternative method of depleting B-cells by 
targeting B-lymphocyte stimulator (BLyS, also known as BAFF) has failed to 
consistently demonstrate efficacy in RA (71). 
Co-stimulatory blockade: Abatacept is a fusion protein of recombinant cytotoxic 
T-lymphocyte associated protein 4 (CTLA-4) and the Fc portion of human IgG1.   
By binding to CD80/86 on antigen-presenting cells, and thus preventing ligation 
of CD28 on the T-cell membrane, this drug prevents the co-stimulatory signal 
required to activate T-cells.   Abatacept is superior to placebo (72) and non-
inferior to adalimumab (73) in RA. 
1.1.6.4 JAK inhibition 
Many cytokine receptors (including IL-6R) transduce their signal via janus kinases 
(JAKs), named after the Roman deity Janus for their two phosphate-binding 
domains.   Receptor ligation triggers phosphorylation of the intracellular part of 
the receptor by JAK; this then recruits signal transduction and activation of 
transcription (STAT) proteins which are themselves phosphorylated by JAK.   
Phosophorylated STAT (pSTAT) then migrates to the nucleus to act as a 
transcription factor for cytokine-dependent genes.   Three JAKs (numbered 1-3) 
have thus far been identified.   Inhibition of JAK activity as therapy for RA has 
two main conceivable advantages: use of a biological “bottleneck” to block 
signalling of multiple cytokines with one agent, overcoming cytokine redundancy 
and obtaining a greater chance of clinical efficacy; and the ability to deliver 
these small molecules orally, as opposed to the parenteral administration 
required for large proteins such as Mabs.   Tofacitinib is a JAK1/3 inhibitor which 
has shown efficacy greater than MTX (74) and similar to adalimumab (75) in RA; 
it is licensed for use in the United States of America but is not currently 
approved by the European Medicines Agency due to concerns over its side effect 
profile.   Baricitinib, a selective JAK1/2 inhibitor,  has demonstrated efficacy in 
a phase III trial (76), and other JAK inhibitors with different specificities are 
being developed (77). 
  37 
 
 
 
1.1.7 Treatment strategies 
Modern treatment of RA typically follows a “treat-to-target” strategy aimed at 
achieving low disease activity or remission, especially in early RA (78).   Various 
regimens have been employed toward this goal, including step-up (78, 79), 
parallel (80) and step-down (81) combination DMARDs.  All these approaches 
seem superior to sequential DMARD monotherapy at reducing disease activity 
and preventing radiographic progression, but it is unclear which is the most 
effective (82-84), and about a third of patients can achieve good control with a 
single DMARD (84, 85).     Due to the side-effect profiles and costs of biologics 
(around £9,000 per year per patient), prescription in the UK is restricted to 
patients who have a 28-joint disease activity score (DAS28) greater than 5.1 
(reflecting severe active disease) and have failed two conventional DMARDS (12).   
Initial therapy with TNF blockers in a step-down approach achieves high rates of 
low disease activity, but many patients still either do not respond or remain 
reliant on their biologic drug (86).    In keeping with international guidelines (66) 
our unit prefers initial methotrexate therapy with bridging intramuscular or 
intra-articular corticosteroids, stepping up to combination DMARD therapy and 
then to biologic drugs if low disease activity is not reached. 
Early initiation of treatment has been shown to improve treatment response (87) 
and functional status (88), and improve long-term radiological outcomes (89).   
In one study, even a short delay in treatment (>4 months) was associated with 
worse disease activity 2 years later (80).   Current guidance (66) emphasises the 
importance of early intervention, as well as treating to target with regular, 
frequent clinical review, and use of the multi-disciplinary team including 
physiotherapists, occupational therapists and specialist nurses. 
1.1.8 IL-6 in rheumatoid arthritis 
A variety of cytokines have been implicated in RA pathogenesis, particularly 
TNF-α as outlined above.   In recent years considerable attention has been paid 
to another pro-inflammatory cytokine, interleukin 6 (IL-6), both in understanding 
its pathogenic role in RA and also its potential as a therapeutic target for various 
inflammatory or autoimmune disorders.   IL-6 is found at high concentrations in 
the serum (90), synovial tissue (91) and synovial fluid (92) of RA patients.   First 
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identified as a driver of B-lymphocyte proliferation, it was originally named B-
cell stimulatory factor 2.   In the intervening three decades, it has become 
apparent that IL-6 has a myriad of immunological and inflammatory functions, 
and its therapeutic blockade is now a valued treatment option in active RA. 
1.1.8.1 IL-6 molecular biology and signalling 
IL-6 is a 21 - 28kDa glycoprotein encoded by the IL6 gene on chromosome 7.   In 
human plasma, it is normally present at a concentration of 5-10pg/ml, though 
this can increase hugely in infection or inflammation; in severe sepsis, it may 
approach 1µg/ml (though this is in the context of illness which may not be 
survivable).   It exerts its influence by ligating the IL-6 receptor (IL-6R) protein, 
which can be found on the membranes of hepatocytes, vascular endothelial 
cells, and some leukocyte populations (including megakaryocytes, B cells, CD4+ 
T cells, neutrophils, monocytes and macrophages).   IL-6R lacks a 
transmembrane domain, but on ligation will recruit the gp130 protein, which 
does span the cell membrane and can bind janus kinases (JAKs) on its 
intracellular aspect.   Gp130 then dimerises, phosphorylating and activating JAKs 
and subsequently the transcription factor signal transduction and activator of 
transcription 3 (STAT3).   Phosphorylated STAT3 (pSTAT3) then continues an 
intracellular signalling cascade which leads to altered gene expression.   The 
above process, referred to as “cis-” or “classical” signalling, occurs in cells 
carrying membrane-bound IL-6R (mIL-6R).   However, IL-6R also exists in a 
soluble form (sIL-6R), generated either by alternative splicing or (more 
commonly) by shedding of mIL-6R by the membrane-bound protease ‘a 
disintegrin and metalloprotease 17’ (ADAM17).   The complex of IL-6 and sIL-6R 
can then bind gp130 (which is expressed ubiquitously), and thus transduce a 
signal.  This “alternative” form of IL-6 signalling, or “trans-” signalling, means 
that IL-6 can transduce a signal in virtually any cell in vivo (93)   Most 
intriguingly, evidence is emerging that cis- and trans-signalling may generate 
anti- and pro-inflammatory responses respectively (94).  SIL-6R may also have an 
inhibitory impact on IL-6 signalling, as the IL-6/sIL-6R complex can also be 
sequestered by circulating soluble gp130, preventing ligation of membrane-
bound gp130 or mIL-6R (93). 
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Figure 1 - IL-6 ligates (a) membrane-bound IL-6R or (b) sIL-6R, in this case 
generated via cleavage of IL-6R by ADAM17. The IL-6/IL-6R complex binds to 
gp130, with subsequent activaiton of the JAK/STAT pathway. From: 
Calabrese et al. Nat Rev Rheumatol 2014; 10(12):720-7 
 
1.1.8.2 Role of IL-6 in RA Pathophysiology 
In vitro experiments have shown that IL-6 can induce several features of 
inflammation, including production of chemokines and leukocyte adhesion 
molecules (95), demargination of neutrophils (96), angiogenesis (97) and 
proliferation of fibroblast-like synoviocytes (98).   Il-6 can also drive bone 
damage by stimulating production of RANKL (which induces osteoclastogenesis) 
(98), and matrix metalloproteinases (which degrade cartilage) (99).   Beyond the 
joint, IL-6 is responsible for the liver’s acute phase response – a term for the 
collective expression of various proteins in response to infectious or 
inflammatory insult, which can be quantified in clinical practice by serum C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR) or plasma viscosity.   
IL-6 also drives the phenomenon of anaemia of chronic disease by inducing 
expression of hepcidin by the liver, which impairs release of iron from body 
stores and thus reduces the availability of iron for erythrocyte precursors in the 
bone marrow.   This leads to a characteristic normochromic, normocytic 
anaemia with normal (or elevated) serum ferritin but reduced serum iron and 
transferrin saturation.   IL-6 also plays a role in the generation of autoimmunity 
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in mouse models of arthritis, with co-stimulation of IL-6 and TGF-β required for 
generation of Th-17 cells in vitro (100).   
1.1.8.3 Tocilizumab and IL-6 blockade in RA 
The above data suggested that selective blockade of IL-6 could be a viable 
therapeutic strategy.   To this end, tocilizumab is a humanised monoclonal 
antibody directed against both soluble and membrane-bound forms of the IL-6R; 
its epitope is the cytokine binding site on the IL-6R, making it in effect a 
competitive antagonist of IL-6. 
An extensive phase III programme has demonstrated tocilizumab’s efficacy in RA 
in DMARD-naive patients (101), inadequate responders to DMARDS (102-106), and 
patients who have not responded to with anti-TNF drugs (107-109).   At a 
standard dose of 8mg/kg in combination with conventional DMARDS, tocilizumab 
led to ACR20 responses of approximately 60% by 24 weeks (102, 105).  Doses of 
4mg/kg typically gave more modest responses which were nevertheless superior 
to placebo (103, 108).   Onset of action was rapid, with falls in mean tender and 
swollen joint counts observed after 4 weeks (110), and drug efficacy was 
maintained in long-term follow-up studies of up to 5 years (111, 112).   
Improvements in functioning and independence, as assessed by the Health 
Assessment Questionnaire (HAQ) were also observed (102, 105, 106, 108).  
Efficacy in patients who had failed anti-TNF was less impressive than for anti-
TNF-naive patients, but remained superior to placebo (107, 108, 110).   Several 
studies also demonstrated the ability of tocilizumab to reduce radiographic 
progression (103, 104, 113); this reduction was observed even in the presence of 
persistent synovitis or high disease activity (114), a feature also described with 
anti-TNF agents and rituximab.    Whilst tocilizumab was initially licensed for 
intravenous (IV) delivery,  a subcutaneous  formulation has been approved on 
the basis of two RCTs which demonstrated non-inferiority of subcutaneous 
tocilizumab 162mg weekly compared to IV (115, 116). 
In contrast to the other biologic agents licensed for the treatment of RA, 
tocilizumab appears effective as monotherapy, with only small additional 
benefit attained from combination with methotrexate (109, 113, 117).   One 
trial did, however, suggest superiority of combination therapy for the higher 
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response targets of ACR70 (37% vs. 16%) and DAS28 remission (34% vs. 17%) (117) 
suggesting that concomitant DMARD use is probably best practice in order to 
obtain good disease control or remission in as many patients as possible.   In 
addition, several studies demonstrated significantly greater efficacy of 
tocilizumab monotherapy compared to conventional DMARD monotherapy (101, 
104, 111).   This stands in contrast to studies of anti-TNF agents which have 
consistently shown significant improvement in efficacy when these agents are 
used in combination with MTX, and which have struggled to demonstrate 
superiority of anti-TNF agents over DMARDS when used as monotherapy (118).   
This contrast is best exemplified by the ADACTA study, a head-to-head 
comparison of tocilizumab 8mg/kg monotherapy against adalimumab 
monotherapy which demonstrated superiority of tocilizumab for ACR50 (47% vs. 
28%), EULAR response (78% vs. 55%) and DAS28 remission rates (40% vs. 11%) 
(119).   These findings were not significantly altered by use of scoring systems 
which did not rely on the acute phase response.   Studies also demonstrated that 
the ability of tocilizumab monotherapy to reduce radiographic progression (104, 
113). These findings are highly relevant to clinical practice as up to 30% of RA 
patients on biologics are not prescribed MTX despite international guidelines 
(120). 
1.1.8.4 Toxicity of tocilizumab  
The most common adverse event attributed to tocilizumab is infection.   A 
serious infection rate of 47 per 1000 patient years was reported in a meta-
analysis of pooled clinical trial data (121), with similar rates reported in phase IV 
post-marketing studies (111, 122, 123).  These figures are comparable to those 
seen with TNF inhibitors. Bacterial pneumonia was the most commonly reported 
infection. The meta-analysis detected 7 cases of TB in 1,870 patients treated 
with 8mg/kg tocilizumab (121) with pre-treatment screening for TB 
recommended in treatment guidelines.  However, the biological role of IL-6 in 
tuberculosis is unclear, and all the large phase III studies screened for latent TB 
prior to enrolment.   Use of live or attenuated vaccinations is not recommended, 
though vaccination against influenza remains effective (124). 
In pooled clinical trial data, tocilizumab increased mean haemoglobin by around 
1g/dl within 6 weeks (in keeping with IL-6 driving anaemia of chronic disease), 
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but was associated with dose-related falls in mean neutrophil and platelet 
counts (121), probably due to neutrophil margination and reduced platelet 
production respectively.   Liver transaminase level increases were similar levels 
in patients treated with MTX monotherapy and tocilizumab monotherapy. The 
percentage of patients with alanine transaminase (ALT) levels >3 times the 
upper limit of normal was 1.9% with tocilizumab monotherapy, 3.7% with MTX 
monotherapy and 5.7% with combination tocilizumab and DMARD (121).   A 
significant proportion of these patients were able to continue on a reduced dose 
of tocilizumab.  EULAR guidelines recommend blood tests every 4-8 weeks for 6 
months, and 3-monthly thereafter.  Treatment should be terminated if 
transaminases are elevated >5x the upper limit of normal (ULN) or persistently 
>3x ULN; elevations 1-3x ULN can be managed with dose reduction to 4mg/kg or 
treatment interruption (125).   Treatment should also be terminated if 
neutrophil count falls <500/mm3, and interrupted at counts of 500-1,000/mm3 
(125). 
Other reported adverse events include bowel perforation, predominantly in 
patients with previous diverticulitis or on concomitant corticosteroid or NSAID 
therapy (126), and one reported case of leukoencephalopathy (127).  Data are 
limited on pregnancy are limited; recent guidelines from the British Society of 
Rheumatology advise stopping treatment three months before conception, but 
note that “exposure early in the first trimester is unlikely to be harmful” (128).   
No increased risk of malignancy has yet been detected in clinical trials or long-
term follow-up studies (111, 121); however, large-scale observational studies 
addressing this issue are currently lacking. 
1.1.8.5 Tociluzmab efficacy in other inflammatory conditions  
Given IL-6’s role in Th-17 cell generation, tocilizumab has been used 
experimentally in seronegative spondyloarthritides.  The BUILDER studies (129) 
aimed to evaluate tocilizumab’s efficacy in ankylosing spondylitis.   
Unfortunately, analysis of preliminary results showed no indication of efficacy, 
and the studies were terminated.   Case reports have suggested efficacy of 
tocilizumab in some patients with psoriatic arthritis (130, 131).   More 
interestingly, a recent phase II study (132) reported promising results with 
tocilizumab being used to treat giant cell arteritis (GCA), a large vessel vasculitis 
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which commonly demonstrates significant elevations in ESR and CRP.   85% of 
patients treated with tocilizumab reached disease remission at 12 weeks 
(compared to 40% on placebo), with no disease relapses recorded after 52 weeks 
of follow-up; the tocilizumab group also required significantly smaller 
cumulative doses of corticosteroids.   Similarly impressive results have been 
obtained in the related condition of polymyalgia rheumatica (133) and in the 
rare lymphoproliferative disorder Castleman’s disease, where B-cell proliferation 
is driven by abnormal production and signalling of IL-6 (134). 
1.2 Cardiovascular disease 
Cardiovascular disease (CVD) describes a process of progressive blood vessel 
dysfunction and occlusion which results in tissue damage and subsequent patient 
disability or death.   Accumulation of lipid plaques (“atheroma”) in arterial 
walls, a state known as atherosclerosis, leads to restriction of blood flow and 
tissue ischaemia; depending on the vessels involved, this may manifest clinically 
as angina (coronary arteries supplying the myocardium, also known as coronary 
heart disease [CHD]), transient ischaemic attack (carotid or cerebral arteries 
supplying the brain) or intermittent claudication (femoral and more distal 
arteries supplying the legs).   Plaque rupture and subsequent thrombus 
formation can occlude the vessel entirely and cause tissue infarction, 
manifesting clinically as myocardial infarction, stroke or critical limb ischaemia.  
Prompt restoration of lumen patency by pharmacologic thrombolysis or 
percutaneous angioplasty may salvage ischaemic tissue and prevent disability or 
death.    
The scale of the global CVD burden is intimidating.   With 17.5 million deaths in 
2012 (equating to 31% of all deaths), it is the largest single cause of death 
worldwide (135).   In the UK, CHD is the single largest cause of death with 
around 73,000 people dying from this disease every year; this equates to roughly 
one victim every seven minutes.   Most of these deaths result from one of the 
175,000 myocardial infarctions that occur annually in the UK.   Stroke, 
meanwhile, causes 40,000 deaths per year.   When combined with related 
conditions including atrial fibrillation, cardiomyopathy and heart failure, CVD 
costs the UK economy an estimated £19 billion per year (136).   Of note, 
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however, the number of deaths from CHD has halved in the last fifty years, due 
to advances in both disease prevention and treatment (137). 
Scotland has an especially poor record of cardiovascular health with over 7,000 
deaths from CHD annually.   Whilst mortality rates have improved over the past 
fifty years, they remain 30-40% higher than in England (137), and treating and 
preventing CVD is a priority for the Scottish Government (138).   Scotland has 
high levels of smoking, obesity and social deprivation, all of which impact CVD 
prevalence and mortality (139) and which are taken into account by the Scottish 
ASSIGN CVD risk calculation algorithm.  
1.2.1 Pathophysiology of cardiovascular disease 
1.2.1.1 Blood vessel anatomy 
To understand the pathophysiology of atherosclerosis, it is necessary to outline 
the anatomy of a typical artery.   All but the smallest vessels are composed of 
three layers: the tunica intima; tunica media; and tunica adventitia.   The 
innermost tunica intima immediately surrounds the blood-containing lumen and 
consists of a single layer of endothelial cells on a thin membrane of type IV 
collagen, laminin and proteoglycans.    Vascular endothelial cells together form 
a highly functional tissue which interacts with blood and the rest of the vessel 
wall, regulating nutrient exchange, vascular tone and coagulation.   An internal 
elastic lamina lies between the intima and the tunica media.   The media is a 
layer of smooth muscle cells which can alter vessel tone to maintain local blood 
pressure and flow, resting on an external elastic lamina.  The outermost tunica 
adventitia is a loose arrangement of connective tissue, fibroblasts, nerves and 
capillaries which supply the vessel wall. 
1.2.1.2 Atheroma formation 
The pathogenesis of an atheromatous plaque is increasingly well understood, and 
may be described in four stages (Figure 2). 
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Figure 2 - Stages of atheroma formation. A: Endothelial activation (adhesion 
molecules denoted in blue).   B: Fatty streak formation with foam cells.   C: A 
mature lesion (fibrous cap denoted in gray).   D: Plaque rupture (thrombus 
denoted in black). (author’s own design) 
 
1 - Endothelial activation and the initial lesion: In most models of 
atherosclerosis, the disease process is initiated by activation of the vascular 
endothelium.   Activated endothelial cells upregulate adhesion molecules such as 
vascular cell adhesion molecule 1 (VCAM-1) and intracellular adhesion molecule 
1 (ICAM-1) and chemokines including monocyte chemotactic protein 1 (MCP-1), 
macrophage colony-stimulating factor (M-CSF) and IL-8, permitting recruitment 
of circulating leukocytes (particularly monocytes) into the tunica intima (140-
142).   Endothelial activation seems to be driven predominantly by complex, 
disturbed blood flow patterns and the resultant wall stresses; arterial segments 
with disturbed flow (eg. carotid bifurcation, aortic arch) are more prone to 
atheroma formation, whilst uniform shear stresses lead to endothelial expression 
of atheroprotective genes including endothelial nitric oxide synthase (eNOS) and 
cyclooxygenase 2 (COX-2)(143).   Suppression of these genes, particularly eNOS, 
can manifest as endothelial dysfunction, a phenotype characterised by 
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diminished production of nitric oxide (with reduced vasodilatory and anti-
oxidant capacity) and a pro-coagulant state.   Perhaps most importantly, 
dysfunctional endothelium becomes more permeable to apoB-containing 
lipoproteins, especially small dense low density lipoprotein (LDL) particles which 
are prone to oxidative modification; these particles can themselves activate 
endothelium and thus potentiate the disease process (144).   Of note, TNFα can 
also upregulate VCAM-1 (145) and pro-thrombotic factors (146) and reduce eNOS 
and COX-2 activity (147).   
2 - The fatty streak: Monocytes recruited to the tunica intima differentiate into 
tissue macrophages.   These macrophages ingest oxidised LDL (oxLDL) and other 
lipoproteins via scavenger receptors, a family of cell surface molecules used to 
clear pathogens or apoptotic cell debris (148).   Scavenger receptors play a key 
role in atherosclerosis as oxidative modification of the apoB molecule on LDL can 
prevent it from binding to the LDL receptor and being cleared in the 
conventional manner (148).   The resulting lipid-laden macrophages are known 
as foam cells, from the microscopic appearance of their lipid droplets; 
accumulation of these cells leads to the first visible form of atheroma, termed 
the “fatty streak”.   The importance of LDL-cholesterol (LDL-c) as a driver of this 
process will be explored later. 
3 - The mature stable lesion: Over time, the immature “fatty streak” lesion is 
modified by migration of smooth muscle cells (SMCs) from the media to the 
intima.   Driven by endothelial cells, macrophages and T-lymphocytes (149), 
SMCs proliferate and produce extracellular matrix molecules to form a fibrous 
cap over the lesion.   Underlying the cap is a lipid-rich core of LDL, free 
cholesterol and apoptotic and necrotic macrophages; a rich milieu of 
lymphocytes, dendritic cells and mast cells also accumulates, in a pattern 
remarkably similar to a synovitic joint.   In this environment, macrophages may 
secrete extracellular matrix-degrading enzymes, and the stability of the mature 
plaque is reliant on the balance between these and the viability and matrix 
products of SMCs (150). 
4 - Plaque rupture & thrombosis: Stable atheromatous plaques may be 
asymptomatic, and significant clinical manifestations of atherosclerosis are 
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usually due to plaque rupture and thrombus formation.   Macrophages again 
seem critical to this event: macrophages of a “pro-inflammatory” or M1 
phenotype, predominate at the rupture-prone shoulder region of the plaque, 
with both M1 and M2 macrophages observed around the fibrous cap (151).   
Exposure of subendothelial connective tissue or the necrotic core triggers 
platelet aggregation and activation of the coagulation cascade; this leads to 
lumen occlusion and downstream tissue ischaemia and infarction.   Circulation 
can be restored, tissue saved and mortality avoided by prompt administration of 
antiplatelet or anti-thrombolytic drugs (152), or by percutaneous angioplasty 
(153). 
1.3 Cholesterol and lipoprotein metabolism 
Several types of lipid, and the lipoprotein structures in which they are 
transported around the body, play roles in the development of atherosclerosis.   
Most prominent amongst these is cholesterol. 
Cholesterol is a lipid with numerous key roles in mammalian biology.   It is a key 
component of the cell membrane, and is also a precursor molecule for bile 
acids, steroid hormones and vitamin D.   Its structure is shown in Figure 3 – it is a 
planar molecule composed almost entirely of carbon and hydrogen, with a 
molecular weight of 386Da. 
 
Figure 3 - Structure of cholesterol, with carbon atoms numbered 1 – 27.   
Adapted from “Medical Biochemistry” 2nd Ed., Baynes & Dominiczak, 
Elsevier Mosby (Philadephia). 
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A typical Western daily diet contains around 500mg (1.2mmol) of cholesterol, 
predominantly in meat, eggs and dairy products.   Normally, approximately half 
of this is absorbed by the gut.   However, cholesterol may also be synthesised de 
novo by human cells.   The majority of cholesterol synthesis occurs in 
hepatocytes, though gut, adrenal glands and gonads also contribute.   Beginning 
with the molecule acetyl CoA (itself derived from fatty acids or amino acids), 
this process is lengthy with numerous intermediate molecules and crucial 
enzymes.   However, the rate-limiting step occurs early on with the conversion 
of HMG CoA to mevalonate by the enzyme HMG CoA reductase (Figure 4).   
Statins, inhibitors of HMG CoA reductase, typically reduce total serum 
cholesterol by around 20%, and this translates to a relative risk reduction in 
cardiovascular mortality of 25-30% (153). 
 
Figure 4 - Abridged schematic of cholesterol biosynthesis (author’s original 
design) 
 
  49 
 
 
 
Free cholesterol accounts for around 30% of circulating cholesterol.   The 
remainder is bound to various long chain fatty acids to make cholesterol esters.   
Neither free nor esterified cholesterol are particularly soluble in water, and so 
cholesterol in serum is almost entirely transported within specialised molecular 
structures called lipoproteins.   
1.3.1 Lipoprotein structure 
Lipoproteins are roughly spherical particles measuring 5 to 1,200 microns in 
diameter.   They consist of a phospholipid monolayer membrane which holds 
proteins called apoproteins embedded within.   This allows the lipoprotein to be 
very soluble in water whilst bearing large quantities of poorly-soluble content 
internally, mainly triglyceride and cholesterol.   Lipoproteins exist on a spectrum 
of size and density.   The largest and least dense are chylomicrons, followed by: 
very low-density lipoprotein type 1 (VLDL1) or type 2 (VLDL2); remnant particles 
following VLDL metabolism, including intermediate-density lipoprotein (IDL); 
low-density lipoprotein (LDL); and high-density lipoprotein (HDL).    The largest 
and least-dense particles contain large amounts of triglyceride, with TG content 
reduced in smaller, denser particles.   LDL and HDL are triglyceride-poor and 
cholesterol-rich.  
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Figure 5 - Schematic structure of a lipoprotein particle.   The external coating 
consists of a phospholipid monolayer bearing at least one apoprotein.   
Triglycerides and cholesterol (largely cholesterol esters) are present in the 
core. Adapted from “Medical Biochemistry” 2nd Ed., Baynes & Dominiczak, 
Elsevier Mosby (Philadephia). 
 
Apoproteins, whilst making up only a small proportion of lipoprotein particle 
mass, are vitally important as they can bind with receptors on cell membranes 
and activate or inhibit enzymes which direct the metabolic fate of the particle.   
Apoproteins A (AI and AII) are present on HDL, and allow HDL to bind to 
hepatocytes for cholesterol transfer; multiple copies of apoAI or apoAII can be 
present on each HDL particle.   Apoprotein B, in the form of apoB100, is present 
on VLDL, IDL and LDL, and binds to the LDL receptor (LDLr).   Each particle 
contains only one apoB100 protein.   For the purposes of this thesis, “apoB” will 
refer to this apoB100 molecule; a shortened form of apoB, apoB48, is present on 
chylomicrons, but cannot bind to the LDLr.   ApoE is present on remnant 
particles and also binds to the LDL receptor, whilst apoCI, CII and CIII may be 
transferred between different lipoprotein subclasses and act as a regulator for 
enzymes such as lipoprotein lipase (LPL) and cholesterol ester transfer protein 
(CETP).   One unusual lipoprotein particle of import is known as lipoprotein (a), 
or Lp(a).   This is essentially an LDL particle (containing one apoB100 molecule) 
linked to a glycoprotein of between 200 and 800kDa called apo(a).   Lp(a) has 
been found to a strong independent predictor of cardiovascular disease (154). 
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1.3.2 Lipoprotein receptors 
In recent years it has become apparent that there exists a family of molecules 
derived from or related to the LDLr, and some of these play notable roles in lipid 
metabolism.   The VLDL receptor (VLDLr) is structurally similar to the LDLr but 
can bind to a broader repertoire of apoE allelic variants in concert with lipases; 
hence, VLDLr preferentially metabolises triglyceride-rich VLDL and remnants in 
tissues such as heart, skeletal muscle, liver, adipose tissue and macrophages 
(155).    Another functionally prominent molecule is the LDL receptor-related 
protein (LRP-1), a large protein which binds apoE (but not LDL), and binds 
remnant lipoproteins in conjunction with LDLr. 
Separate from the LDLr family, but of key importance in cholesterol-rich 
lipoprotein metabolism are a broad range of cell-surface molecules known as the 
scavenger receptors.   These receptors are present on leukocytes, especially 
macrophages, and can act to trigger the immune response by binding to a variety 
of pathogen-associated molecular patterns (PAMPS) or bacterial products such as 
lipopolysaccharide (LPS).   However, most scavenger receptors are also capable 
of binding and internalising LDL which has been modified by acetylation or 
oxidation (156).   This is of clinical relevance as oxidised LDL (oxLDL) may 
undergo conformational change in the apoB molecule rendering it unable to bind 
to the LDLr; it then instead becomes prone to removal by macrophages in, 
amongst other places, the subendothelial space, leading to foam cell formation.   
Peritoneal macrophages from ApoE -/- mice with multiple scavenger-receptor 
knockouts demonstrated reduced foam cell formation (156), although further 
studies using this animal model have not demonstrated reduction in 
atherosclerotic burden (157, 158).   Probable targets are outlined in Table 2, 
though it is likely that this represents incomplete knowledge as well as an 
element of redundancy in this broad family of molecules.   As oxidation can 
occur in virtually any inflammatory environment, it stands to reason that the 
immune system would have multiple mechanisms for clearing such epitopes 
effectively before they cause tissue damage or generate autoimmune responses.   
Scavenger receptor B-1 can also bind HDL, and has been proposed as a candidate 
for the putative hepatic HDL receptor. 
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Scavenger 
receptor 
Lipoprotein binding Pathogen recognition 
SR-AI/II AcLDL, oxLDL Listeria monocytogenes, Staphycoccus aureus, 
Neiserria meningitides, Streptococcus 
pyogenes, Group B Streptococcus 
MARCO AcLDL LPS, Streptococcus pneumonia, Neiserria 
meningitides 
CD36 AcLDL, oxLDL Microbial diacylglycerides, Mycoplasma 
pneumonia, Staphylococcus aureus 
SR-B1 AcLDL, oxLDL, native 
LDL, native HDL 
Hepatitis C receptor 
CD68 OxLDL Unknown 
LOX-1 OxLDL Unknown 
CD163 None Streptococcus mutans, Staphylococcus aureus, 
E. coli 
FEEL-1 AcLDL Staphylococcus aureus, E. coli 
Feel-2 AcLDL Staphylococcus aureus, E. coli 
SCARA5 none Staphylococcus aureus, E. coli 
 
Table 2 - Major known scavenger receptors and their lipid or pathogenic 
ligands. AcLDL = acetylated low-density lipoprotein.   oxLDL = oxidised low-
density lipoprotein.   LPS = lipopolysaccharide. From Greaves & Gordon J 
Lipid Res 2009; 50 Suppl:S282-6. 
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1.3.3 Lipoprotein function & cholesterol transport 
The major pathways of cholesterol (and triglyceride) are outlined in Figure 6. 
 
 
Figure 6 - Metabolism of the apoB-containing lipoproteins. VLDL = very low 
density lipoprotein. IDL = intermediate density lipoprotein. LDL= low density 
lipoprotein. LPL = lipoprotein lipase. HPL = hepatic lipase. LDLr = LDL 
receptor. SR = scavenger receptor.  (Author’s own design) 
 
Following a meal, chylomicrons are synthesised by enterocytes in the small 
bowel, and carry dietary triglyceride and cholesterol to peripheral tissues.   
Chylomicrons are hydrolysed by lipoprotein lipase (LPL), losing some triglyceride 
into recipient cells, and the resulting remnant particles are taken up by the liver 
via LDLr & LRP-1.   These are processed and provided with an apoB100 molecule, 
and released into the circulation as triglyceride-rich VLDL1.   VLDL1 itself 
relinquishes triglycerides through the hydrolytic action of LPL, and so is 
sequentially modified to VLDL2 and then IDL.   By this point, the particle has lost 
all apoproteins except apoB100.   IDL may then be taken up by the liver via LDLr, 
as the particle’s reduction in size leads to conformational change in apoB which 
permits effective binding to LDLr.   Alternatively, it may be further transformed 
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in LDL by hepatic lipase (HPL) bound to hepatic sinusoidal cells.   LDL particles 
hold little triglyceride but proportionally large quantities of cholesterol, and are 
the major carriers of cholesterol in blood.   LDL may be taken up by liver or 
peripheral tissues via LDLr (“receptor-dependent” uptake), though excess or 
modified LDL may preferentially be consumed by phagocytic cells in the reticulo-
endothelial system or vessel wall, probably via scavenger receptors. 
 
 
Figure 7 - Reverse cholesterol transport and the life cycle of HDL.  LCAT = 
lecithin cholesterol acetyltransferase.  CETP = cholesterol ester transfer 
protein.  SR-B1 = scavenger receptor B1.  ABCA1 = ATP-binding cassette 
A1.  (Author’s own design) 
 
HDL stands distinct from the other lipoproteins as it has its own metabolic cycle 
known as reverse cholesterol transport, outlined in Figure 7.   This is the 
mechanism whereby excess cholesterol is exported from cells; humans cannot 
metabolise the cholesterol ring, and instead must transport it to the liver for 
excretion in bile.   HDL in its nascent phase (“pre-β HDL”) exists as a discoidal, 
lipid-poor particle bearing apoAI synthesised by the liver.   It is able to accept 
free cholesterol exported from peripheral cells by ATP-binding cassette 
transporters, predominantly ABCA1.   Though other active members of this 
family exist, ABCA1 appears to be the rate limiting protein involved.   Genetic 
defects in ABCA1 cause the rare Tangier disease, characterised by accumulation 
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of cholesterol in peripheral tissues and extremely low levels of HDL-c.   Free 
cholesterol within HDL is esterified by the lecithin-cholesterol acetyltransferease 
(LCAT) enzyme which is bound to the particle; the particle then becomes 
spherical and is known as HDL3.   HDL3 then exchanges cholesterol esters with 
apoB-containing lipoproteins in return for triglycerides under the action of 
cholesterol ester transfer protein (CETP), increases in size and becomes HDL2.   
HDL2 can then bind to the class B scavenger receptor (SR-B1) on hepatocytes, 
transfer cholesterol into the cell, and shrink back into a pre-β HDL particle. 
1.3.4 Regulation of intracellular cholesterol levels 
Accumulation of excess intracellular cholesterol can be highly toxic to cells, and 
so intracellular cholesterol levels are tightly controlled.   The major regulatory 
proteins involved are the sterol regulatory element binding proteins (SREBP) and 
the liver X receptors (LXR).   SREBPs act to increase intracellular cholesterol 
levels, whilst LXRs perform the opposite function. 
SREBP exists in two isoforms; SREBP1 is mainly involved in fatty acid 
biosynthesis, whilst SREBP2 regulates cholesterol.   When a cell is cholesterol 
replete, SREBP is inactive, bound to the endoplasmic reticulum by a complex 
including oxysterols (intermediate molecules in cholesterol synthesis which are 
now recognised to have metabolic functions of their own) and the SREBP 
cleavage activation protein, or SCAP.   When cellular cholesterol stores run low, 
the lack of oxysterols liberate the SCAP/SREBP complex that then travels to the 
golgi apparatus.   Here, SREBP is cleaved by proteolytic enzymes, and can travel 
to the nucleus where it acts as a transcription factor to increase expression of 
the LDLr and HMGCoA reductase.   This increases cellular cholesterol levels both 
by uptake from the serum and by de novo synthesis. 
LXRs also exist in two forms.   LXRα is particularly involved in cholesterol 
regulation, and is expressed in gut, adipose tissue and liver.   LXRβ is expressed 
more broadly, and has roles in nervous system and immune system function.   In 
conditions of excess intracellular cholesterol, oxysterols bind to and activate 
LXRα or LXRβ.   This allows LXR to form a heterodimer with its partner retinoic 
acid receptor (RXR).   This heterodimer can then act as a transcription factor, 
binding to a genetic locus called the LXR response element.   Expression of 
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cholesterol export proteins such as ABCA1 and ABCG1 is upregulated (allowing 
for increased cholesterol efflux to HDL) whilst LDLr expression is repressed 
(reducing cholesterol intake from LDL).    
Three other protein families warrant mention in regards to cholesterol 
metabolism.   Firstly, the peroxisome proliferation activating receptors (PPARs) 
are nuclear receptors which, like LXR, form heterodimers with RXR, and can 
then act as transcription factors by binding to PPAR-response elements on gene 
promoters.   PPARα is present in liver, skeletal muscle, brown adipose tissue and 
macrophages.   On ligation, PPARα increases expression of LPL and other 
enzymes involved in fatty acid uptake and oxidation, and reduces expression of 
apoCIII.   This removal of triglyceride from the lipoprotein pool leads to 
increased clearance and reduced synthesis of VLDL, and an increase in average 
LDL particle size with reduction in overall LDL concentration [FRUCHART2009].   
Serum HDL also increases due to increased hepatic synthesis of apoAI and AII, 
and through increased cholesterol efflux to HDL from macrophages in an ABCA1-
dependent manner (159).   Fibrates, drugs which act as PPARα agonists, have 
been used for many years as a treatment for hypertriglycerideaemia.   PPARβ/δ 
and PPARγ are involved in adipocyte proliferation and glucose metabolism 
respectively; the latter is the target for the thiazoladinedione drugs, used to 
lower blood glucose levels in type 2 diabetes mellitus. 
Secondly, the forkhead transcription factors FoxO1, FoxO3a and FoxO4 are 
implicated in a wide range of cellular processes including the cell cycle, cell 
survival, adipocyte differentiation and insulin signalling (160); indeed, FoxO1 
knockout in mice leads to embryonic lethality.   Activation of FoxO1 stimulates 
gluconeogenesis and reduces pancreatic insulin production (161), and has been 
shown to inhibit expression of SREBPs (162).   Knockout of other FoxO molecules 
in ApoE-/- mice leads to increased liver triglyceride content, progressing to 
steatosis in the context of a high-fat diet, elevated serum levels of IL-6, and 
increased atherosclerosis (163). 
Finally, much attention has recently been paid to the proprotein convertase 
subtilisin/kexin (PCSK) family, particularly PCSK9.   In hepatocytes, PCSK9 binds 
to and degrades the LDLr, thus reducing hepatic uptake of LDL.   A phase III trial 
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of evolocumab, a monoclonal antibody directed against PCSK9, reduced 
circulating LDL-c by over 50% (164), and also appears to reduce serum Lp(a) by a 
similar mechanism (165). 
1.3.5 Lipoproteins and CVD risk 
In the general population, several strands of evidence have firmly established 
that high serum LDL-c and low serum HDL-c levels are associated with increased 
risk of cardiovascular disease (CVD). Cholesterol is abundant in the 
atherosclerotic plaque, and familial hypercholesterolaemia—a genetic condition 
that results in elevated serum levels of LDL—leads to a greatly increased CVD 
risk from the age of 30.   Furthermore, statins, drugs which block cholesterol 
synthesis, lower both LDL-c and CVD risk (166-168); a meta-analysis of five large 
RCTs demonstrated mean reductions in TC and LDL-c of 20% and 28% 
respectively, with subsequent reduction of relative risk of major coronary events 
of 34% in primary prevention and 30% in secondary prevention (169).   Regression 
analysis indicated that for every 1% reduction in LDL-c, we would expect a 1% 
reduction in mortality from CHD (170).   Consequently, statins are recommended 
for primary and secondary prevention of myocardial infarction (MI) and 
ischaemic stroke (171).   All instruments for calculation of CVD risk, such as 
SCORE (Systematic Coronary Risk Evaluation; Europe), ASSIGN (assessing 
cardiovascular risk using Scottish Intercollegiate Guidelines Network [SIGN] 
guidelines; Scotland), QRISK® (UK) and the Framingham Heart Study risk 
calculators (USA) make use of the total cholesterol to HDL-c ratio (termed the 
‘atherogenic index’) in some way. 
A comprehensive review of the literature was published by the Emerging Risk 
Factors Collaboration (ERFC), which gathered data relating to risk of CVD from 
68 long-term prospective studies involving over 350,000 patients (172).   ‘Non-
HDL’ cholesterol (as a surrogate for LDL-c) correlated strongly with coronary 
heart disease (CHD), and an inverse correlation was seen between HDL-c and 
CHD, both in a log–linear pattern (Figure 8); these relationships were 
independent of each other.   However, after adjusting for serum cholesterol 
levels, no association of serum triglycerides with CHD was observed, a finding 
which goes against conventional wisdom.   Similar, but much less pronounced, 
relationships were shown for ischaemic stroke.  
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Figure 8 - Hazard ratios for coronary heart disease across quantiles of TG, 
HDLc, and non–HDLc levels, based on 302,430 non-RA patients from 60 
studies.  Adapted from Emerging Risk Factors Collaboration JAMA 2009; 
302:1993-2000 
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Despite the strong associations described in the literature, some evidence has 
emerged that questions the causality within the relationship between HDL-c and 
atherogenesis. In 2012, Voight et al. reviewed case–control studies of single 
nucleotide polymorphisms (SNPs) known to affect serum lipoprotein levels. They 
found that, although SNPs that correlated with high LDL-c levels conferred an 
increased risk of MI, only 6 of 15 SNPs associated with higher serum HDL-c levels 
were associated with MI risk, and all 6 SNPs were also associated with other 
effects on either triglycerides or LDL-c (173).   Moreover, a Mendelian 
randomization was performed using the LIPG gene encoding endothelial lipase 
(an enzyme that hydrolyzes HDL) in which 2.6% of the population carry a SNP 
that elevates serum HDL-c without affecting any other risk factor for CVD (174).   
A meta-analysis of six prospective cohort studies revealed no association 
between MI risk and the increased HDL-c levels associated with this SNP (173).   
These data, together with the lack of beneficial effect on CVD risk of cholesterol 
ester transfer protein (CETP) inhibitors, which inhibit reverse cholesterol 
transport and thus increase HDL levels (175) suggest that whilst HDL-c is a 
valuable biomarker in atherosclerosis, it might not be a causative agent. These 
studies do not, however, negate the potential for HDL particles modified as a 
result of inflammatory processes to be causally related to atherogenesis. Further 
studies are needed to examine this potential.    
1.4 Cardiovascular disease in RA 
The risk of cardiovascular death in patients with RA is increased by around 50% 
compared to age- and sex-matched controls, with individual observational 
studies generating standardized mortality ratios (SMRs) from 1 to 3 (176, 177).   
One Dutch cross-sectional study found RA conferring a risk of cardiovascular 
disease similar to type 2 diabetes mellitus (178), a finding replicated in a much 
larger Danish database analysis (179).   This increased risk is only partially 
explained by conventional risk factors (180, 181)   Whilst cardiovascular 
mortality has declined significantly over recent decades in the general 
population (137), a meta-analysis of 17 studies conducted over a period of 50 
years showed no change in standardized mortality ratio (SMR) for CVD over time 
(182), though none of the studies included covered the “treat-to-target” era.  A 
prospective cohort study of 2,519 patients recruited into the Norfolk Arthritis 
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Register between 1990 and 2004, and followed for up to 7 years, found that CVD 
mortality did fall over time but only in line with changes also seen in the general 
population (183).   Relative risks of incident CVD (184) or CVD-mortality (177) 
seem to be slightly higher for myocardial infarction than for ischaemic stroke.   
One meta-analysis showed that inception cohorts, which tend to include patients 
with less than 2 years of symptoms, generated lower SMRs than cohorts including 
those with established disease (mean SMR 1.2 v 1.9) (185).   Some studies have 
found increased prevalence of surrogates for CVD in early RA, including 
endothelial dysfunction (186), increased carotid intima-media thickness and 
presence of carotid plaque (187).    
Supporting the paradigm of atherosclerosis as an inflammatory condition, 
increasing RA disease activity appears to associate with a worsening 
cardiovascular phenotype.   Inflammatory markers or clinical disease scores such 
as DAS28 can predict increasing carotid intima-media thickness (188), incident 
CVD (189-191), and CVD mortality (192, 193).   Whilst many of these studies use 
single timepoint measurements of disease activity, a Swedish case-control study 
found RA patients with CVD to have higher time-averaged ESR than RA controls 
without CVD (194).   Similar outcomes have been found for time-averaged DAS28 
in an early-RA inception cohorts (189, 195) and CDAI in a large US-based registry 
(191).   This latter analysis suggested that a 10 point reduction in time-averaged 
CDAI was associated with a 21% reduction in risk of MACE (a composite outcome 
of MI, stroke of CV death).   An analysis of the South Korean KARRA cohort (196) 
showed that cumulative inflammatory burden, as measured by “area under the 
curve” ESR, predicted the presence of carotid plaque in a manner which was 
synergistic with conventional risk factors.   This implies that reduction of CVD 
risk in these patients requires both adequate disease control and management of 
conventional risk factors, as is the case in the non-RA population. 
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Figure 9 - Percentage of RA patients with detectable atherosclerotic plaque 
on carotid artery ultrasound, as stratified by the number of conventional CV 
risk factors and tertile of ESR-AUC (ESR area-under-curve).   Adapted from 
Im et al. Rheumatology 2015; 54(5):808-15. 
 
Based on the above findings, current EULAR guidelines (197) recommend 
multiplying estimated CVD risk by 1.5 when the patient has two of the following 
three clinical features: seropositivity for RF or ACPA; disease duration of >10 
years; or severe disease with extra-articular manifestations.   Recent data using 
the SCORE algorithm suggest, however, that this practice may still 
underestimate CVD risk in many patients.   In one Spanish cohort (198) of RA 
patients who were calculated to be low risk for CVD (SCORE of zero), 24% had 
ultrasound evidence of carotid artery plaque.   Additionally, in a Dutch RA 
inception cohort, use of the adapted SCORE calculator (i.e. with the CV risk 
multiplied by 1.5) tended to underestimate the observed rate of incident 
cardiovascular disease, especially in those with the lowest SCORE result (199). 
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1.4.1 Effect of DMARDS on CVD risk 
 
In accord with the hypothesis of inflammation driving cardiovascular disease, 
therapeutic suppression of RA disease activity has been shown to ameliorate CVD 
risk.   Most data concerning conventional DMARDS in this regard is derived from 
studies of methotrexate, with relatively little on other agents such as 
Sulfasalazine or hydroxychloroquine.   The effect of methotrexate therapy on 
CVD risk was first studied in a cohort of 1,240 RA patients, followed up for an 
average of 6 years (200).   The 588 RA patients receiving methotrexate 
demonstrated a 70% reduction in CV mortality compared to those not receiving 
methotrexate; no similar effect was found with other DMARDS, though few 
events were seen with these agents, and confidence intervals were wide.   A 
meta-analysis (201) suggested a 21% reduction in risk for total CVD (n of 
studies=10) and 18% reduction in risk for MI (n=5). 
 
1.4.2 Effect of anti-TNF therapy on CVD risk 
 
The advent of biologic therapies has been accompanied by a large number of 
studies examining the effect of these drugs on cardiovascular disease, with 
reference to a number of clinical or surrogate endpoints.   As the first biologics 
to enter clinical practice, the TNF inhibitors have been subjected to the greatest 
scrutiny.   Roubille (202) conducted a systematic literature of observational 
studies and RCTs dating from 2005 onwards examining the effect of anti-TNF on 
different CVD outcomes.   A total of 28 studies were analysed, with over 230,000 
subjects included.   Reductions in relative risk were found for MI (RR 0.59, [95% 
C.I. 0.36-0.97] n=6), stroke (RR 0.57 [0.35-0.92] n=6) and MACE (RR 0.30 [0.15-
0.57] n=4), with a non-significant reduction in risk for congestive cardiac failure 
(RR 0.75 [0.49-1.15], n=7).   In contrast, corticosteroids and non-steroidal anti-
inflammatory drugs (NSAIDS) increased the risk of cardiovascular events.   Of 
note, results were not uniform, and not all studies demonstrated reductions in 
risk with therapy.   However, is likely to be because not all patients who 
received anti-TNF displayed a clinical response to it.   One study drawing data 
from the British Society for Rheumatology Biologics Registry (BSR-BR) stratified 
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7,515 patients receiving anti-TNF depending on clinical response (response was 
defined as a fall in DAS28 of >1.2 after 6 months, or a fall of >0.6 which resulted 
in a DAS28 of ≤5.1) (203).   Responders in the registry had a myocardial 
infarction incidence of 3.5/1,000 patient years, compared to 9.4/1,000 patient 
years in non-responders, leading to an incidence rate ratio of 0.38 for responders 
relative to non-responders.   This lends further weight to the concept of 
inflammatory burden being a driver behind atherogenesis. 
 
1.4.3 Effect of tocilizumab on CVD risk 
 
Relatively little data exists regarding CVD risk with other biologics.   This is 
partly because of the difficulty inherent in detecting significant changes in 
outcomes which are not especially common.   Whilst nationwide prevalence of 
cardiovascular disease is high, an individual’s absolute risk may be low, requiring 
very large numbers of study recruits followed for a long time to generate enough 
events to confidently pronounce a statistically significant difference between 
groups.   The process of atherogenesis is also kinetically modest, and so the 
effects of a therapeutic intervention on atheroma formation (and thus CV 
events) may take several years to become apparent.   A 6-months randomised 
controlled trial, such as may commonly be used for new RA drugs, may therefore 
be a poor tool for evaluating CVD risk, and so cohort studies using clinic 
databases or disease registries (with large patient numbers and long periods of 
follow-up) are often preferred.   Pooled data from extension phases of 
tocilizumab RCTs (121), with mean treatment duration of 2.4 years, failed to 
demonstrate excess CVD risk from treatment.   A more recent post-hoc analysis 
of 5 RCTs and their extension studies (204) identified 50 incidences of MACE in 
14,683 patient years of follow-up (median duration of follow-up 4.5 years).   A 
multivariate analysis indicated that baseline DAS28 and TC/HDL-c ratio were 
independently associated with MACE.   A greater reduction in DAS28 by 24 weeks 
was associated with a smaller incidence of MACE, though no association was seen 
for changes in serum lipids or ESR.   Unfortunately, the nature of the analysis 
meant no comparison of MACE risk in placebo-treated patients was possible.    
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There is, however, evidence in favour of IL-6 blockade from large-scale genetic 
studies.   Two consortia (205, 206) performed Mendelian randomizations, 
studying the effect of a single nucleotide polymorphism (SNP) (Asp358Ala) which 
increases proteolytic cleavage of mIL-6R and subsequent loss of IL-6R from the 
surface of leukocytes and hepatocytes.   This leads to reduced IL-6 signalling on 
these cells, and subsequently higher serum IL-6 and lower CRP and fibrinogen.   
Possession of this SNP led to per-allele reductions in CVD risk of 5% and 3.4% 
respectively.   Whilst these effects appear modest, this is likely to be a result of 
the much lower levels of IL-6 signalling in these populations compared to 
patients with RA, and the correspondingly greater reduction in IL-6 signalling 
following tocilizumab which one would see in RA.   Additionally, the very large 
numbers of patients and events in these analyses permit a strongly statistically 
significant result.   Extrapolation of these results to tocilizumab is not without 
risk, however, as the Asp358Ala SNP reduces only cis-signalling, whilst 
tocilizumab blocks both soluble and membrane-bound forms of the IL-6R and 
thus also blocks trans-signalling.   Trans-signalling blockade may therefore lead 
to clinical consequences not seen in the Asp358Ala population. 
 
1.4.4 Effects of other agents on CVD risk 
Relatively little data exists on the effects of other biologic therapeutics on CVD 
risk in RA.   The only source for information regarding CVD risk of other biologic 
agents appears to be a retrospective interrogation of the US Medicare database, 
which provides medical insurance cover for more than 90% of US residents over 
65 years of age (207).   With almost 75,000 patient years of follow-up, this study 
suggested that anti-TNF drugs were associated with an increased risk of MI 
compared to abatacept, and that tocilizumab had the lowest risk of a composite 
outcome of acute MI or coronary revascularization.   Tocilizumab was in fact 
associated with a high risk of MI in biologic naïve patients, though this had broad 
confidence intervals due to low numbers (only 11 instances of MI in the biologic-
naïve population).   Whilst the analysis adjusted for a variety of cardiovascular 
risk factors, confounding by “contraindication” (i.e. tocilizumab being avoided 
in patients at high risk of CVD due to its perceived worsening of lipid profiles) is 
a risk in this retrospective analysis.   One other prospective observational study 
(208) assessed markers of CVD risk (but not cardiovascular events) in 36 patients 
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commencing abatacept, rituximab and tocilizumab.   Arterial stiffness, as 
measured by pulse wave velocity, was reduced at 3 months by tocilizumab and 
12 months by rituximab. 
1.4.5 Potential mechanisms behind CVD in RA 
 
There are several proposed mechanisms for how high-grade inflammation, as 
seen in RA, may contribute to accelerated atherogenesis (209).   Inflammation 
can drive endothelial dysfunction and upregulation of adhesion molecules and 
platelet-activating agents in the vasculature, leading to a pro-thrombotic state 
and encouraging leukocyte migration into the intima.   Pro-inflammatory 
cytokines can also increase pro-oxidative stress, and thus oxidation of 
lipoproteins, and act on skeletal muscle or adipose tissue to increase insulin 
resistance.   As noted above, some of these parameters can be measured and 
used as surrogates for clinical CVD, and have been found to be prevalent in even 
early RA.   The extensive literature behind these mechanisms is beyond the 
scope of this thesis, but one crucial component to atherogenic effects of 
inflammation is its effects on lipid profiles, and how they may relate to the 
development of cardiovascular disease. 
1.5 Lipids and CVD in RA - the “lipid paradox”  
Several studies have attempted to compare lipid profiles in patients with RA to 
those of controls (210-216).   Although not all of these studies report consistent 
results, it is generally accepted that active RA leads to a fall in both LDL- and 
HDL-cholesterol levels (217, 218), This ‘lipid paradox’ phenomenon - the 
reduction in levels of serum lipids in a disease associated with increased CVD 
risks – is also seen in other autoimmune inflammatory diseases and sepsis, in 
which greater inflammatory burden is associated with lower levels of circulating 
lipids.   Consistent with these findings are reports from numerous studies of 
increases in serum lipid fractions with successful anti-inflammatory treatment, 
which will be discussed further in a subsequent section. Nevertheless, some 
studies have obtained conflicting results regarding total cholesterol, HDL-c, LDL-
c and triglyceride levels in RA; the inconsistencies might be explained by the 
small numbers included in the cohorts studied (usually less than 100 patients), as 
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well as the considerable demographic and disease-related heterogeneity 
between studies (for example, early versus advanced disease, active versus 
quiescent disease or male versus female). In addition, few placebo-controlled 
studies exist in this area, and on many occasions data was gathered 
retrospectively. 
1.5.1 Does dyslipidaemia in precede clinical RA?  
The findings described above raise the question of whether it is possible to 
discern a ’pre-rheumatoid’ serum lipid pattern, which might prove useful in 
early diagnosis of the disease and/or defining the risk of CVD in RA.   To address 
this question, van Halm et al. examined lipid profiles in samples from 79 blood 
donors who later developed clinical RA; on average, these patients had 4% higher 
total cholesterol, 9% lower HDL-c, AND 17% higher trigylceride levels compared 
with control samples matched for storage time, and donor age and gender (219).   
This lipid profile was apparent up to 10 years before the development of RA 
symptoms. More recently, the Rochester Epidemiology Project medical records 
linkage system was used to identify the lipid profiles of 577 patients with RA, 
from 5 years before until 5 years after diagnosis (220).   Despite having lower 
rates of statin use compared with the control population, the patients with RA 
displayed a mean reduction in total cholesterol (10%) and LDL-c (17%) in the 5 
years preceding diagnosis; no statistically significant change in HDL-c and 
triglyceride levels was observed, and thus the total cholesterol to HDL ratio 
progressively fell in patients with RA during the 5 years before diagnosis.  
1.5.2 Using lipid profiles to predict CVD in RA 
Given the seemingly paradoxical fall in LDL-c levels in a condition that associates 
with an increase in CVD mortality, the question arises: do levels of serum lipids 
predict CVD risk in RA, as they do in the normal population? Surprisingly, until 
very recently this question had not been widely studied.   In 2010 an analysis of 
the AMORIS cohort failed to demonstrate a significant relationship between TC 
and development of CVD (221).   The following year, however, a retrospective 
cohort study my Myasoedova et al. involving 651 patients investigated the 
associations between inflammatory markers, lipids and CVD risk.   This paper 
confirmed that the risk of developing CVD was increased in patients with a 
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higher inflammatory burden, with a lower total cholesterol to HDL-c ratio 
associated with risk (222).   Most interestingly, in contrast with the linear 
association seen in individuals without RA, the relationship between total 
cholesterol and CVD risk was represented by a U-shaped curve in patients with 
RA, with risk increasing at total cholesterol levels below 4 mmol/l. LDL-c 
displayed a similar but non-statistically significant relationship (Figure 10).    In 
both values the confidence intervals were wide, but exploratory analysis showed 
that in patients with ESR >25mm/hr, the risk of incident CVD was higher for 
patients with LDLc <1.5mmol/L compared to those with LDLc >2mmol/L (Figure 
11). 
 
 
 
Figure 10 - Hazard ratio for incident cardiovascular disease (shadow = 95% 
confidence interval) at different serum levels of total cholesterol and LDL-
cholesterol.   From Myasoedova et al . Ann Rheum Dis 2010; 70:482-487 
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Figure 11 - Hazard ratio for incident cardiovascular disease in patients with 
low LDL-c (thick line) or high LDL-c (thin line) at different levels of ESR.   
From Myasoedova et al. Ann Rheum Dis 2010; 70:482-487 
 
Subsequent, larger studies have replicated and refined these observations.   
Zhang el al also conducted a retrospective cohort study, though from a large US 
commercial healthcare plan, with complete data on over 20,000 patients with 
366 myocardial infarctions.   This showed a U-shaped relationship between LDL-c 
and MI, with a linear inverse relationship between HDL-c and MI (223).   Liao et 
al looked at data from another commercial database in the USA, enrolling 16,085 
RA patients and a total of 32,000 patient years of follow-up.   Here the end-
point was “major adverse cardiac event” (MACE), a composite of myocardial 
infarction, coronary artery bypass graft, coronary revascularization or stroke.   A 
U-shaped curve was demonstrated between MACE and LDL-c, though statistical 
analysis failed to yield a significantly increased odds ratio for all but the highest 
quintile of LDL-c (224).   Most recently, Navarro-Millan et al used data from the 
National Veteran’s Health Administration cohort to identify more than 37,000 RA 
patients (90% of whom were male, with mean age of 63 years), with 896 MIs and 
122 cardiovascular deaths.   In this study, a U-shaped curve was again 
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demonstrated for the association between LDL-c and MI (190).   Again, however, 
very broad confidence intervals were displayed, and no relationship was seen 
between LDL-c and cardiovascular death.   Reassuringly, and in keeping with 
previous results, there was an inverse relationship between HDL-c and MI, and a 
log-linear relationship between CRP and MI.   In these studies, statistical 
significance is rarely met, and confidence intervals tend to be broad.   
Nevertheless, the reproducibility of this data and its consistency with what is 
already known about lipidaemic changes in inflammation make it seem likely 
that there is at least a subset of RA patients who have significant inflammatory 
burden which leads to both elevated CVD risk and lower LDL-c levels.   
Intriguingly, these findings are mirrored in end-stage renal failure, which 
commonly manifests as a chronic inflammatory state. In a prospective study of 
800 patients starting dialysis, those displaying signs of inflammation or 
malnutrition (C-reactive protein [CRP] ≥ 10 mg/l, hypoalbuminaemia [serum 
albumin < 36 mg/l] or serum IL-6 ≥ 3.09 pg/ml) displayed higher CVD risk with 
reducing serum levels of total cholesterol (225).   Importantly, the opposite and 
anticipated relationship is seen in patients without these signs of inflammation, 
underlining the confounding effect of inflammation on CVD risk. 
 
1.5.3 The lipid paradox—potential mechanisms 
Many factors could influence lipid metabolism and increase cardiovascular risk in 
RA. These influences could include shared risk factors (such as smoking), genetic 
pathways, effects of therapeutics (corticosteroids, for example), or might 
reflect specific molecular interactions driven by the inflammatory process itself. 
The molecular factors that potentially drive the interaction between 
inflammatory disease and altered lipid metabolism are not entirely understood; 
however, several credible mechanistic pathways have come to the fore in recent 
years.  Logically, in evolutionary terms, immune defence, which requires high 
levels of both leukocyte cell division and death, protein synthesis, cell motility 
and host tissue responses to damage and repair, should be integrated with 
metabolic function, in order that appropriate energy and endocrine homeostasis 
is maintained at a time of ‘high demand’. Thus, cytokines might have direct 
effects on lipid metabolism, in the same way we know an acute inflammatory 
response alters carbohydrate metabolism and insulin resistance, and engenders a 
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hypercoagulable state.   It has been demonstrated in a cohort of post-operative 
patients that serum IL-6 levels correlated inversely with TC and LDL-c (226) 
whilst administration of exogenous IL-6 reduces serum TC and alters VLDL 
subclasses in humans (227, 228).   TNF-α and bacterial lipopolysaccharide (LPS) 
can achieve similar results (229).   Whilst this may confer survival advantage in 
the acute setting, such responses could become maladaptive in the context of 
chronic high-grade inflammation, such as seen in RA.    
Inflammation might also promote changes in the levels and composition of 
lipoprotein subfractions, which are not detectable using standard laboratory 
lipid profiling. Small, dense LDL particles - detectable on NMR spectroscopy - 
have been shown to cross the endothelium more easily and are more prone to 
oxidative damage than larger, less dense particles (230).   Elevated levels of 
these small LDL particles have been observed in severe active RA (216), although 
these findings remain controversial (217).   Conversely, small, dense HDL 
particles isolated from healthy individuals have been found to be effective at 
protecting LDL from atherogenic oxidation (and subsequent uptake by 
macrophages) .[KONTUSH2003] Furthermore, serum levels of these small 
particles are diminished in RA (216), a finding which has been associated with 
coronary calcification in one report (217). 
HDL from patients with RA has been observed to have impaired antioxidant and 
reverse cholesterol transport capacity, correlated with disease activity, 
compared with HDL-c from healthy individuals (231).   Interestingly, these 
functions of HDL were inversely correlated with serum myeloperoxidase activity, 
suggesting that the inflammation in RA might lead to oxidative modification of 
lipids that alters their properties and activities.   Moreover, a 2012 cross-
sectional study described low levels of the cardioprotective HDL-2 lipid 
subfraction in patients with RA (232).   The changes observed in HDL function 
can be so marked that a distinction is made between ’proinflammatory’ and 
‘anti-inflammatory’ HDL based on their antioxidative capacity.   A 
comprehensive proteomic analysis (233) demonstrated the proinflammatory HDL 
phenotype to be more prevalent with increasing RA disease activity and was 
associated with increased levels of molecules such as apolipoprotein J, 
fibrinogen, haptoglobin, serum amyloid A (SAA) and several complement factors, 
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and reduced levels of serum paraoxonase-1 (a hydrolytic enzyme which might 
protect LDL from oxidation (234), compared with patients with anti-
inflammatory HDL. As a consequence, in RA, the ability of HDL particles to 
protect LDL particles from oxidation might be impaired in the inflammatory 
state.    
Additionally, a variety of other lipoprotein-associated molecules might be 
altered in RA and, as a result, contribute to accelerated atherogenesis. 
Lipoprotein(a) (Lp(a)), has been shown to be elevated in the serum of patients 
with RA in comparison with control individuals (235).   Furthermore, in the 
PROCARDIS study (154), Lp(a) was strongly and independently associated with 
CVD, a finding supported by a meta-analysis.  Indeed, Lp(a) is probably a causal 
factor in CVD, as suggested by the observation that single nucleotide 
polymorphisms (SNPs) linked to higher Lp(a) lipoprotein concentrations are 
predictive of CVD (154).   In RA, group IIA phospholipase A2 (sPLA2-IIA) was 
positively and negatively correlated with plasma levels of small, dense LDL and 
small HDL particles, respectively, and has been linked to the increased uptake of 
small, dense LDL in tissues (216).   Furthermore, platelet-activating factor 
acetylhydrolase (PAF-AH), which circulates in complex with LDL and HDL, might 
have a variety of proatherogenic functions, including impairment of reverse 
cholesterol transport (236).   Thus, all these molecules are upregulated in 
inflammation or the acute-phase response and could contribute to CVD risk.    
1.5.4 Lipid modulatory effects of antirheumatic therapy 
Many data informing inflammation–lipid interactions have emerged since the 
advent of biologic therapies in the past decade. The increased research focusing 
on this association in part reflects increased interest and recognition of the 
clinical importance of this phenomenon, but is especially a consequence of the 
availability of these new therapeutic agents; biologic agents can be thought of 
as highly specific ‘molecular scalpels’, which offer unprecedented opportunity 
for molecular dissection of interactions between the immune system and 
metabolic processes in humans. Such studies thereby provide a window into the 
biological mechanisms underlying the lipid paradox and offer clues as how best 
to improve the clinical outlook for patients. 
 72 
 
 
 
1.5.4.1 Conventional DMARDs and corticosteroids 
A number of studies have addressed the effects of conventional DMARDs on lipid 
profiles.   Park et al. (237) performed a 1-year prospective cohort study that 
enrolled 42 DMARD-naive patients with RA.   In the 27 individuals (64%) who met 
the American College of Rheumatology (ACR) criteria for 20% improvement 
(ACR20), mean serum HDL-c increased by 21%, a change not seen in ACR20 non-
responders. Furthermore, in ACR20 responders, LDL-c, triglycerides and Lp(a) 
remained unchanged, and the LDL-c:HDL-c ratio decreased by 13%.   The 12-
month change in serum CRP levels inversely correlated with change in serum 
HDL-c (r = -0.38). Interestingly, no difference in 12-month lipid levels was 
observed between corticosteroid users (prednisolone <10 mg/day) and non-
users, suggesting that these changes were brought about by DMARDs reducing 
rheumatoid disease activity.   Boers and co-workers (238) analysed data from the 
Dutch Combinatietherapie Bij Reumatoide Artritis (Combination Therapy in Early 
RA; COBRA) study, which randomized 134 patients newly diagnosed with RA to 
receive sulfasalazine (2 g/day) as a monotherapy or in combination with 
methotrexate (7.5 mg/week), together with a high but rapidly tapered dose of 
prednisolone (starting at 60 mg/day and decreasing to 7.5 mg/day over 7 
weeks). Serum HDL-c levels increased by a remarkable 50% in both treatment 
groups, but this elevation was achieved much quicker in steroid users compared 
to non-users (16 and 40 weeks, respectively).   Despite a parallel increase in 
total cholesterol, the total cholesterol:HDL-c ratio fell.  The same study 
assessed data from a separate cohort of patients with established RA, and found 
that serum HDL-c levels were 25% lower in those with active disease compared 
with those in remission. Georgiadis et al. (239) treated 58 DMARD-naive patients 
with a steady dose of methotrexate (mean 15 mg/week) together with 
prednisolone (initially 7.5 mg/day, then tapered according to response), and 
compared them to 63 healthy controls.   In keeping with the findings of Boers 
and colleagues, after 1 year of treatment, elevations in total cholesterol and 
HDL-c levels were seen, although the total cholesterol to HDL-c ratio fell. Again, 
no change was observed in serum LDL-c, and a strong inverse relationship 
between CRP and HDL-c was observed. These findings have been complimented 
by the suggestion that methotrexate could impair foam cell formation in THP-1 
macrophages by promoting cholesterol efflux (240).   In addition, Munro et al. 
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(241) showed hydroxychloroquine to be associated with a reduced total 
cholesterol to HDL-c ratio when compared with intramuscular gold, a finding 
which was later replicated in a larger patient sample (242).  
Recently, post-hoc analyses of two studies have looked at lipid changes in the 
context of a more aggressive, “treat-to-target” strategy.   This is an important 
step as it reflects current best practice in clinical rheumatology, and 
subsequently more profound changes in disease activity may produce 
correspondingly larger changes in lipid profile.   The largest dataset yet 
available is derived from the Treatment of Early Rheumatoid Arthritis (TEAR) 
study, which was set up to compare different treatment strategies in early RA.   
755 patients, 90% of whom had RA duration of less than one year and 75% of 
whom were DMARD-naïve, were randomized to: methotrexate (MTX) 
monotherapy, escalating to MTX + Sulfasalazine + hydroxychloroquine (“triple 
therapy” if low disease activity was not achieved after 6 months; MTX 
monotherapy escalating to MTX+ etanercept; triple therapy from baseline; and 
MTX + etanercept from baseline.   459 participants had bloods taken for lipid 
analysis at baseline and 24 weeks (providing, essentially, three treatment 
groups, as the two “step-up” arms were on MTX monotherapy for the duration of 
this part of the study).   Significant elevations from baseline in TC, HDL-c and 
LDL-c were seen in all three groups, with no clear differences between the 
treatment groups.   No differences in lipid effects were seen between patients 
who achieved DAS28 <3.2 and those who did not; change in DAS28 correlated 
with change in LDL-c, but this effect did not persist in a multivariate analysis.   
However, change in LDL-c was significantly associated with change in CRP in 
multivariate analysis (243).   A recent paper reported on these patients after 
two years of follow-up (244).   At 48 weeks, cholesterol levels remained 
significantly higher than at baseline, and decreases in CRP, ESR and DAS28 all 
significantly associated with increases in TC, LDL-c and HDL-c after adjusting for 
conventional risk factors.   Groups were generally similar in their lipid profiles, 
though the magnitude of increase in LDL-c was less in the triple-therapy group; 
indeed, patients who escalated from MTX to triple therapy displayed reductions 
in LDL-c, perhaps due to the inclusion of hydroxychloroquine as per the results 
of Munro (241) and Morris (242). 
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The Targeting Synovitis in Early RA (TASER) study was another RCT (16), where 
111 patients with newly diagnosed, DMARD-naïve RA followed a “treat-to-target” 
protocol for 18 months as follows: MTX monotherapy; triple therapy; MTX + 
etanercept.  Oral corticosteroids were discouraged but bridging IA or IM steroid 
was given liberally.   The patients were randomized to standard treatment (with 
disease activity assessed clinically) or additional assessment of synovitis with 
doppler ultrasound scanning (USS); in this second group, patients with a low 
DAS28 but active disease on USS had their treatment escalated as above.   
During the analysis of the study, I had the opportunity to perform a post-hoc 
analysis of lipid profiles in this cohort.   After exclusion of patients taking 
statins, etanercept or oral steroid, a total of 48 patients had lipid data at 
baseline and 18 months.   In contrast to TEAR, no change was seen in TC or LDL-
c.   However, HDL-c increased by an average of 22%, with a subsequent fall in 
mean TC/HDL-c ratio.   LDL-c levels at baseline correlated modestly with CRP 
(r=-0.36).   A preliminary version of this analysis was presented at the EULAR 
2013 congress in poster form, which can be found in Appendix B.    These studies 
allow us to conclude that conventional DMARD therapy is capable of increasing 
HDL-c, though the evidence for LDL-c being influenced by DMARDS is less 
consistent. 
1.5.4.2 TNF-α blockade 
A wealth of data is now available concerning the effects of TNF inhibition, 
particularly from national registries for biologic agents. Despite initial concern 
about potentially serious adverse effects of these potent anti-inflammatory 
agents, evidence now demonstrates a substantial mortality benefit for patients 
who respond clinically to them (203).   A number of studies have investigated 
lipid profiles after treatment of RA with biologic anti-TNF therapy. In 2011, van 
Sijl et al (245) published a meta-analysis of 15 studies, involving a total of over 
700 patients with RA, with disease duration ranging from 1 to 20 years, treated 
between 2004 and 2010.   Most patients received infliximab, and the majority of 
studies included patients on concurrent methotrexate and corticosteroids.   
Using multivariate linear mixed models, van Sijl and colleagues estimated lipid 
levels at various time points from baseline until 6 months after cessation of 
therapy, and found that 5 of the 15 studies observed considerable increases in 
serum levels of TC and, generally, serum triglyceride levels also increased.   
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Furthermore, 9 of 14 studies that included assessment of serum HDL-c levels 
showed marked increases in serum HDL-c.   Taken together, these data resulted 
in a summary estimate that a 10% increase in total cholesterol and a 7% increase 
in HDL-c occur within 6 months of TNF-blockade.   Interestingly, serum HDL-c 
levels seemed to rise rapidly and plateau by 6 weeks, whereas total serum 
cholesterol continued to rise steadily for up to 6 months in studies with this level 
of follow-up (Figure 12).   A more recent meta-analysis, (246) which included 
data from some different studies, also showed increases in total cholesterol and 
HDL-c levels, without change in serum LDL-c concentrations or the total 
cholesterol to HDL-c ratio. 
 
 
Figure 12 - Change in serum TC (left) and HDL-c (right) through 26 weeks of 
treatment with anti-TNF agents.   Data derived from a meta-analysis of 15 
studies.   Graphic adapted from Robertson et al. Nat Rev Rheumatol 
2013;9(9):513-23 
 
Although insufficient data was available to reliably assess changes in LDL-c or 
apolipoproteins in meta-analyses, several short-term studies have reported rapid 
increases in serum LDL-c or apoB levels after treatment with anti-TNF agents 
(247-249).   In addition, etanercept substantially reduced the amount of SAA 
within HDL particles over the course of a 3-month cohort study comprising 
patients with ankylosing spondylitis (250).   Moreover, infliximab therapy is 
capable of improving paraoxonase-1 activity, and thus the antioxidative capacity 
of HDL, regardless of serum HDL-c concentrations (251).   Evidence from a 
randomized trial suggests that TNF inhibition also leads to a dose-dependent 
reduction in serum Lp(a) concentrations in psoriatic arthritis (252).     
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1.5.4.3 IL-6 blockade 
Tocilizumab is currently the only licensed agent for IL-6 blockade in clinical 
practice.   I conducted a literature search which revealed eight clinical trials of 
tocilizumab which reported lipid changes (Table 1); elevations in serum total 
cholesterol, HDL-c, LDL-c and triglyceride levels (if measured) were universally 
reported (101, 102, 104-106, 110, 117, 123, 253).   Notably, effects on the 
atherogenic index were inconsistent, but increases in LDL-c levels by around 15–
20% were seen in multiple studies, which is consistent with IL-6-driven lipid 
changes observed in vivo and in vitro described earlier, although more detailed 
mechanistic studies would be of value.  
Tocilizumab therapy consistently had greater effects on lipid profiles than 
DMARDs such as methotrexate; however, in a head-to-head comparison, 
combination therapy of tocilizumab with methotrexate produced a numerically 
greater rise in total cholesterol levels than tocilizumab monotherapy (101).   
Furthermore, while the directional change in levels of lipids is consistent across 
therapies which block IL-6R or TNF pathways, the magnitude of LDL-c elevation 
seems greater with the former, as reported in the ADACTA head to head study 
(253).   ADACTA also identified reductions in HDL-associated serum amyloid A 
(SAA), secretory phosopholipase A2 (sPLA2), and Lp(a) which were significantly 
greater following tocilizumab compared with adalimumab. Of interest, two 
parallel genetic studies examined a SNP associated with IL-6R blockade, and thus 
lower IL-6R signalling in the general population (205, 206).   Although these 
studies did not show association of the SNP with lipid changes (probably as the 
study population had normal levels of inflammation, and so lipids were not 
altered by higher levels of systemic inflammation), both studies reported a lower 
risk of CHD in carriers of the IL-6R associated SNP.    
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Study 
name 
Study design Lipd changes observed in tocilizumab 
groups 
CHARISMA 
(2006)  
16 week, 359 patients 
Placebo and 7 
treatment arms 
TC, TG and HDL-c increased in all 
treatment groups.   TC:HDL-c ratio 
increased in 8 mg/kg tocilizumab. 
SAMURAI 
(2007)  
52 week, 366 patients 
Tocilizumab 
monotherapy or 
DMARDs  
TC, TG and LDL-c increased in 38%, 17% and 
26% of patients respectively.  
HDL-c increased to above ULN in 24% of 
patients; no change in TC:HDL-c ratio. 
OPTION 
(2008)  
24 week, 623 patients  
Tocilizumab   4mg/kg 
or 8mg/kg, or placebo 
8mg/kg: TC, HDL-c and LDL-c increased by 
0.9 mmol/l (18%), 0.1 mmol/l (7%) and 0.6 
mmol/l (20%), respectively 
TOWARD 
(2008)  
24 week, 1,220 
patients 
Tocilizumab 8mg/kg 
or placebo 
TC, HDL-c and LDL-c increased by 0.8 
mmol/l, 0.1 mmol/l and 0.5 mmol/l, 
respectively 
TC:HDL-c ratio increased by >30% in 12% 
tocilizumab group & 7% of placebo group 
AMBITION 
(2010)  
24 week, 673 patients 
Tocilizumab 8mg/kg 
monotherapy or MTX 
Increase TC to >240 mg/dl in 13.2% and 
0.4%, with no change in 24% and 46.8%, for 
tocilizumab and MTX groups 
LDL-c increased to >160 mg/dl in 3.1% and 
0%, with no change in 11% and 22%, for 
tocilizumab and MTX groups 
REACTION 
(2011)  
24 week, 229 patients 
study of tocilizumab  
± MTX 
As monotherapy, TC increased 12.9mg/dl 
(7%); with MTX, TC increased 17.7 mg/dl 
(9%) 
ADACTA 
(2016) 
8 week, 324 patients 
tocilizumab 8mg/kg 
or adalimumab  
TC, HDL-c and LDL-c increased by 0.8 
mmol/l, 0.1 mmol/l and 0.5 mmol/l 
respectively for tocilizumab; all changes 
significantly greater than adalimumab 
group. 
Table 3 - Overview of key phase III/IV tocilizumab studies reporting lipid 
outcomes 
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Whilst the above studies assessed changes in serum levels of cholesterol 
subfractions, novel methods of analysis have emerged which convey much more 
information about lipid profiles in vivo.   Nuclear magnetic resonance 
spectroscopy (NMR) is one such technique which uses variations in magnetic 
properties of different atomic nuclei to quantify molecules or particles, and has 
been widely used in analysis of lipoproteins.    The MEASURE study was a double-
blind RCT evaluating the effects of tocilizumab on serum lipids and associated 
molecules as measured by NMR.   132 patients were randomised to tocilizumab 
or placebo, with all participants converting to open-label tocilizumab after 16 or 
24 weeks.   The primary outcome data of MEASURE (254) showed that 12 weeks 
of treatment with tocilizumab did not lead to significant increases in either 
small, dense LDL particles or oxidized LDL (particles typically suspected of being 
pro-atherogenic); instead, elevated LDL-c was driven by increases in larger LDL 
particles.   In addition, tocilizumab led to reductions of greater than 30% in a 
variety of pro-atherogenic or pro-thrombotic factors including Lp(a), HDL-
associated SAA, sPLA2, fibrinogen and D-dimers; paraoxonase, an anti-oxidant 
thought to be atheroprotective, increased following tocilizumab.    Tocilizumab 
led to improvements in many surrogates for cardiovascular risk, and conferred a 
more anti-inflammatory phenotype to HDL, suggesting that it may be capable or 
reducing cardiovascular risk.   This hypothesis, however, remains to be tested in 
long-term cardiovascular outcome studies. 
1.5.4.4 Other biologic agents 
Limited data are available on the lipidaemic effects of the other biologic agents 
used in the treatment of RA. My literature search identified a small number of 
papers reporting the effects of treatment with rituximab.   A small pilot study 
(255) with 5 RA patients reported that after 16 weeks’ treatment, mean total 
cholesterol levels fell by 8.5% and HDL-c levels increased by an average of 35%, 
whereas LDL-c concentrations increased in 2 patients but fell in the other 3, 
with an overall mean reduction of 3%.   Interestingly, the results of a different 
small study (256) suggested HDL composition might also be favourably affected 
by rituximab therapy, with evidence for a reduction in HDL-associated SAA. A 
recent study from Russia treated 55 RA patients with rituximab and stratified 
them according to clinical response (257).   The patients who responded 
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clinically demonstrated increased of 23% in HDL-c, and reduction in the CVD 
surrogates of arterial stiffness and CIMT.       
1.5.4.5 JAK inhibition 
Phase III trials of tofacitinib in patients with RA, a dual JAK1–JAK3 inhibitor, 
have shown serum levels of LDL-c and HDL-c to be elevated by up to around 21% 
and 14% within 12 months, respectively (258).   These increases were 
substantially higher than the increases seen after treatment of patients with RA 
using the anti-TNF antibody adalimumab (Figure 13) in the ORAL Standard head–
to-head comparison trial, despite similar ACR20, ACR50 and ACR70 responses 
(75).    
 
 
 
Figure 13 - Effects on LDL-c and HDL-c following treatment of active RA with 
adalimumab, tofacitinib or placebo in a head-to-head RCT.   Adapted from 
Robertson et al. Nat Rev Rheumatol 2013;9(9):513-23 
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Similar results have been obtained from a phase II trial of tofacitinib in patients 
with active ulcerative colitis, with LDL-c and HDL-c levels both increasing dose-
dependently (259).   An earlier dose-ranging study of tofacitinib in RA supported 
the observations described above and demonstrated changes in levels of lipids 
within 2 weeks of commencing therapy, with levels reaching a plateau after 6-8 
weeks (103).   Preliminary results of phase II trials of other jakinibs, however, 
have been inconsistent; as such careful observation of cohorts will be 
mandatory, with addition data evaluated as they emerge.  Similarly as new 
kinase inhibitor studies (for example, regarding targeting of SYK) arise, 
examination of the potential effects of such agents on lipid biochemistry, and 
thereby the potential to modify ongoing vascular risk in patients with chronic 
inflammatory diseases, will be important.    
These findings suggest that, whereas suppression of inflammation partially 
underlies the increases in lipid levels, factors specific to different treatment 
modalities also operate and influence the degree to which lipid profiles change.   
Such therapy-specific factors could comprise as yet poorly defined pathways 
independent of those responsible for the primary disease modifying effects, 
which are thus implicated in driving lipid changes.(Figure 14) 
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Figure 14 - Schematic of lipid changes in RA over time, with a broad 
correlation between disease activity and lipids which is reversed to some 
degree by different disease-modifying therapeutics.   Adapted from 
Robertson et al. Nat Rev Rheumatol 2013;9(9):513-23 
  
1.5.5 Serum lipids and predicting CVD risk in RA – ongoing and 
future research 
Despite the advances in knowledge of the lipid–inflammation paradigm that we 
have described, substantial gaps in our understanding remain, which invite 
further study. Although the lipid changes seen after treatment of RA might 
reflect the variable ‘correction’ of an inflammatory dyslipidaemia, long-term 
mortality data are not yet available for many drugs, including biologic agents, 
and thus the cardiovascular effects of these agents cannot be confirmed. This 
point is particularly relevant for tocilizumab and the JAK inhibitors, which seem 
to have the most profound effects on LDL-c levels. The TRACE-RA study (Trial of 
Atorvastatin for the Primary Prevention of Cardiovascular Events in Rheumatoid 
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Arthritis), which aimed to investigate this issue, was terminated early for futility 
owing to the low numbers of cardiovascular events being recorded.   However, a 
specific CVD endpoint study is currently underway: ENTRACTE will compare 
tocilizumab with etanercept in RA patients with RA who have risk factors for CVD 
(ClinicalTrials.gov identifier NCT01331837).   The results of this study will 
usefully inform on several important issues pertinent to cardiovascular disease in 
RA. Nevertheless, such outcomes will be some time in coming and, in the 
interim, mechanistic studies in humans that integrate interventions in immune 
pathways with detailed metabolic examination of lipid biochemistry will be 
informative, especially as rodent models are poor surrogates for investigation of 
such interactions. This approach will benefit understanding not only in the 
context of inflammatory disease but potentially also in evaluating mechanisms of 
risk attribution in the ‘normal’ population.    Similarly the clinical use of lipid 
measurements in RA to predict CVD risk requires further development. At 
present, the most useful predictor of CVD seems to be the total cholesterol to 
HDL-c ratio; this value either does not change or only modestly ‘improves’ with 
successful anti-inflammatory therapy owing to concomitant rises in both total 
cholesterol and HDL-c levels in serum, with the latter sometimes being 
proportionally greater.  
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1.6 Objectives 
 
1. To analyse the long-term effects of IL-6 blockade on lipoproteins, and 
their relationship with disease activity, from analysis of data from the 
MEASURE study. 
2. To analyse the utility of a novel NMR-derived biomarker, GlycA, for 
assessing disease activity and changes in serum lipoproteins in RA 
following tocilizumab therapy. 
3. To provide mechanistic explanations of the findings of MEASURE by 
conducting KALIBRA - a basic science study in a cohort of human subjects 
with RA, examining the effects of tocilizumab on the kinetics of LDL. 
4. To provide mechanistic explanations of the findings of KALIBRA at the 
cellular & molecular level using in vitro techniques. 
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1.7 Hypotheses 
 
1. Changes in serum lipoproteins in IL-6 blockade are a result of reductions 
in RA disease activity, as quantified by clinical, biochemical and NMR-
derived measures. 
2. Elevations in serum LDL-c following IL-6 blockade are a result of reduced 
catabolism of LDL by macrophage foam cells. 
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2 The MEASURE study 
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2.1 Methods 
MEASURE was a randomised, multi-centre, placebo-controlled trial, comparing 
changes in lipid profiles following tocilizumab or placebo in patients with active 
RA despite methotrexate.   The study was performed in a double-blind manner 
for 24 weeks, with open-label tocilizumab therapy given to all participants 
thereafter.   The results of this trial after 12 weeks of therapy have already 
been published (254).   The data I had available to analyse for my thesis was 
different to that already published in three aspects.   Firstly, results were 
available up to 52 weeks, which allowed me to see if changes observed in the 
first 12 weeks were maintained over a longer follow-up period.   Secondly, 
results were generated from an updated NMR platform patented by LipoScience, 
who performed the original sample analysis.   This in theory would make the 
results more accurate and reliable.   Lastly, clinical and laboratory measures of 
disease activity were provided for each patient at each timepoint, including a 
novel NMR-based quantification of the acute phase response called GlycA.    
A description of the methods of the MEASURE study is available in the McInnes et 
al. 2013 manuscript.    For completeness, a summary of the methods is 
presented here, with particular emphasis on the analyses novel to my thesis. 
2.1.1 Patients  
132 patients with active RA (according to ACR criteria) of more than 6 months 
duration were enrolled.  Patients had active disease despite stable MTX therapy, 
requiring swollen joint count (SJC) and tender joint count (TJC) both ≥6, plus 
either CRP >10mg/L or ESR >28m/hr.   MTX was continued during the study, but 
initiation of lipid-lowering, glucose-lowering or antihypertensive drugs, or a 
change in dose of these drugs, were prohibited in-study and within 12 weeks of 
baseline measurements.   Glucocorticoids were permitted at doses ≤10mg/day; 
dose alterations were prohibited.   Patients who had failed a TNF-inhibitor 6 
months before baseline, or failed two TNF-inhibitors at any time, were 
excluded. 
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2.1.2 Procedures 
The study was conducted at 34 sites across the UK, USA and Canada.   Patients 
were randomly assigned by a voice response system, in a double-blind manner 
and in a 1:1 ratio, to TCZ 8mg/kg or placebo intravenously every 4 weeks with 
continuing stable doses of oral MTX.   Patients were then offered open label TCZ 
at 24 weeks, or at 16 weeks for those patients who had not reached 20% 
improvement in SJC or TJC by that point.    Blinded clinical assessments and 
blood sampling were performed at baseline and weeks 1, 2, 4, 8, 12, 16, 20 and 
24.   Open label assessments and sampling were performed every 12 weeks until 
week 104.    
2.1.3 Patient allocation 
Patient numbers through the study are illustrated in 
Figure 15.   Sixty-three patients were randomised to placebo+MTX and sixty-nine 
to TCZ+MTX.   One patient was misrandomised to placebo, and two in the 
TCZ+MTX group were excluded from my analysis (one with no baseline data and 
one with baseline data only).   Due to patients withdrawing consent, sixty and 
sixty-three patients in the two groups were included in the week 24 analysis; at 
week 52, the groups had fifty-three and fifty-five patients respectively. 
 88 
 
 
 
 
 
Figure 15 - Patient allocation and flow through the MEASURE study to week 
52. 
 
2.1.4 Assays 
Commercial assays were used to measure high sensitivity C-reactive protein 
(CRP) and ESR (Covance Laboratories, Indiana, USA).   Serum lipid subclasses and 
the GlycA signal were quantified by nuclear magnetic resonance (LipoScience, 
North Carolina, USA).   Further biomarkers not discussed in this thesis were also 
measured and detailed in print (254). 
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2.1.5 GlycA 
GlycA is a signal observed with NMR analysis of serum that can be numericalised 
to yield a serum ’level’ that is amenable to reliable and reproducible 
quantification for clinical purposes.  It is generated by N-acetyl-methyl groups 
on enzymatically glycosylated proteins, mainly α1-acid glycoprotein, 
haptoglobin, α1-antitrypsin, α1-antichymotrypsin and transferrin, and has been 
shown to reflect systemic inflammation in two large healthy cohorts (260, 261) 
and one RA cohort (262).   As the GlycA signal is a composite score generated 
from the carbohydrate side-chains of several circulating acute phase proteins, it 
exhibits less biological variability than CRP and is not subject to the same 
confounding issues with pregnancy, anaemia, serum protein concentrations, and 
abnormal red blood cell shape or size as is ESR.  It thus may offer substantial 
advantages over existing measures that are established in clinical practice.   
2.1.6 Statistical analysis 
The primary outcome measure was the change in small LDL particle number 
following TCZ therapy compared to placebo at 12 weeks.   For this study I 
analysed the secondary endpoints of changes in lipoprotein particles at 24 and 
52 weeks.   Values were displayed as mean ± 95% confidence interval for 
normally-distributed data, or median ± IQR for non-parametric data.   Between-
group comparisons were performed using student’s t-test or Wilcoxon Rank Sum 
test.   Changes from baseline were assessed using paired t-test or Wilcoxon 
matched-pairs test.  Correlation coefficients were calculated by Spearman’s r 
value as many of the data were non-parametric.   Normality of data was 
assessed by comparing population mean and median values, and inspecting 
values plotted on a histogram.   As in the original manuscript, for data up to and 
including week 24, the analysis used last-observation-carried-forward only in 
samples taken before escape therapy (i.e. week 12 values carried forward to 
week 24 in those who received escape therapy).    No other data was imputed.   
This meant that patients with missing values were excluded, and so different 
timepoints had different sample sizes as described in “Patient Allocation” 
above; in effect, the majority of my analysis was conducted on a per-protocol 
basis. 
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The original power calculations estimated that a sample size of 120 patients (60 
per arm) would be able to detect a difference of 30% in small LDL particles at 
week 12 in patients treated with TCZ compared to placebo.  
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2.2 Results 
2.2.1 Lipid particle changes 
A series of figures demonstrate the changes observed in lipid parameters over 52 
weeks of the study.   In the TCZ+MTX group, levels of large VLDL/chylomicrons 
and small VLDL particles (the latter making up more than half of the total 
VLDL/chylomicron mass) both increased significantly from baseline by the week 
2 assessment (Figure 16).   The degree of change was significantly different from 
that in the placebo+MTX group (Figure 17).   By week 52, the placebo group 
“caught up” with change in large VLDL but a significant difference remained 
between the groups for small VLDL (Figure 17). 
Total LDL particles increased with treatment, driven by rises in IDL and large LDL 
particles (Figure 18).   Again, these changes were apparent at the week 2 
assessment.   Small LDL particles did not change.   The between-groups 
differences were significant for large LDL but not IDL (Figure 19).   Notably, 
whilst there seems to be no clear difference in total or large LDL in Figure 18 at 
week 24, this is because the placebo+MTX group had higher median levels at 
baseline; hence Figure 19 illustrates the difference in percentage change from 
baseline.   In all parameters, there was no difference in percentage change 
between the groups at 52 weeks. 
Total HDL particles increased in the TCZ+MTX group, again with the bulk of the 
change seen by week 2, driven solely by an increase in small HDL particles 
(Figure 20).   This represented a significant difference in percentage change 
from baseline compared to the placebo+MTX group.   Once again, the 
placebo+MTX group displayed a “catch-up” pattern after switching to open label 
treatment at week 24, and no significant difference was seen between the 
groups at week 52 (Figure 21). 
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Figure 16 - Absolute values of VLDL/chylomicron particles from baseline to 
week 52.   * p<0.05  ** p<0.01  *** p<0.001   **** p<0.0001 in TCZ+MTX group 
compared to baseline. 
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Figure 17 - Percentage change from baseline in VLDL/chylomicron particles 
to week 52.              * p<0.05  ** p<0.01  *** p<0.001  **** p<0.0001 between 
groups. 
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Figure 18 - Absolute values of LDL particles from baseline to week 52.   * 
p<0.05  ** p<0.01      *** p<0.001  **** p<0.0001 in TCZ+MTX group compared 
to baseline. 
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Figure 19 - Percentage change from baseline in LDL particles to week 52.   * 
p<0.05  ** p<0.01  *** p<0.001  **** p<0.0001 between groups. 
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Figure 20 - Absolute values of HDL particles from baseline to week 52.   * 
p<0.05  ** p<0.01  *** p<0.001  **** p<0.0001 in TCZ+MTX group compared to 
baseline. 
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Figure 21 - Percentage change from baseline in HDL particles to week 52.   * 
p<0.05  ** p<0.01  *** p<0.001  **** p<0.0001 between groups. 
 
Mean VLDL particle size increased with treatment, with changes evident by week 
2 (Figure 22).   However, this change was only just statistically significant, and 
the degree of change from baseline was numerically but not significantly greater 
in the TCZ+MTX group (Figure 23).   Mean LDL size increased numerically (in 
keeping with the observation that large LDL particle number increased - Figure 
22) but neither this increase nor the difference in change between the two 
groups reached statistical significance (Figure 23).   Mean HDL size fell 
significantly by week 24 in the TCZ+MTX group, again with an apparent change 
by the week 2 assessment (Figure 22).   HDL size in the TCZ+MTX group fell by 
more than the placebo+MTX group, but the difference in change from baseline 
between the groups was no longer significant at week 52 (Figure 23), again 
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indicating “catch up” by the placebo+MTX group switching to open-label 
treatment. 
 
Figure 22 - Absolute values of mean lipoprotein particle size from baseline to 
week 52.   * p<0.05  ** p<0.01  *** p<0.001  **** p<0.0001 in TCZ+MTX group 
compared to baseline. 
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Figure 23 - Percentage change from baseline in mean lipoprotein particle 
size to week 52.           * p<0.05  ** p<0.01  *** p<0.001  **** p<0.0001 between 
groups 
 
 
2.2.2 GlycA & clinical response 
I used access to GlycA values and clinical data from each timepoint in two ways.   
I first assessed the performance of GlycA as a measure of RA disease activity, 
and then moved on to exploring relationships between measures of disease 
activity and the lipid values I have described above.  
2.2.2.1 Baseline parameters 
Data on age, sex and measures of disease activity at baseline in the placebo and 
treatment groups are shown in  
Table 4.   There were no significant differences between the groups in any 
parameter.   The cohort generally had high levels of disease activity, particularly 
illustrated by the high mean DAS28 and CDAI scores.  However, inflammatory 
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markers at baseline were more varied.   34 patients in total had CRP <5mg/L at 
baseline, with 11 patients having ESR <18mm/hr at baseline (the “normal” cut-
off ranges used by laboratories in our centre).   No defined normal ranges yet 
exist for GlycA.   Akinkuole et al (260), described a large healthy cohort with a 
median (IQR) GlycA value of 369µmol/L (327 - 416).   Only one other RA cohort 
(n=166) has been analysed so far for GlycA (262).   In this group, median (IQR) 
GlycA was found to be 398µmol/L (348 – 473).   Compared to the MEASURE 
cohort, this group had lower disease activity, as reflected in a median (IQR) CRP 
of 4.0mg/L (1.2 – 11) and median (IQR) ESR 15mm/hr (7 – 36); median DAS28-CRP 
was 3.09, with median DAS28-ESR 3.86. 
 
Placebo  + MTX 
(n=62) 
TCZ + MTX 
(n=68) 
p for 
difference 
Age, years (mean (range)) 56 (25-72) 56 (35-76) 0.92 
Female, n (%) 46 (74) 57 (84) 0.176 
CRP, mg/L 8.7 (3.9-18.1) 9.3 (5.1-26.9) 0.25 
ESR, mm/hr 38 (26.3-58) 38 (28-58) 0.64 
GlycA, µmol/L (mean (SD)) 476 (117) 484 (107) 0.68 
SJC (28 joints) 10 (8-16) 11 (7-16) 0.93 
TJC (28 joints) 16 (10-23) 16 (12-23) 0.86 
Patient global VAS, mm  63 (49-74) 63 (47-81) 0.48 
DAS28-CRP (mean (SD))  5.80 (0.95) 5.91 (1.06) 0.53 
DAS28-ESR (mean (SD)) 6.54 (1.01) 6.62 (1.05) 0.66 
CDAI (mean (SD)) 41.0 (14.1) 41.4 (14.4) 0.86 
 
Table 4 - Patient demographics and parameters of disease activity at 
baseline visit.  Data presented as median (IQR) unless otherwise indicated. 
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To assess GlycA’s function as a biomarker of RA disease activity, I combined the 
baseline data of all 130 participants into one cohort and correlated GlycA levels 
at baseline with other measures of disease activity.  These are outlined in  
Table 5.   GlycA levels correlated strongly with CRP, modestly with ESR, and not 
at all with joint counts or CDAI.   Correlation with DAS28 scores was statistically 
significant but numerically very modest.    
 GlycA  
 r P 
CRP 0.70 <0.0001 
ESR 0.44 <0.0001 
SJC -0.04 0.69 
TJC -0.11 0.20 
VAS 0.35 <0.0001 
DAS28-CRP 0.28 0.002 
DAS28-ESR 0.20 0.025 
CDAI 0.01 0.88 
 
Table 5 - Correlation between GlycA and markers of disease severity in 
whole cohort at baseline assessment (n=130) using Spearman’s coefficient. 
 
It could be argued that GlycA’s poor correlation with joint counts reduces its 
utility as a marker of disease activity.   For context,  
Table 6 shows that CRP also correlated only moderately with ESR, and that 
neither acute phase marker correlated at all with joint counts, patient’s visual 
analogue scale or CDAI.   Patterns of correlation between GlycA and acute phase 
markers or composite disease activity scores are illustrated in Figure 24. 
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CRP versus  r  p   ESR versus r  p  
ESR 0.36 <0.0001    
 
  
SJC 0.07 0.42 SJC 0.14 0.12 
TJC -0.01 0.89 TJC 0.05 0.61 
VAS 0.29 <0.001  VAS  0.19 0.03 
CDAI 0.12 0.19 CDAI 0.13 0.14 
 
Table 6 - Correlation between CRP or ESR and markers of disease severity in 
whole cohort at baseline assessment (n=130) using Spearman’s coefficient. 
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Figure 24 - Spearman's correlation coefficients between GlycA and 
measures of disease activity at baseline (n=130). 
 
2.2.2.2 Longitudinal behaviour of GlycA 
One advantage of a placebo controlled study was that a subset of patients (the 
placebo+MTX group) was followed up for several weeks with no active change in 
 104 
 
 
 
their treatment.   In effect, this allowed the above observations in active RA to 
be replicated by repeating correlations in this group using data taken at 2 and 12 
weeks after baseline.    
Table 7 shows that the strength of GlycA’s correlation with CRP and ESR 
remained approximately steady throughout 12 weeks of placebo treatment.   
The same was true for DAS28-CRP.   At week 12 GlycA’s association with swollen 
joint count became statistically significant but remained numerically modest; 
the same is true for DAS28-ESR at week 2, an association which fell and lost 
significance by week 12. 
  Week 0   Week 2   Week 12   
  r  p  r  p  r  p  
CRP 0.71 <0.0001  0.78 <0.0001  0.71 <0.0001  
ESR 0.40 0.002 0.58 <0.0001  0.47 <0.001 
SJC 0.03 0.81 0.23 0.074 0.31 0.016 
TJC -0.20 0.12 0.08 0.51 0.20 0.12 
VAS 0.22 0.081 0.16 0.21 0.09 0.51 
DAS28CRP 0.23 0.070 0.37 0.004 0.38 0.003 
DAS28ESR 0.11 0.38 0.34 0.007 0.12 0.37 
 
Table 7 - Spearman's correlation coefficient between GlycA and other 
measures of disease activity in the placebo group (n=62) at baseline, week 2 
and week 12. 
 
2.2.2.3 Baseline GlycA as a predictor of clinical response 
To test our hypothesis that GlycA would serve as a useful predictor of treatment 
response, receiver-operating characteristic (ROC) curves were generated.   Using 
data from the TCZ + MTX group (n62) I used CRP, ESR and GlycA measures at 
baseline and after two weeks of tocilizumab therapy as predictors of clinical 
response.   Since DAS28 scores (and therefore EULAR response rates) are 
frequently skewed by large changes in ESR or CRP with tocilizumab, for the 
purposes of this analysis I divided participants depending on whether or not they 
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reached a state of low disease activity, as measured by a CDAI of <10, at week 
24.   
Figure 25 shows that neither baseline (AUC = 0.60) or week 2 (AUC = 0.53) 
measures of GlycA functioned as a good predictor of CDAI status at week 24.   
CRP and ESR returned similar results.   A baseline GlycA of <430µmol/L predicted 
reaching CDAI low disease activity with sensitivity of 56% and specificity 70% 
(likelihood ratio 1.888).   This compares to a baseline CRP of <6.1mg/L 
predicting low CDAI with sensitivity of 63% and specificity 81% (likelihood ratio 
3.264) and baseline ESR of <24mm/hr predicting low CDAI with sensitivity of 25% 
and specificity 85% (likelihood ratio 1.679).   I concluded that GlycA was superior 
to ESR but less effective than CRP at predicting clinical response in tocilizumab-
treated RA patients.   However, none of these measures were particularly 
effective, and no baseline or week 2 measures returned sensitivity and 
specificity values strong enough to be considered useful in clinical practice. 
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Figure 25 - ROC curves for ability of CRP, ESR and GlycA levels at baseline 
(left) and week 2 (right) to predict attainment of CDAI low disease activity in 
the TCZ+MTX group (n=62). 
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Despite the strong association between GlycA and CRP, there remained several 
patients with discordant results for these two measures (i.e. one value high and 
one low).   I hypothesised that GlycA could provide extra information on disease 
burden in these patients.   To test this, I analysed baseline data from patients 
with CRP <5mg/L and stratified them into those with low or high GlycA.   For a 
cut-off GlycA point, I chose 416µmol/L as this was the upper quartile of values in 
a healthy, non-RA cohort.   This yielded 34 patients, 19 of whom had “low” 
GlycA (median 368µmol/L, IQR 317–398) and 15 with “high” GlycA (median 
447µmol/L, IQR 430-498).   There were no differences between the groups in 
baseline DAS28-CRP, DAS28-ESR or CDAI score, indicating that GlycA seemed to 
add little to CRP when ascertaining disease activity (Figure 26). 
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Figure 26 - Baseline values of (A) GlycA, (B) DAS28-CRP, (C) DAS28-ESR 
and (D) CDAI in patients with CRP<5md/L and low or high GlycA.   P value 
calculated by Mann-Whitney U test. 
 
2.2.2.4 Change in disease activity markers with treatment 
Changes in levels of GlycA, acute phase reactants, clinical measures of disease 
activity and composite disease activity scores are outlined below.   Figure 27 
shows absolute values from baseline to week 52.   Figure 28 shows the 
percentage change or value change from baseline to week 52, with asterisks 
denoting statistical significance for between-group differences at 24 and 52 
weeks.   Values are presented as mean ±95% C.I. or median ± IQR, depending on 
normality of data.  P values were generated using student’s t-test or Mann-
Whitney U test depending on normality of data.  
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Figure 27 - Measures of disease activity from baseline to week 52. 
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Figure 28 - Change in measures of disease activity from baseline to week 52. 
* p<0.05  ** p<0.01  *** p<0.001  **** p<0.0001 between groups. 
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As expected, CRP and ESR fell profoundly and rapidly in the TCZ+MTX group, 
reaching median values of 0.34mg/L and 7mm/hr by week 2, and staying at 
around this level for the duration of the study.   In a similar manner, median 
GlycA in the TCZ+MTX group fell from 464µmol/L to 315µmol/L at week 2, 
before plateauing at 290µmol/L by week 12.   As one would expect, joint counts, 
VAS and CDAI scores fell more gradually, with the lines of DAS28 scores sitting 
somewhere in the middle.   Significant differences between the groups in the 
degree of change from baseline were present in all parameters at week 24.    
2.2.3 Relationships between clinical and lipid measures 
I next set out to see if there were any discernible relationships between our 
observed changes in lipoproteins and those in disease activity, at baseline, and 
at week 24.   GraphPad Prism assists this process by allowing generation of 
correlation matrices: tables which lay out r values between different variables in 
a form which allows rapid presentation of quite a large amount of data.   The p 
values for each calculation are laid out in a separate, identically-formatted 
table.   This allows the user to scan for relationships, either individually or in 
patterns, which can then be interrogated further by e.g. scatter plot.   It is this 
technique which I will make use of in the following pages, as it allows the results 
of numerous correlation calculations to be summarised relatively cogently.   
Rather than simply duplicate every result in the form of a scatter plot, before 
correlations were calculated I decided that scatter plots would be generated at 
each timepoint for: small LDL particles (the primary outcome measure of the 
study); large LDL particles (as the LDL component that appeared to be most 
affected by tocilizumab therapy); and any other particles which appeared to 
have strong relationships in the correlation matrices. 
2.2.3.1 Relationships at baseline 
Spearman’s r values between acute phase markers (GlycA, CRP and ESR) and 
clinical disease scores (DAS28 and CDAI) in the whole cohort at baseline are 
outlined in Table 8 and Table 9.   Small LDL particle number did not associate 
with any clinical measures (Figure 29).   A significant but modest inverse 
correlation was seen between large LDL particle number and all clinical 
measures apart from ESR.   On reviewing the scatter plots, there did appear to 
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be generally lower lipoprotein levels in those with high CRP or GlycA (Figure 30).   
On the other hand, I did not think there was any clear visible pattern of 
relationship between large LDL and DAS28 or CDAI scores, despite the p values 
being below 0.05.   More impressive associations were observed with small HDL 
particle number, where the strongest correlation was seen with CRP (r=-0.47, 
p<0.0001)(Figure 31).   Again, the scatter plots of composite disease scores were 
much less convincing that those of CRP or GlycA.   Of note, r and p values for 
GlycA tended to be quite similar to those of CRP throughout the correlation 
matrix.   
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r values VLDL   LDL   HDL  
  Total Large Medium Small Total IDL Large Small Total Large Medium Small 
GlycA -0.01 0.00 -0.05 0.03 -0.08 -0.12 -0.28 0.14 -0.25 -0.15 0.19 -0.31 
CRP -0.14 -0.09 -0.18 -0.06 -0.14 -0.21 -0.27 0.12 -0.44 -0.17 0.14 -0.47 
ESR 0.04 -0.05 -0.10 0.13 0.00 0.04 -0.11 0.04 -0.22 -0.07 0.10 -0.23 
DAS28-CRP -0.03 0.09 -0.02 -0.04 -0.21 -0.11 -0.26 -0.02 -0.16 0.06 0.16 -0.35 
DAS28-ESR 0.01 0.08 -0.02 0.02 -0.16 -0.02 -0.19 -0.06 -0.06 0.13 0.16 -0.26 
CDAI 0.01 0.12 0.04 -0.04 -0.17 -0.06 -0.18 -0.05 -0.01 0.13 0.11 -0.19 
             
             
p values VLDL  LDL  HDL  
  Total Large Medium Small Total IDL Large Small Total Large Medium Small 
GlycA 0.93 0.97 0.59 0.76 0.36 0.16 0.001 0.11 0.004 0.078 0.027 <0.001 
CRP 0.11 0.28 0.037 0.50 0.11 0.017 0.002 0.17 <0.0001 0.058 0.11 <0.0001 
ESR 0.66 0.61 0.25 0.13 0.96 0.65 0.23 0.61 0.011 0.45 0.28 0.010 
DAS28-CRP 0.75 0.30 0.79 0.61 0.017 0.23 0.003 0.83 0.073 0.49 0.067 <0.0001 
DAS28-ESR 0.89 0.35 0.82 0.84 0.069 0.79 0.033 0.47 0.51 0.15 0.074 0.003 
CDAI 0.94 0.16 0.69 0.68 0.053 0.46 0.042 0.54 0.91 0.15 0.21 0.030 
Table 8 - Spearman's r value (top) and p value (bottom) for measures of disease activity and lipid NMR values at baseline in whole 
cohort (n=130).   Green = p<0.05.   Red = p<0.01 
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 values Particle size  
  VLDL LDL HDL 
GlycA 0 -0.15 0.08 
CRP -0.06 -0.17 0.06 
ESR -0.11 -0.07 0.08 
DAS28-CRP 0.11 -0.11 0.18 
DAS28-ESR 0.07 -0.06 0.21 
CDAI 0.13 -0.06 0.17 
    
    
p values Particle size  
  VLDL LDL HDL 
GlycA 0.97 0.084 0.35 
CRP 0.53 0.061 0.5 
ESR 0.22 0.42 0.34 
DAS28-CRP 0.23 0.19 0.035 
DAS28-ESR 0.41 0.49 0.017 
CDAI 0.13 0.48 0.05 
 
Table 9 - Spearman's r value (top) and p value (bottom) for measures of 
disease activity and mean lipid particle size at baseline in whole cohort 
(n=130).   Green = p<0.05.   Red = p<0.01 
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Figure 29 - Spearman's correlation coefficients between small LDL particles 
and measures of disease activity at baseline (n=130). 
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Figure 30 - - Spearman's correlation coefficients between large LDL particles 
and measures of disease activity at baseline (n=130). 
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Figure 31 - Spearman's correlation coefficients between small HDL particles 
and measures of disease activity at baseline (n=130). 
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2.2.3.2 Correlations at week 24 
Reflecting the analysis performed at baseline (above), the same correlation 
matrix-based approach was performed for the TCZ+MTX group (n=62) at week 
24.   R and p values are shown in  
Table 10 and Table 11.  In contrast to calculations at baseline, significant 
positive correlations were seen between small LDL particle number and GlycA 
(r=0.36, p=0.004) and ESR (r=0.32, p=0.012) though not CRP (r=0.12, p=0.36) or 
composite disease activity scores.   Scatter plots in Figure 32 for GlycA and ESR 
showed the majority of patients had low values for both particle number and 
inflammatory markers; I was not personally convinced of a strong relationship in 
either graph.   None of the relationships with large LDL particles appeared 
significant (Figure 33). 
In contrast to the baseline results, at week 24 small HDL particle number 
seemed to correlate more strongly with DAS28 and CDAI scores.   Review of the 
scatter plots in Figure 34 suggested a real relationship with composite scores but 
with significant variation around the regression line.   Whilst CRP showed a 
significant relationship (r=0.30, p=0.020), conclusions must be drawn cautiously 
as only a few participants had elevated CRP by this point.   Nevertheless, the 
few that did have elevated CRP tended to have lower small HDL particle 
numbers.  
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r values VLDL       LDL       HDL  
  Total Large Medium Small Total IDL Large Small Total Large Medium Small 
GlycA 0.18 0.14 0.30 0.07 0.22 0.09 -0.18 0.36 0.13 -0.10 0.16 0.10 
CRP -0.10 0.00 -0.02 -0.17 0.00 -0.05 0.01 0.12 -0.08 0.12 0.15 -0.30 
ESR 0.05 0.04 0.09 0.02 0.14 0.00 -0.15 0.32 -0.09 -0.03 0.02 -0.06 
DAS28-CRP -0.13 0.04 -0.07 -0.16 -0.12 -0.16 0.04 -0.08 -0.22 0.12 0.08 -0.50 
DAS28-ESR 0.01 0.07 0.04 -0.01 -0.04 -0.09 -0.08 0.06 -0.12 0.07 0.13 -0.38 
CDAI 0.03 0.19 0.05 -0.02 -0.10 -0.01 -0.01 -0.09 -0.11 0.09 0.06 -0.40 
             
p values VLDL       LDL       HDL  
  Total Large Medium Small Total IDL Large Small Total Large Medium Small 
GlycA 0.16 0.29 0.017 0.61 0.078 0.50 0.16 0.004 0.32 0.45 0.20 0.42 
CRP 0.45 0.99 0.89 0.20 0.97 0.70 0.94 0.36 0.56 0.35 0.25 0.020 
ESR 0.72 0.74 0.49 0.89 0.27 0.98 0.23 0.012 0.49 0.84 0.89 0.64 
DAS28-CRP 0.30 0.73 0.60 0.21 0.34 0.23 0.74 0.55 0.08 0.37 0.54 <0.0001 
DAS28-ESR 0.94 0.56 0.78 0.95 0.76 0.50 0.53 0.62 0.33 0.56 0.31 0.002 
CDAI 0.80 0.14 0.69 0.90 0.44 0.94 0.93 0.51 0.38 0.47 0.62 0.001 
 
Table 10 - Spearman's r value (top) and p value (bottom) for measures of disease activity and lipid NMR values at week 24 in 
TCZ+MTX group (n=62).   Green = p<0.05.   Red = p<0.01
 121 
 
 
 
 
r values Particle size  
  VLDL LDL HDL 
GlycA 0.2 -0.31 -0.08 
CRP 0.08 -0.06 0.16 
ESR 0.08 -0.2 0.03 
DAS28-CRP 0.08 0.05 0.24 
DAS28-ESR 0.04 -0.04 0.2 
CDAI 0.1 0.04 0.2 
    
    
p values Particle size 
  VLDL LDL HDL 
GlycA 0.12 0.013 0.51 
CRP 0.56 0.67 0.22 
ESR 0.52 0.11 0.82 
DAS28-CRP 0.53 0.71 0.06 
DAS28-ESR 0.78 0.78 0.11 
CDAI 0.43 0.74 0.11 
 
Table 11 - Spearman's r value (top) and p value (bottom) for measures of 
disease activity and mean particle size at week 24 in TCZ+MTX group (n=62).   
Green = p<0.05.   Red = p<0.01   
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Figure 32 - Spearman's correlation coefficients between small LDL particles 
and measures of disease activity at week 24 (n=62). 
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Figure 33 - Spearman's correlation coefficients between large LDL particles 
and measures of disease activity at week 24 (n=62). 
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Figure 34 - Spearman's correlation coefficients between small HDL particles 
and measures of disease activity at week 24 (n=62). 
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2.2.3.3 Correlations in degree of change at week 24 
Table 12 and Table 13 show a correlation matrix between change from baseline 
in disease activity measures and change from baseline in lipid parameters at 
week 24 in the TCZ+MTX group.   Small LDL particles appeared to fall in 
participants with large falls in GlycA, though the statistical values were modest 
(r=0.29, p=0.019) and no such relationship was seen for CRP, ESR or composite 
scores (Figure 35).       
Large LDL particle change correlated inversely with GlycA and ESR; no significant 
pattern was reached with CRP but the scatter plots for all three parameters 
appear to show increases in large LDL particle number in participants with large 
falls in their inflammatory markers (Figure 36).   The scatter plot led me to 
suspect that a relationship did exist between CRP and large LDL; to investigate 
this further I plotted change in large LDL in the top and bottom quartiles of CRP 
change.    Figure 37 shows that the degree of change in large LDL was no 
different in subjects with large fall in CRP (lowest quartile) compared to 
subjects with a modest fall or rise in CRP (top quartile).   No relationships were 
apparent between large LDL particles and composite disease scores. 
Small HDL particle levels tended to increase in participants with greater falls in 
disease markers.   Correlations for small HDL particles were significant for CRP 
and both DAS28 scores; non-significant numerical trends existed in other 
parameters.   Review of the scatter plots (Figure 38) confirmed a general trend 
of particle increase in those patients with greatest falls in CRP and ESR, but no 
clear relationship with CDAI. 
Large HDL particle change also showed clear inverse correlation with CRP, ESR 
and GlycA; Figure 39 clearly shows falls in large HDL associating with increasing 
inflammatory markers, and elevations in those with the greatest fall in 
inflammatory markers.   Figure 39 also reflects the complete absence of 
relationship between CDAI or DAS28 and large HDL particle change.
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r values VLDL   LDL  HDL  
  Total Large Medium Small Total IDL Large Small Total Large Medium Small 
GlycA -0.12 0.01 -0.08 -0.08 -0.02 -0.13 -0.35 0.29 -0.28 -0.33 0.05 -0.22 
CRP -0.21 -0.24 -0.15 -0.11 0.05 -0.04 -0.18 0.19 -0.34 -0.33 0.08 -0.31 
ESR -0.02 0.27 -0.09 0.00 0.06 0.23 -0.26 0.14 -0.27 -0.37 0.07 -0.24 
DAS28-CRP -0.26 -0.19 -0.14 -0.23 0.06 -0.06 0.00 0.06 -0.25 -0.03 0.13 -0.28 
DAS28-ESR -0.28 -0.13 -0.16 -0.22 0.10 -0.07 -0.13 0.19 -0.14 -0.09 0.19 -0.28 
CDAI -0.17 -0.12 -0.10 -0.15 0.00 0.04 0.01 -0.04 -0.18 0.01 0.09 -0.17 
             
p values VLDL  LDL  HDL  
  Total Large Medium Small Total IDL Large Small Total Large Medium Small 
GlycA 0.34 0.91 0.51 0.51 0.90 0.30 0.005 0.019 0.025 0.008 0.72 0.082 
CRP 0.098 0.058 0.24 0.37 0.72 0.75 0.16 0.13 0.007 0.010 0.55 0.013 
ESR 0.89 0.032 0.48 0.98 0.64 0.069 0.037 0.28 0.031 0.003 0.58 0.060 
DAS28-CRP 0.044 0.13 0.29 0.0716 0.67 0.65 1.00 0.63 0.049 0.81 0.31 0.030 
DAS28-ESR 0.029 0.31 0.21 0.087 0.43 0.57 0.33 0.14 0.27 0.46 0.13 0.027 
CDAI 0.19 0.34 0.44 0.25 0.99 0.75 0.94 0.76 0.15 0.94 0.49 0.17 
Table 12 - Spearman's r value (top) and p value (bottom) for change from baseline in measures of disease activity and change in 
lipid NMR values at week 24 in TCZ+MTX group (n=62).   Green = p<0.05.   Red = p<0.01
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r values Particle size  
  VLDL LDL HDL 
GlycA 0.14 -0.41 -0.06 
CRP -0.03 -0.18 -0.09 
ESR 0.11 -0.15 -0.12 
DAS28-CRP 0.02 0.03 0.07 
DAS28-ESR 0.03 -0.05 0.04 
CDAI 0 0.04 0.08 
    
    
p values Particle size  
  VLDL LDL HDL 
GlycA 0.29 0.001 0.63 
CRP 0.84 0.16 0.5 
ESR 0.4 0.26 0.36 
DAS28-CRP 0.88 0.81 0.56 
DAS28-ESR 0.84 0.72 0.78 
CDAI 0.99 0.73 0.52 
 
Table 13 - Spearman's r value (top) and p value (bottom) for change from 
baseline in measures of disease activity and change in mean particle size at 
week 24 in TCZ+MTX group (n=62).   Green = p<0.05.   Red = p<0.01 
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Figure 35  -Spearman's correlation coefficients between changes in small 
LDL particles and measures of disease activity at week 24 (n=62). 
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Figure 36 - Spearman's correlation coefficients between changes in large 
LDL particles and measures of disease activity at week 24 (n=62). 
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Figure 37 - Change in large LDL particle number at week 24 in top and 
bottom quartiles of CRP change.   Analysis by Mann-Whitney U test. 
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Figure 38 - Spearman's correlation coefficients between changes in small 
HDL particles and measures of disease activity at week 24 (n=62). 
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Figure 39 - Spearman's correlation coefficients between changes in large 
HDL particles and measures of disease activity at week 24 (n=62). 
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2.3 Discussion 
2.3.1 Lipoprotein changes 
The changes in lipoproteins seen in the TCZ+MTX group were similar to those 
previously published, with some exceptions.  For the primary outcome measure, 
small LDL particle number, I found no difference between the groups at 24 
weeks.   This mirrors the findings of the original analysis, and is reassuring on 
clinical grounds given that small, dense LDL particles are believed to be the 
most pro-atherogenic.   I also found a significant increase in large LDL particles; 
the original analysis reported a median increase of 19%, but also found a 13% 
increase in the placebo+MTX group that led to no significant difference between 
the groups.   I believe that my own findings are more believable given the 
evidence of LDL-c increases in tocilizumab phase III trials.    
Whilst small LDL particle number is generally accepted to be a marker of CVD 
risk, the clinical relevance of an increase in large LDL is not as clear.  This is 
despite them carrying more cholesterol mass than small LDL particles, and thus 
contributing more to measured LDL-c.   The largest prospective study to look at 
this issue (263) performed NMR analysis on serum from 27,673 healthy women in 
the Women’s Health Study.   They were then followed up for 11 years for 
incident CVD (n=1,015).   After adjustment for known risk factors, large LDL 
particle number did not predict incident CVD (HR of top quintile compared to 
bottom quintile 0.86, 95% CI 0.72-1.03, p=0.21) whilst small LDL particle number 
did (HR of top quintile compared to bottom quintile 1.76, 95% CI 1.41−2.18, 
p<0.001).  Other, smaller studies have generated similar results (264-266), 
including one in RA patients (217).   However, one cross-sectional study of 5,538 
subjects from the MESA study (267) suggested a positive association between 
large LDL particles and carotid IMT after adjusting for small LDL particle 
number, given that the two measures tend to inversely correlate.   Another 
study of 656 Alaskan Inuit suggested a contribution of large LDL to carotid 
plaque score, but not carotid IMT (268).    
Despite the balance of the literature as detailed above, some caution is required 
before stating that tocilizumab’s LDL-c increase is not pro-atherogenic.   This is 
for two reasons.   Firstly, it is not at all clear that NMR subparticle quantification 
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is superior to traditional lipidaemic risk factors for CVD risk quantification.   
Indeed, in the Women’s Health Study, LDL particle number’s ability to predict 
incident CVD became non-significant when added to two models which adjusted 
for (1) LDL-c, HDL-c and triglyceride, or (2) the total/HDL-c ratio.   Secondly, 
the trials above were not performed in the context of a high-grade inflammatory 
state such as RA, which of course generates counter-intuitive relationships 
between serum cholesterol and CVD risk.   My personal view is that these 
findings are both mechanistically explanatory and clinically reassuring.   The 
ultimate solution to this conundrum would of course be a study on RA patients 
with NMR lipoprotein quantification before and after tocilizumab with long-term 
follow up for CVD outcomes.   Whilst it would be interesting to use MEASURE for 
this purpose, the relatively small patient numbers (and thus likely low numbers 
of CVD events) make it unlikely that the MEASURE cohort could be effectively 
used in this manner. 
 I found no change in medium-sized VLDL, whilst the original analysis found an 
increase of 58% from baseline at 12 weeks.   The magnitude of change was also 
different; for example, large VLDL increased by median 62% at week 12 in the 
TCZ+MTX group in my analysis, compared to 206% in the original.   This is likely 
related to the use of a newer NMR platform at LipoScience for generating 
lipoprotein values.   The clinical significance of these findings is uncertain.  
Large VLDL particle number correlated strongly to serum TG and all VLDL 
particle sizes predicted increasing CVD risk with increasing concentration in the 
Women’s Health Study (263).   This may simply reflect the TG-induced increase 
in small dense LDL, though triglycerides did also increase following treatment in 
MEASURE (254).   In the Women’s Health Study no further analysis was 
performed on VLDL to adjust for other lipid measures.    
The significant increase in small HDL particles replicates the original analysis, 
though I failed to find any decrease in medium HDL.   RA patients have lower 
levels of small HDL particles than controls (216, 217); our observed increase can 
be seen as a normalisation of abnormally low levels.   Some studies indicate a 
protective association between small HDL on NMR and CVD, including one in RA 
(217), though others do not(263, 266).   Perhaps more important than the 
quantity of HDL particles is their makeup and function, as detailed in the 
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original report.   Unfortunately however I did not have access to any other HDL-
related parameters, such as SAA or paraoxonase. 
In all lipoprotein parameters, there was no difference in change from baseline 
between the TCZ+MTX groups and placebo+MTX at 52 weeks, demonstrating that 
the placebo+MTX group underwent the same lipoprotein changes as the active 
treatment group following 24 weeks of open-label tocilizumab.   This can 
reassure investigators that the changes observed in the TCZ+MTX group were due 
to tocilizumab rather than an unknown confounder between the groups.   It also 
makes it unlikely that any additional lipoprotein changes occur beyond 24 weeks 
of treatment, although as previous graphs have demonstrated the majority of 
changes appeared to take place by the week 2 assessment.   These observations 
are a reassuring validation of the integrity of the study and the original 
publication.    The one exception to the above is small VLDL particles; although 
the numerical values were identical at week 52, the two groups had different 
baseline values.   I believe this is likely a non-significant finding, as with thirty 
different parameters being analysed there is a possibility that one will be 
different purely by chance given an alpha of 0.05. 
2.3.2 GlycA as a marker of inflammation / RA activity 
Our results from analysis of the cohort at baseline show GlycA to be a reliable 
indicator of the acute phase response.   It correlated well with CRP and more 
modestly with ESR, and maintained these associations in repeated measures over 
12 weeks in the placebo+MTX group.   Similarly, GlycA values in our cohort were 
higher than those seen in a healthy cohort, and an RA cohort with less severe 
disease and lower ESR and CRP.   However, there was no relationship found with 
CDAI score.   It could be argued that the weakness of these associations is 
evidence against GlycA’s utility as a biomarker for inflammation.   I believe this 
is unfair, as I have demonstrated that ESR and CRP also correlate very poorly 
with CDAI, and with each other.   Indeed, it is for this very reason that the 
clinician performs multiple measures and compares and contrasts them, or uses 
them together in a composite score such as DAS28.   GlycA was also unable to 
act as a marker for ongoing disease activity in those patients with low CRP.   It 
would be interesting to see how well GlycA and other markers reflected disease 
activity as measured by another objective, quantitative marker of inflammatory 
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burden such as MRI or USS, as this may provide evidence of further utility as a 
biomarker.   Further studies would be required to evaluate this possibility.  
There remains a strong appetite amongst rheumatology researchers for a 
biomarker which can predict response to a given therapy.   Unfortunately, GlycA 
was unable to convincingly do so, though ESR and CRP did not fare much better.   
The ability of GlycA to predict radiographic progression could not be evaluated 
in this study as no such data were available.   
The sharp fall in GlycA following the start of tocilizumab treatment was similar 
to that seen with ESR and CRP, with median levels below that of a non-RA 
cohort.   This potential “supra-normalisation” implies that, like CRP, the GlycA 
signal is exquisitely dependent on IL-6.   This is perhaps surprising as other IL-6 
related peptides such as fibrinogen and CRP can be glycosylated but make 
negligible contributions to the overall GlycA signal (261).   Moreover, glycan 
processing is currently understood to be influenced by various inflammatory 
signals, including TNFα (269) and endothelial dysfunction (270).   On the other 
hand, the proteins whose N-acetyl-methyl groups generate the GlycA signal are 
well recognised as acute-phase proteins, and will inevitably be upregulated by 
IL-6. GlycA, like CRP or ESR, should therefore be interpreted with caution in the 
context of IL-6 blockade.  It may, however, be useful in quantifying disease 
activity in other conditions associated with excessive IL-6 signalling, and 
research is ongoing into GlycA’s behaviour in treatment-naive RA and vasculitis 
(M. Klearman, personal communication).   Moreover, it has been reported that 
GlycA has clinical associations with cardiovascular disease outcomes, for 
example ischemic stroke, independent of CRP and traditional cardiovascular risk 
factors.  These observations suggest that the two inflammatory markers be 
differentially regulated and may provide overlapping but distinct clinical 
information for patient evaluation.  
2.3.3 Clinical response in the cohort 
Of note, some steady improvement in clinical parameters was seen even beyond 
24 weeks.   I have certainly had personal experience in my clinical career of 
meeting RA patients on biologic agents who describe prolonged, gradual 
improvements in their condition beyond 6 months of therapy.   Alternatively, the 
 137 
 
 
 
phenomenon may have been in part due to the lack of imputed data in my 
analysis, as the seven patients who dropped out between weeks 24 and 52 had a 
mean week 24 CDAI of 23.4, compared to mean 19.2 in those that went on to 
complete 52 weeks; hence, their dropping out of the study probably contributed 
to lower week 36 and 52 median values.   Perhaps the simplest explanation is 
that from week 24, patients in the TCZ+MTX group moved from a blinded 
treatment regimen to open-label tocilizumab, and the knowledge of their 
current therapy generated a placebo effect.   
Reassuringly, the placebo + MTX group generally demonstrated little or no 
change in GlycA or other measures of disease activity until changing to open 
label tocilizumab at week 24.   From this point on, the curves tended to mirror 
the changes seen in the TCZ+MTX group, and there were no significant 
differences between the groups in the degree of change from baseline in any 
parameters at week 52.   One unexpected feature was the improvement in 
swollen joint count seen in the placebo+MTX group by week 2, and maintained 
until the week 24 crossover point.   This was responsible for the falls in DAS28-
CRP, DAS28-ESR and CDAI seen in this group during the placebo phase of the 
trial.   However, the change in SJC was much more pronounced in the TCZ+MTX 
group, leading to a statistically significant difference between the groups at 24 
weeks. 
2.3.4 Lipoprotein correlations  
High levels of CRP (typically greater than around 40mg/l) and GlycA seemed to 
drive down large LDL particle number at baseline, and strong responses to 
treatment (as measured by acute phase reactants) tended to lead to an increase 
in these particles.   The same seemed to be true of small HDL and CRP, ESR and 
GlycA, with low particle numbers in patients with high inflammatory markers.   
Large HDL particles also tended to increase in those with the largest falls in 
inflammatory markers after 24 weeks.   These observations support the 
hypothesis of IL-6 being a driver of lipid change in both the HDL and LDL 
compartments, rather than cholesterol elevations being an “off-target” effect of 
the drug. 
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Nevertheless, correlations between inflammatory and lipoprotein markers were 
generally modest, and were more commonly seen with acute phase reactants 
than CDAI or DAS28.  IL-6, as tocilizumab’s profound and rapid changes in 
inflammatory markers demonstrate, is the main driver of the acute phase 
response; this could lead us to conclude that IL-6 contributes more to 
dyslipidaemia in RA than other molecular or cellular components of the disease.    
This view is supported by the LDL changes seen with tocilizumab, which are of 
greater magnitude and consistency than seen in TNF-α blockade or conventional 
DMARDS.   Alternatively, part of the reason may simply be the greater 
reproducibility of biochemical tests compared to joint counts and visual 
analogue scale scores, which are subjective and prone to inter- and intra-
individual variation.    
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3 The KALIBRA study 
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3.1 Rationale 
The previous chapters have shown that there is abundant evidence of 
tocilizumab causing elevations in LDL-c, whilst the MEASURE study showed that 
this increase is predominantly in large LDL particles.   This increase appears to 
associate more with the acute phase response than joint counts or other clinical 
measures of disease activity. 
The mechanisms behind these observations, however, remain unclear.   One 
possibility is that tocilizumab increases production of LDL or one of the 
“upstream” apoB-containing lipoproteins by the liver.   This would potentially 
provide more substrate for atherogenesis, and so may increase cardiovascular 
risk in an already high-risk patient population.   Alternatively, the changes may 
be due to reduced catabolism of LDL, in the form of reduced consumption of LDL 
particles by peripheral tissues.   This hypothesis of increased LDL catabolism in 
certain patients has its origin in studies of hypertriglyceridemic patients in the 
1980s.   These studies showed a “bell-shaped curve” relationship between serum 
LDL-c and triglycerides.   As serum triglyceride levels rise to around 2mmol/L 
(i.e. towards the upper limit of the normal range), serum LDL levels steadily 
increase.   This appears to be because these LDL particles (which are derived 
from triglyceride-rich VLDL) themselves contain increased triglyceride.   This 
results in conformational changes in the apoB molecule, making it less able to 
bind to the LDL receptor (LDLr).   However, at triglyceride levels above 
4mmol/L, LDL levels begin to fall, because the LDL particles become abnormally 
small and more susceptible to removal by mechanisms independent of the LDLr.   
However, even more pertinently to our study, work in our centre with rabbits 
showed that suppressing reticuloendothelial lipoprotein uptake with IV ethyl 
oleate slowed catabolism of LDL which had been altered to resist LDLr-
dependent uptake (271).   Given the shared role of macrophages in the 
reticuloendothelial system, atherogenesis and inflammatory arthritis, it stands 
to reason that a similar scenario of altered LDL clearance may be at work in RA 
and, by extrapolation, following IL-6 blockade.   This is clinically important, as if 
tocilizumab reduces the fractional catabolic rate of LDL by the 
reticuloendothelial system, this would suggest a potential athero-protective role 
for IL-6 blockade in RA.   Such changes would be in keeping with the recognised 
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effects of systemic inflammation to suppress circulating levels of lipids, and the 
apparent ‘normalisation’ of several lipid parameters observed in MEASURE. 
We therefore hypothesised that IL-6 blockade with tocilizumab would reduce the 
removal rate of LDL-c, leading to qualitative and quantitative changes in LDL 
particles and in apoB levels. 
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3.2 Methods 
3.2.1 Patient recruitment  
KALIBRA was a multi-centre mechanistic study conducted in Glasgow.   Patients 
were recruited from three centres (Glasgow Royal Infirmary, Stobhill Hospital 
and Gartnavel General Hospital), whilst all study procedures took place in the 
Glasgow Clinical Research Facility (CRF) at the Western Infirmary, Glasgow.   
Patients were identified in RA clinics by consultant or trainee rheumatologists in 
or when attending for screening for biologic therapy by specialist nurses.   
Posters advertising the study were placed in RA clinic rooms and day wards 
(Appendix C).   In addition, I was able to look through details of patients who 
were scheduled to come for biologics screening, and so identify potential 
candidates, or exclude ineligible participants, in advance.  
Patients were required to meet the following inclusion criteria.   These ensured 
our cohort reflected the patients who would receive tocilizumab in routine 
clinical practice: 
 Diagnosed rheumatoid arthritis according to ACR 2010 criteria  
 Eligible for tocilizumab therapy according to NICE guidelines, i.e.  
 DAS28≥5.1 in keeping with severe active disease 
 Failure to tolerate or respond to two or more conventional DMARDs 
including methotrexate. 
 Age 25 to 75  
 Able to provide written informed consent  
 Absence of contraindication to biologic therapy 
 Suitable for tocilizumab therapy in the opinion of the consultant 
rheumatologist most directly responsible for their care 
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Exclusion criteria ensured that subjects did not have co-morbidities which might 
interfere with cholesterol metabolism and thus make interpretation of lipid 
parameters difficult: 
 Known familial dyslipidaemia 
 ApoE 2/2 homozygosity 
 Diabetes mellitus 
 Fasting total cholesterol >6.5mmol/L, or fasting triglycerides >3mmol/L 
 Treatment with any known lipid-lowering therapy, including statins, 
fibrates, bile-acid sequestrants or ezetimibe. 
 Pregnancy 
 Untreated hypothyroidism, or recent (6 weeks) change in thyroxine dose 
 Known hypersensitivity or contraindication to heparin 
 Concomitant use of oral glucocorticoids at a steady dose was permitted.   
Intramuscular steroid, a common method of steroid delivery in our area, 
was not permitted during the study.   Intra-articular steroids were 
permitted in exceptional circumstances (i.e. if refusal would cause 
unacceptable patient suffering or would result in withdrawal from the 
study) at a maximum cumulative dose of 40mg triamcinolone. 
 Concomitant use of DMARDS, NSAIDs or other analgesia at a steady dose 
was permitted. 
All patients were compensated for their time with £200 for participating in the 
study.   Travel expenses in the form of bus fares or taxi receipts were also 
reimbursed.   Patients were introduced to the study verbally by myself or a 
Rheumatology specialist nurse, and provided with an information leaflet 
(Appendix D).   After at least 48 hours, the subject would discuss the study with 
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me in person or over the telephone.   If the subject wished to participate, a 
screening visit was arranged where written informed consent was obtained.   
The consent form is shown in Appendix E.   At the screening visit, the patient 
was assessed for inclusion and exclusion criteria.   This included blood samples 
being drawn for inflammatory markers, lipids, fasting glucose and ApoE genetic 
testing. 
3.2.2 Procedures 
After screening, a four-week period was allowed if necessary for washout of 
previous biologic drugs such as anti-TNF agents.   The first 5-day kinetic study 
then took place, followed by a period of at least ten weeks to allow a minimum 
of three infusions of TCZ 8mg/kg.   The second kinetic study was carried out two 
weeks after the third TCZ infusion.   If the dosing schedule was interrupted, a 
further three consecutive infusions of TCZ were required before performing the 
second kinetic study.   
The labour-intensive nature of lipoprotein isolation, and the sample-processing 
capacity of our biochemistry lab, meant that one kinetic study could take place 
every two weeks.   Coupled with the timescale described above, this meant that 
recruitment was carefully staggered; patients were enrolled in “blocks” of no 
more than five at a time.   This was because by the time the fifth participant 
had completed their first kinetic study, ten weeks had passed since the 
enrolment of the first participant, who was then due their second kinetic study. 
3.2.3 Kinetic blood sampling rationale 
Kinetic studies are conducted using a stable deuterated isotope of the amino 
acid leucine (5,5,5-d3 leucine), a component of many proteins including apoB.    
When this is administered IV, d3-leucine is rapidly taken up by hepatocytes.  A 
substantial quantity is incorporated rapidly into newly-synthesised apoB 
molecules in a manner indistinguishable from native leucine.   The labelled apoB 
is used in the synthesis of VLDL-1 from chylomicron remnants, and remains with 
that particle as it is metabolised by lipoprotein lipase and hepatic lipase to 
VLDL-2, IDL and finally LDL.   At serial timepoints after administration, serum 
samples can be taken and mass spectrometry used to quantify the percentage of 
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apoB enrichment in d3-leucine.   Graphing the tracer/tracee ratio against time 
for different particles can yield a graph similar to Figure 40 below. 
 
Figure 40 - Example curves of labelled apoB in generation of VLDL-1 and 
transfer to VLDL-2. 
 
This example graph shows rapid incorporation of labelled apoB into VLDL-1, 
peaking at around two hours.   This peak then falls off as VLDL-1 is cleared and 
metabolised by LPL to VLDL-2, as reflected by the appearance of a VLDL-2 apoB 
peak at around 5 hours.   Levels of labelled VLDL-2 apoB will themselves fall in 
the same manner, and similar curves may be plotted for the downstream 
particles IDL and LDL, each with distinctive rates of rise (as new particles are 
formed incorporating the labelled apoB) and fall (as they are metabolised by 
lipolysis or cleared from the circulation).   Mathematical modelling can then be 
used to calculate the synthetic and catabolic rates of the apoB-containing 
lipoproteins; this process is outlines later. 
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3.2.4 D3-Leucine production 
Manufacture of the d3-leucine solution for the study was carried out by Tayside 
Pharmaceuticals (Dundee, UK) on behalf of NHS Greater Glasgow & Clyde.   
Leucine was suspended in glass vials of 45ml 0.9% sodium chloride at a 
concentration of 10mg/ml, and was stored in the dark at 0 – 5oC in the pharmacy 
unit of the Western Infirmary, Glasgow.    
3.2.5 Tocilizumab supply 
All tocilizumab used in the study was graciously provided without charge by 
Roche Products Ltd, under an agreement with NHS Greater Glasgow & Clyde.   
This was stored and reconstituted in the sterile products unit of Glasgow Royal 
Infirmary.   On completion of the study, patients who demonstrated a clinical 
response to the drug and who wished to continue were switched to NHS stock in 
either IV infusion or subcutaneous form, depending on the patient’s preference. 
3.2.6 Kinetic blood sampling timetable 
On day 1, the patient was admitted to the Clinical Research Facility (CRF) having 
fasted overnight.   At 08:00, an 18G or 20G cannula was inserted in the 
antecubital fossa and baseline blood samples were taken.   5mg/kg of d3-leucine 
was then administered as an IV bolus through a cannula in the other arm.   The 
patient remained in a semi-recumbent position throughout the day except for 
natural breaks.   Blood samples were taken in EDTA vacutainers through the 
cannula at the following timepoints: 2min, 5 min, 10min, 15min, 20min, 30min, 
45min, 1h, 1.5h, 2h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 11h, and 13h.   The patient 
was fasted throughout the day, and encouraged to drink plenty of water.   
Following the 10h sample, the patient was provided with a low-calorie 
(1,000kcal) meal.   The patient was allowed home after the 13h sample. 
Further fasting samples were taken on day 2 (24h, 36h), day 3 (48h), day 4 (72h) 
and day 5 (96h).   After the day 5 sample was taken, unfractionated heparin 
70IU/kg was administered as an IV bolus.  After 12 minutes, blood samples were 
taken through the cannula for hepatic lipase and lipoprotein lipase activity 
measurements, and stored on ice for transportation to the university 
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biochemistry laboratory.   It was calculated that for each kinetic study a total of 
266ml of blood would be drawn over the course of one week, with most of that 
volume coming in the first 12 hours. 
Three patients lived several miles away from the CRF, but in relatively close 
proximity to my own home.   These patients agreed to have blood samples on 
Tuesday – Thursday taken at their home address by me, with the samples being 
refrigerated and transferred the following day to our centre’s laboratory. 
3.2.7 Assessments 
Day 1 assessments for all patients included swollen and tender joint counts, 
patient’s global assessment by visual analogue scale (VAS) and physician’s global 
assessment by VAS, all of which I performed myself.   Blood samples were taken 
for FBC, CRP and ESR, which were processed in standard fashion at NHS GGC 
laboratories.   Samples were also taken for betaquant (direct measurement of 
TC, VLDL-c, LDL-c, HDL-c and TG), CETP activity, apolipoproteins, lipoprotein 
fraction composition, Lp(a) and insulin. 
3.2.8 Lipoprotein sample handling and processing 
Measurement of blood cholesterol, triglyceride and lipoprotein parameters were 
all performed by the University of Glasgow Centre for Vascular Biochemistry, in 
the Western Infirmary Glasgow, under supervision of Prof. Caslake.   Plasma 
from kinetic study blood samples was isolated by centrifugation.   Density-
gradient ultracentrifugation was then used to isolate the apoB-containing 
fractions – VLDL-1, VLDL-2, IDL and LDL.   ApoB from each fraction was 
precipitated, delipidated and measured by gas chromatography mass 
spectrometry (GCMS) to ascertain the proportion of tracer in apoB at each 
timepoint. 
3.2.9 Pooling of serum for subfraction analysis 
Serum samples were taken on day 1 of each kinetic study for Beta-quantification 
(Betaquant); this is the gold standard technique of directly measuring LDL-c by 
ultracentrifugation.   Values for total cholesterol, VLDL-c, HDL-c and 
triglycerides are also generated by this technique.    
 148 
 
 
 
However, it is recognised that there can be significant intra-individual variation 
in serum lipid levels throughout the 96 hours that the kinetic studies span, 
despite the patients fasting for at least 8 hours before each sample.   It was 
therefore not appropriate to use day 1 serum samples (readings reflecting one 
timepoint) for the lipid subfraction values which were to be used in generating 
kinetic data (readings spanning numerous timepoints across five days).   Lipid 
subfraction and some apolipoprotein values were instead obtained by taking 
small volumes of leftover serum from kinetic timepoint samples and pooling 
them.   For each kinetic study in each patient, three serum pools were 
constructed:  pool A was composed of samples from the first day; pool B from 
the second and third days; and pool C from the final two days.   Subfractions 
were then isolated from each pool, and the mean of the three values was used in 
subsequent calculations.   Specific calculation methods are discussed where 
relevant in the results section. 
3.2.10 Data recording  
Demographic data, clinical data, routine haematology and biochemistry 
assessments, and kinetic study sampling times were recorded on a paper case 
report form, generated as a collaborative effort between myself and the 
Robertson Centre for Biostatistics, University of Glasgow (Appendix X).   The 
form also included data on concomitant medications, adverse events, and dates 
of tocilizumab infusions.   During the study the case report forms were stored in 
the CRF in a locked filing cabinet, in a room only accessible by electronic pass.   
As each participant completed the study, their case report form was redacted of 
patient-identifiable information and passed to the Robertson Centre for secure 
storage.   Photocopies of the sheets containing kinetic study sampling times 
were forwarded to Prof. Caslake for use in kinetic modelling. 
3.2.11 Statistical analysis and compartmental modelling 
The primary outcome measure was the change in fractional catabolic rate of 
LDL.   Secondary outcome measures included serum lipoprotein compositions and 
levels of other proteins and particles as detailed above.   As much of the data 
was non-parametrically distributed (as determined by visual inspection of 
histograms and comparing sample means to medians), differences between 
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baseline and treatment were usually assessed by the Wilcoxon matched-pairs 
test.   Correlations were all measured by Spearman’s correlation coefficient.   
Raw data was stored on MS Excel, with statistical analyses and graphs generated 
on GraphPad Prism 6.  
Tracer/tracee ratios for apoB, together with apoB pool sizes, in each fraction 
are used to derive kinetic parameters in SAAMII modelling software (SAAM 
Institute, Seattle).   Some years ago, [DEMANT 1996] our unit generated a multi-
compartmental model for apoB metabolism, illustrated by Figure 41 below. 
 
 
Figure 41 - Schematic of the compartmental model of apoB synthesis and 
transfer down the delipidation cascade. 
 
Compartment 1 represents plasma leucine which is in equilibrium with an 
intracellular compartment (2).   As leucine is also taken up by other protein-
synthesising cells / pathways, compartments 3 and 4 are used to denote the 
uptake and release of leucine by protein pools in the body that have slow 
turnover rates.   Intracellular compartment 2 feeds directly into compartment 5 
which represents apoB synthesis and incorporation into lipoproteins in 
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hepatocytes.   VLDL-1 is present in compartments 6-8; VLDL-2 in compartments 
9-11; IDL in compartments 12 and 13; and LDL in compartment 14.   Whilst the 
majority of newly formed apoB is used for production of VLDL-1 from 
chylomicron remnants, previous similar kinetic studies have demonstrated that 
small amounts of apoB may be incorporated into any of the four lipoprotein 
classes. [PACKARD2000]   There is a delipidation cascade, driven by lipoprotein 
lipase and hepatic lipase, from compartment 6 to 7 to 9 to 10 to 12 to 14.   
Compartments 8, 11 and 13 represent “remnant” populations generated 
enzymatically, which are slowly cleared from the system without progressing 
further down the delipidation cascade.   From compartment 14, LDL-associated 
apoB may transfer to compartment 15 (representing extravascular LDL) or be 
excreted.   Using this model, rates of transfer from one fraction to the next can 
be calculated, as well as rates of de novo synthesis (between compartment 5 
and 6, 9, 12 or 14) and catabolic rate of LDL. 
3.2.12 Determination of sample size 
The primary outcome measure for KALIBRA was the fractional catabolic rate 
(FCR) of LDL-related apoB.   In normal subjects, the FCR is around 0.3 pools per 
day.   In those with increased catabolism due to hypertriglyceridemia in a 
previous study, the FCR is around 0.5 pools per day; this corresponded to a large 
decrease in LDL-c of around 1.5mmol/l.[PACKARD2000]   In contrast, a study of 
lipid kinetics using ciprofibrate showed an increase in mean LDL catabolic rate 
from 0.32 to 0.38 pools per day, in the context of a 22% fall in LDL-c.   This is 
broadly similar to the rises of around 20% in LDL-c seen in the tocilizumab phase 
III programme, and reflects a biologically significant change in FCR. 
Using these figures, we used a conservative change in FCR of around 0.05 pools 
per day to determine power.   A sample size of 15 subjects allows us to detect a 
difference in fractional catabolic rate of 0.05 with SD 0.05 at 90% power and 
alpha error at 5%.   This sample size is typical for kinetic trials of this type, and 
was felt to be achievable given the RA population available between the three 
recruitment sites.   Nevertheless, we realised that this could be an ambitious 
target given the stringent inclusion and exclusion criteria, and a study protocol 
which was potentially very inconvenient for patients.   We were therefore aware 
that that a sample size of 15 may be unattainable in the time available to carry 
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out the study, and so set an informal target of at least 10, and ideally 12, 
recruits.   The consensus of the investigators was that a sample size smaller than 
10 was unlikely to generate statistically significant data, and any “positive” 
results would be treated with scepticism on peer review.     
3.2.13 Ethical approval 
Ethical approval for the study was sought from the West of Scotland Regional 
Ethics Service (WosRES) Research Ethics Committee (REC) 3, reference 
12/WS/0171.   A meeting of the REC was attended by me on 26th July 2012, and 
provided a provisional opinion on 3rd August.   Questions and concerns 
articulated in the provisional opinion included: Amending the patient 
information sheet to include details on tocilizumab and heparin, the number of 
blood tests being performed, and the fact that samples would be stored for 
future research; how samples and confidential information would be stored; how 
adverse events would be documented; and concern from lay members of the 
panel on the quantity of blood being taken during the kinetic studies.   These 
were responded to in writing on 23rd August 2012, and REC approval was 
obtained on 4th September 2012.   
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3.3 Results – Clinical and Kinetic Outcomes 
3.3.1 Demographics 
Patients were recruited from summer 2013 through to winter 2014.   The final 
kinetic study was performed in February 2015, as in Table 14. 
Study # Source Screening 1st Kinetic study 2nd Kinetic study 
KAL001 GRI 22/07/2013 29/07/2013 04/11/2013 
KAL002 GGH 25/07/2013 12/08/2013 24/02/2014 
KAL003 ST 27/08/2013 09/09/2013 18/11/2013 
KAL004 GGH 12/09/2013 23/09/2013 09/12/2013 
KAL005 GRI 29/01/2014 17/03/2014 09/06/2014 
KAL006 GRI 03/03/2014 31/03/2014 23/06/2014 
KAL007 GRI 18/03/2014 14/04/2014 18/08/2014 
KAL008 GGH 19/09/2014 22/09/2014 08/12/2014 
KAL009 GGH 01/10/2014 13/10/2014 12/01/2015 
KAL010 ST 09/10/2014 27/10/2014 19/01/2015 
KAL011 GRI 30/10/2014 10/11/2014 02/02/2015 
KAL012 GRI 30/10/2014 24/11/2014 23/02/2015 
 
Table 14 - Recruitment sites and dates for KALIBRA participants.  GRI = 
Glasgow Royal Infirmary.   GGH = Gartnavel General Hospital.   ST = Stobhill 
Hospital. 
 
Demographic details of the patient cohort are shown in  
Table 15.   In keeping with observed patterns in our RA clinics, the majority 
were female and seropositive for either RF or ACPA, with a mean age of 55.   
Only four patients took concomitant MTX.   This is probably because patients 
intolerant of MTX were prescribed TCZ instead of anti-TNF; some patients were 
instructed specifically for TCZ by their consultant, whilst others were referred 
simply for “biologics screening” with no drug specified, and TCZ was decided as 
the drug of choice when I reviewed their details in the biologics clinic.   Two 
patients were on “triple therapy” (MTX, SSZ & HCQ) and two were on no 
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conventional DMARDS at all.   Three patients had previously failed or not 
tolerated at least one anti-TNF drug.  
Four adverse events were documented.   One patient developed grade 2 
neutropenia; neutrophil counts recovered spontaneously and re-challenge with 
full-dose TCZ was successful.   Three patients contracted infections.   One 
patient required hospitalisation for an abscess on her back following one dose of 
TCZ, but recommenced her drug after incision & drainage and successful 
treatment with antibiotics.   A severe adverse event (SAE) form was completed 
and the data shared with Roche as per their internal protocols.   One patient 
developed shingles; suspension of TCZ treatment was not required.    
KAL008 developed a paronychia after three doses of TCZ, requiring removal of 
her fingernail and suspension of TCZ.   As she was without treatment for several 
weeks, we were unable to re-treat her with TCZ and perform kinetic studies 
within the available time window, and she was withdrawn from the study.   
However, this was not classed as a SAE given that hospital admission was not 
required and no risk to life or long-term health resulted from the infection.   As 
no post-treatment data was collected for this patient, all analyses hereafter are 
carried out on a “per-protocol” basis using data from the remaining 11 patients. 
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Study   
# 
Age    
(y) 
Sex 
Weight 
(kg) BMI 
Systolic 
BP 
(mmHg) 
Prednisolone 
(mg/d) 
NSAID 
(Y/ N) 
MTX  
(mg/wk) 
SSZ 
(mg/d) 
HCQ 
(mg/d) 
LEF    
(mg/d) 
Previous 
Biologic? 
RF / ACPA 
+ (Y/N) 
KAL001 49 F 63 23.4 138 1 Y 7.5 
   
Y Y 
KAL002 58 F 78 29.0 137 
 
Y 
     
Y 
KAL003 46 M 88 26.3 161 
 
Y 
  
200 
 
Y Y 
KAL004 65 M 78 26.7 121 
  
10 4000 200 
 
Y 
 KAL005 61 F 60 24.3 129 7.5 
   
200 
  
Y 
KAL006 50 F 63 29.2 113 
       
Y 
KAL007 32 F 62 23.9 105 
 
Y 
 
2500 
   
Y 
KAL008 28 F 60 23.4 123 
  
20 
     KAL009 57 F 74 29.6 149 
 
Y 
  
400 10 
 
Y 
KAL010 51 F 48 17.2 146 
 
Y 
 
2000 300 
  
Y 
KAL011 60 F 69 26.3 156 
 
Y 12.5 2500 400 
  
Y 
KAL012 42 F 59 19.3 103 
 
Y 
 
3000 400 
  
Y 
Mean / 
% 
 
49.9 83% F 66.8 24.9 132 4.25 67% 12.5 2800 300 10 25% 83% 
 
Table 15 - Demographic data of KALIBRA cohort at baseline. 
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3.3.2 Clinical outcomes 
Changes in markers of disease activity after TCZ are shown in Figure 42.   At 
baseline, mean DAS28-CRP and DAS28-ESR were 5.16 and 5.61 respectively.   
Mean CDAI was 29.9.   As is typical for IL-6 blockade, CRP and ESR fell markedly; 
at the time of the second kinetic study, all patients had CRP of 2mg/l or less, 
and ESR of 10mm/hr or less.   Tender and swollen joint counts also improved, 
but to a lesser extent.   Mean DAS28-CRP and DAS28-ESR were 2.24 and 1.81 
respectively.   Mean CDAI was 8, with six patients reaching low disease activity 
(CDAI ≤10), and one reaching CDAI remission (CDAI ≤2.8). 
 
 
Figure 42 - Measures of disease activity pre- and post-treatment, presented 
as means ± SD.    * = p<0.05.  ** = p<0.01  *** = p<0.001   **** = p<0.0001 by 
paired t-test. 
 
 
156 
 
 
 
3.3.3 Serum cholesterol by betaquant 
Serum cholesterol levels were first analysed by betaquant.   This is the standard 
industry method of measuring serum LDL-c and uses a combination of 
ultracentrifugation and precipitation; the value given for LDL-c also includes 
cholesterol within IDL and Lp(a).   Betaquant values are shown in  
Table 16.   In accordance with previous studies, total cholesterol, HDL-c and 
LDL-c all increased.   A non-significant rise in TG was noted.  The TC / HDL-c 
ratio did not change. 
 Baseline Treatment  
 Mean 95% C.I. Mean 95% CI p 
TC 4.81 4.30 – 5.32 5.66 4.91 – 6.42 0.003 
VLDL-c 0.69 0.57 – 0.83 0.75 0.57 – 0.93 0.56 
LDL-c 2.90 2.46 – 3.34 3.40 2.72 – 4.09 0.014 
HDL-c 1.23 1.07 – 1.39 1.52 1.39 – 1.64 0.006 
TG 0.93 0.74 – 1.12 1.12 0.84 – 1.41 0.21 
TC/HDL-c 4.08 3.55 – 4.61 3.81 3.17 – 4.46 0.18 
 
Table 16 - Serum lipids as measured by betaquant at baseline and after 
treatment.  All values in mmol/L except TC/HDL-c ratio.   Analysis by paired 
t-test. 
 
3.3.4 Lipoprotein particle composition 
Before running mathematical models to generate kinetic data, it was first 
necessary to analyse the composition of VLDL-1, VLDL-2, IDL and LDL.   This is 
because particle composition is required to calculate apoB pool sizes for each 
subfraction; pool sizes are then required for the kinetic modelling stage.   Each 
particle contains phospholipid (mostly in the particle membrane); protein in the 
form of ApoB; free cholesterol; cholesterol ester; and triglyceride.    
Changes in the mass and composition of VLDL-1, VLDL-2 and IDL are summarised 
in Table 17.    VLDL-1 mass increased, driven by significant increases in all 
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particle constituents except protein, and especially triglyceride.   The 
proportions of the constituents did not change, though there was a non-
significant (p=0.076) fall in proportional protein content.   For VLDL-2 and IDL, 
no changes were observed in particle mass, individual constituent levels or 
constituent proportions.   Figure 43 shows the mean percentage composition of 
VLDL-1, VLDL-2 and IDL, demonstrating the progressive loss of triglyceride and 
proportional increase in cholesterol within the particles as they travel down the 
lipolytic pathway. 
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Mass  Protein  Free cholesterol  
  Baseline Treatment Baseline Treatment Baseline Treatment 
VLDL-1 24.8 44.9 2.6 3.6 1.5 2.5 
    p=0.009   p=0.13   p=0.056 
VLDL-2 24.4 31.2 3.7 4.9 2.1 3.4 
    p=0.28   p=0.24   p=0.24 
IDL 47.7 59.1 8.8 11.2 4.1 5.8 
    p=0.19   p=0.38   p=0.13 
 
 
 
       Cholesterol ester  Triglyceride  Phospholipid  
  Baseline Treatment Baseline Treatment Baseline Treatment 
VLDL-1 3.1 6.5 15.6 24.4 3.5 6.8 
    p=0.002   p=0.012   p=0.030 
VLDL-2 4.3 7.2 10.1 11.6 4.7 6.5 
    p=0.21   p=0.24   p=0.28 
IDL 14.9 20.4 6.1 6.2 8.3 11.2 
    p=0.15   p=0.95   p=0.090 
 
Table 17 - Median lipoprotein masses and constituents at baseline and after treatment.   N=11.   P values generated by Wilcoxon 
matched-pairs test. 
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Figure 43 - Particle compositions before and after TCZ in (A) VLDL-1, (B) 
VLDL-2 and (C) IDL. 
 
To my surprise, LDL mass did not increase significantly.   Free cholesterol 
increased modestly but no significant change was seen in cholesterol ester, 
which made up nearly 40% of the particle’s mass (Figure 44).   Similar results 
were seen when looking at the proportion of LDL that each constituent made up 
(Figure 45).   Figure 46 demonstrates constituent proportions in LDL. 
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Figure 44 - LDL mass and constituents at baseline and after treatment, as 
analysed by Wilcoxon matched-pairs test. 
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Figure 45 - Percentage composition of LDL particles, as analysed by 
Wilcoxon matched-pairs text. 
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Figure 46 - Particle composition before and after TCZ in LDL. 
 
The plots in Figure 44 show that, although median LDL-cholesterol ester (LDL-
CE) content did not change, individual responses varied significantly.   
Stratifying patients by their response showed four patients whose LDL-CE fell, 
and seven who accumulated LDL-CE.   On interrogating their clinical parameters, 
three of the four patients with falls in LDL-CE had low acute phase response at 
baseline, translating to very modest changes in CRP and ESR, despite having 
similar magnitudes of CDAI change (Table 18). 
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Change Baseline 
 
Change 
 
Change 
 
LDL-CE CRP ESR CRP ESR CDAI 
 
(mg/dl) (mg/L) (mm/Hr) (mg/L) (mm/Hr) 
 KAL012 -26.78 1 5 -0.5 6 -19.5 
KAL007  -15.99 55 102 -54.5 -101 -24 
KAL010 -12.58 2 20 -1.5 -18 -28.5 
KAL011 -8.15 1 5 -0.5 -3 -29 
KAL001 0.54 22 33 -20 -31 -21.4 
KAL002 10.73 2.8 17 -2.6 -15 -7.5 
KAL006 10.75 5 27 -3 -25 -13 
KAL004 14.07 29 55 -28.7 -45 -7 
KAL003 16.21 12 70 -11.8 -68 -16.9 
KAL005 23.83 21 31 -19 -26 -26 
KAL009 39.70 51 71 -50.5 -69 -17.5 
 
Table 18 - All participants sorted by change in LDL-cholesterol ester, with 
baseline and change clinical parameters. 
 
Plotting the change in LDL-CE with change in CRP or ESR showed a trend to 
inverse association.   Of note, KAL007 appeared to be acting as an outlier (Figure 
47, KAL007 circled in red).   With exclusion of KAL007, the associations with CRP 
and ESR become statistically significant (r=-0.7964, p=0.0075 and r=-0.8182, 
p=0.0058 respectively).   No association with CDAI change was seen with or 
without inclusion of KAL007. 
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Figure 47 - Scatterplots of relationship between change in LDL-associated 
cholesterol ester and: (A) change in CRP; (B) change in ESR; (C) change in 
CDAI.  Subject KAL007 is circled in red.   R and p values calculated by 
Spearman’s correlation coefficient. 
 
Stratifying the cohort according to their baseline CRP showed a trend towards 
greater increase in LDL-CE in those with CRP≥5mg/l compared to those with 
baseline CRP<5mg/l.   This difference became statistically significant on 
exclusion of KAL007 (Figure 48). 
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Figure 48 - Change in LDL cholesterol ester depending on baseline CRP.   
(A) All patients included.  (B) Excluding KAL007.   Analysis by student’s t-
test. 
 
To investigate the applicability of these observations to more conventional 
methods of serum cholesterol measurement, I repeated the above analyses with 
LDL-c as measured by Betaquant on day 1 of each kinetic study.   On exclusion of 
KAL007, trends towards associations were observed with CRP and ESR, though 
statistical significance was not reached (Figure 49).   Stratifying the cohort by 
baseline CRP showed a non-significant difference in change in LDL-c between the 
groups (mean increase 0.36 v 0.75mmol/L, p=0.14)(Figure 50). 
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Figure 49 - Scatterplots of relationship between change in LDL-cholesterol 
and: (A) change in CRP; (B) change in ESR.   Plots are shown with (left) and 
without (right) inclusion of patient KAL007.   R and p values calculated by 
Spearman's correlation coefficient. 
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Figure 50- Change in LDL cholesterol ester depending on baseline CRP.   (A) 
All patients included.  (B) Excluding KAL007.   Analysis by student's t-test 
with Welch’s correction. 
 
3.3.5 Lipoprotein Kinetics 
Appendix F contains a summary of kinetic modelling outcomes for all 
lipoproteins at baseline, after treatment, and in a normal population based on 
data held on file within out unit.   Parameters which changed significantly after 
tocilizumab are highlighted in red.      
Figure 51 illustrates changes in median total LDL production rate (PR – the sum 
of transfer of apoB from IDL and de novo LDL-associated apoB synthesis from the 
liver) and fractional catabolic rate (FCR).   Unexpectedly, and out of keeping 
with the general pattern of increase in LDL-c, PR fell significantly following 
tocilizumab treatment (763.8 v 442.0 mg/kg/day, p=0.002).   Median FCR, the 
primary outcome measure of the study, fell from 0.53 to 0.27 pools/day 
(p=0.006).   This equates to a median fall from baseline of 30%, as seen in Table 
19.   A graph showing pre-and post-treatment LDL kinetics, using subject KAL004 
as an example, can be found in Appendix G.   This clearly shows a slower 
increase in the tracer/tracee ratio following d3-leucine administration 
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(reflecting reduced production rate), followed by an elongated, shallow 
reduction in the ratio (reflecting reduced catabolic rate). 
 
Figure 51 - Production rate and fractional catabolic rate of LDL.   Analysis by 
Wilcoxon matched-pairs test. 
 
 
 
Production rate (mg/kg/day) 
 
 
Baseline Treatment Value change  % change 
     Mean 796.5 443.9 -352.6 -38.4 
SD 295.7 95.3 287.6 22.3 
Median 763.8 442.0 -348.8 -41.7 
p 
 
0.002 
  
 
 
 
Fractional catabolic rate (pools/day) 
 Baseline Treatment Value change % change 
     
Mean 0.54 0.32 -0.23 -33.08 
SD 0.29 0.17 0.28 30.05 
Median 0.53 0.27 -0.16 -30.19 
p  0.006   
 
Table 19 - Production rate and fractional catabolic rate of LDL.   P value 
generated by Wilcoxon matched-pairs test 
 
At baseline, LDL FCR correlated positively with CRP (r=0.74, p=0.012) though 
non-significantly with ESR (r=0.54, p=0.091).   No relationship was observed with 
CDAI (r=0.04, p=0.91) (Figure 52). 
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Figure 52 - Correlation of LDL FCR with measures of disease activity at 
baseline by Spearman's r. 
 
The degree of change in FCR did not correlate at all with the change in disease 
markers initially, but on removal of participant KAL007 there was a significant 
relationship with CRP (r=0.68, p=0.035) and a non-significant visual trend 
towards correlation with ESR (r=0.50, p=0.15).   Again, no relationship was 
observed with CDAI (Figure 53). 
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Figure 53 – Spearman’s correlation of change in LDL FCR with change in (A) 
CRP, (B) ESR and (C) CDAI.  Left: whole cohort; right: excluding KAL007 
 
LDL production rate did not correlate with LDL cholesterol as measured either by 
day 1 betaquant or LDL particle cholesterol ester content (LDL-CE).   This was 
the case at baseline, post-treatment and with degree of change (Table 20). 
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LDL-CE 
 
LDL Betaquant 
 
 Spearman's r p Spearman's r p 
LDL Baseline   
 
  
 production 
rate all inclusive -0.29 0.39 -0.23 0.50 
 
exc KAL007 -0.49 0.16 -0.44 0.120 
  
  
 
  
 
 
Degree of 
change         
 
all inclusive -0.37 0.26 -0.37 0.26 
 
exc KAL007 -0.32 0.37 -0.29 0.43 
  
  
 
  
 
 
Treatment       
 
all inclusive -0.08 0.82 -0.105 0.88 
 
exc KAL007 0.01 1.00 0.16 0.66 
 
Table 20- Correlations between LDL production rate and LDL cholesterol 
ester content or LDL-c betaquant 
 
However, LDL fractional catabolic rate correlated strongly with both measures of 
LDL cholesterol content at baseline (Figure 54).   The degree of change in FCR 
correlated strongly with LDL-CE, though less so with betaquant values (Figure 
55), and following treatment the FCR was a strong predictor of both LDL-CE and 
LDL-c by betaquant (Figure 56).   Excluding subject KAL007 made no difference 
to the pattern or magnitude of correlations. 
 
Figure 54 – Spearman’s correlation between LDL catabolic rate and serum 
LDL cholesterol levels at baseline 
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Figure 55 - Spearman’s correlation between change in LDL catabolic rate 
and serum LDL cholesterol levels. 
 
 
Figure 56 – Spearman’s correlation post-treatment between LDL fractional 
catabolic rate and serum LDL cholesterol levels. 
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3.4 Results – Secondary Outcome Measures 
3.4.1 LDL Subfractions 
LDL can be divided into subfractions (titled I, II and III) depending on their 
density; LDLI are the least dense, while LDLIII have the greatest density.   No 
significant changes were observed in any subfraction quantity (Figure 57).    
 
Figure 57 - LDL subfraction levels at baseline and after treatment, as 
analysed by Wilcoxon matched-pairs test. 
 
Stratification of the change in LDL subfraction mass by baseline CRP (CRP<5mg/l 
versus CRP≥5mg/l) showed no difference in any subfraction, with or without 
exclusion of KAL007’s data (Figure 58).   Similarly, Spearman’s correlation 
coefficient showed no association between change in LDL I, II or III and change in 
CRP (r=-0.15, p=0.65; r=0.07, p=0.84; r=-0.09, p=0.79 respectively) or ESR (r=-
0.14, p=0.69; r=-0.09, p=0.80; r=-0.10, p=0.78 respectively).   
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However, change in LDL III associated with change in CDAI (r=0.79, p=0.006), 
whilst LDL I and II did not (Figure 59).   In this case, patients with a fall in CDAI 
score of less than 20 points tended to increase their LDL III levels; those with 
greater falls in CDAI either lost LDL III or remained stable.   This observation was 
unexpected, given that a fall of 10 points in CDAI is still clinically significant, in 
contrast to the doubtful biological significance of a CRP fall of <5mg/dl.    
Stratifying the patients depending on their final CDAI score showed that those 
who reached CDAI low disease activity (CDAI <10 after treatment) had on 
average no change in LDL III mass; in the one patient who reached CDAI 
remission (CDAI <2.8 after treatment), LDL III fell by 12.1mg/dl.   In patients 
with CDAI ≥10 after treatment, LDL III mass increased by mean 38mg/dl.   
Comparing the groups with Welch’s corrected t-test did not reach significance 
(p=0.095 for LDL III), as shown in Figure 60.   Welch’s corrected t-test was used 
on this occasion as both parameters were normally distributed on this occasion, 
though the magnitudes of distribution were different. 
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Figure 58 - Change in serum LDL subfraction mass, stratified by baseline 
CRP, with data from KAL007 included (left) or excluded (right).   P value 
generated by Mann-Whitney test. 
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Figure 59 - Spearman's correlation coefficient between change in LDL 
subfraction mass and change in CDAI. 
 
 
Figure 60 - Change in LDL subfractions depending on post-treatment CDAI 
score.   Analysis by Welch's corrected t-test. 
 
 Determination of LDL I, II and III mass also permitted calculation of the 
proportion of total LDL mass made up of each of these subfractions.   Figure 61 
shows changes in the percentage of total LDL mass made up by the respective 
subfractions.   These broadly reflect the patterns of absolute value change 
shown in Figure 57 above, with no statistically significant differences seen after 
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treatment.   Given that patients who demonstrated value increase in a given 
subfraction invariably also demonstrated increase in the proportion of that 
subfraction, no further analysis was performed on this parameter. 
 
 
Figure 61 - Percentage of total LDL mass made up by each subfraction.   P 
value generated by Wilcoxon matched-pairs test. 
 
3.4.2 LDL Particle Diameter 
Peak LDL particle diameter and mean LDL particle diameter were ascertained.   
The average value of both measurements did not change, with individual peak 
and mean particle sizes rising or falling by less than 1% (Figure 62). 
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Figure 62 - Peak (left) and mean (right) LDL particle diameter.   P value 
generated by Wilcoxon matched-pairs test. 
 
3.4.3 Lipoprotein(a) 
Lipoprotein(a) (Lp(a)) serum levels varied markedly at baseline, but fell in all 
patients after treatment (Figure 63).   At baseline, Lp(a) levels associated 
positively but very modestly with CRP (r=0.62, p=0.045) and ESR (r=0.53, 
p=0.095).   A n inverse relationship was observed with CDAI (r=0.58, p=0.063) but 
on examining the scatterplot this did not seem as clear cut as the strong r value 
would suggest (Figure 64).   Similar, non-significant relationships were seen 
between change in Lp(a) and change in CRP (r=0.51, p=0.11), ESR (r=0.44, 
p=0.18) and CDAI (r=-0.54, p=0.094), as seen in Figure 65. 
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Figure 63 - Serum levels of Lipoprotein(a).   P value generated by Wilcoxon 
matched-pairs test. 
 
 
Figure 64 - Spearman's correlation coefficient between baseline Lp(a) and 
baseline CRP, ESR and CDAI. 
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Figure 65 - Spearman's correlation coefficient between change Lp(a) and 
change CRP, ESR and CDAI. 
 
3.4.4 Apolipoproteins 
Serum levels of apolipoproteins at day 1 of each kinetic study, as measured by 
immunoturbidimetry, are shown in Table 21 below.   Significant increases were 
seen in the HDL-associated ApoAI and ApoAII, in keeping with observed increases 
in HDL-c.    
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  Baseline  Treatment  Change (%)    
  Median IQR Median IQR Median p   
    
 
  
 
  
 
  
ApoAI 115.4 100.7 - 124.2 148.5 141.7 - 174.4 28.5 <0.001 *** 
ApoAII 25.0 20.3 - 28.1 35.3 32.0 -38.4 41.3 <0.001 *** 
ApoB 76.0 51.6 - 78.2 103.1 92.3 - 118.3 54.1 0.002 ** 
ApoCII 1.4 0.5 - 2.9 3.6 2.3 - 4.7 100.0 0.042 * 
ApoCIII 5.1 4.0 - 8.3 8.1 5.9 - 11.7 28.5 0.22 ns 
 
Table 21. Median serum levels of apolipoproteins at baseline and after 
treatment.   All values mg/dl unless specified. 
 
A correlation matrix of apolipoproteins with clinical response is shown in Table 
22 below.   Changes in ApoAI and AII, both of which are components of HDL, 
associated with change in acute phase reactants but not CDAI.   ApoB and Apo 
CII did not associate with clinical measures.  On exclusion of data for KAL007, 
their relationships with CRP and ESR strengthened but remained non-significant.  
  
182 
 
 
 
  ApoAI ApoAII ApoB ApoCII ApoCIII 
Whole cohort 
    
  
CRP -0.61 -0.77 -0.08 -0.16 -0.10 
ESR -0.70 -0.80 -0.20 -0.24 -0.22 
CDAI 0.35 0.27 0.40 0.58 0.45 
Excluding 
KAL007           
CRP -0.50 -0.84 -0.44 -0.45 -0.09 
ESR -0.64 -0.87 -0.60 -0.57 -0.22 
CDAI 0.44 0.31 0.38 0.56 0.50 
 
Table 22 - R values describing relationships between change in markers of 
disease activity and change in serum apolipoprotein levels.   R values are 
calculated by Spearman's correlation coefficient.   Green indicates p<0.05.   
Red indicates p<0.01. 
Scatterplots of ApoB (a component of the primary outcome measure) with 
clinical parameters are shown in Figure 66.   
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Figure 66 - Spearman's correlation coefficient between change in serum 
apoB and change CRP, ESR and CDAI, including (left) and excluding (right) 
participant KAL007. 
 
3.4.5 Enzyme activity 
CETP activity is displayed in Figure 67.   Activity rose in all participants apart 
from three; KAL007 reduced by 17.6pmol/µl/hr, equivalent to 32% of baseline 
value.   CETP activity fell by 2pmol/µl/hr and 3.6pmol/µl/hr in the other two 
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subjects.   Median change in CETP activity was an increase of 6.2pmol/µl/hr, or 
11% from baseline.   Excluding KAL007 gives p=0.019 for change from baseline. 
 
Figure 67 - CETP activity with (left) and without (right) participant KAL007.   
P value generated by Wilcoxon matched-pairs test. 
 
No significant changes were seen in average lipoprotein lipase or hepatic lipase 
activity (Figure 68), despite median increases of 19% and 9% respectively.   The 
visible outlier in the graphs below is KAL006, who had increases of 314% in LPL 
activity and 31% in HL activity.   Exclusion of this patient did not change the 
outcome of the test. 
 
Figure 68 - Lipoprotein lipase (left) and hepatic lipase (right) activity.   P 
value generated by Wilcoxon matched-pairs test. 
 
No significant associations were found between changes in any enzyme and 
changes in CRP, ESR or CDAI (Table 23).   Similarly, segregating patients by their 
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baseline CRP, as I have done with previous analyses, did not yield any significant 
differences in change in LPL or HL activity. 
 
Cholesterol ester 
transfer protein 
Lipoprotein 
lipase 
Hepatic 
lipase 
CRP -0.14 -0.15 0.07 
ESR -0.25 -0.22 0.15 
CDAI 0.28 0.26 0.07 
 
Table 23 - R values describing relationships between change in markers of 
disease activity and change in enzyme activity.   R values are calculated by 
Spearman's correlation coefficient. 
 
CETP is known to increase LDL cholesterol ester content by transferring 
cholesterol esters from VLDL-1 and HDL particles in exchange for triglycerides.    
This knowledge was reassuringly confirmed by the observation that changes in 
CETP activity associated positively (though not reaching statistical significance) 
with change in LDL-CE content and inversely with change in HDL-c.   These data 
are demonstrated in Figure 69.   
 
Figure 69 - Spearman's correlation coefficient between change in CETP 
activity and (left) change in LDL-cholesterol ester, and (right) change in HDL-
cholesterol as measured by betaquant. 
 
3.4.6 PCSK9 
PCSK9 activity analysis was performed in light of its role in regulating LDLr 
activity and recent interest in PCSK9 inhibitors in clinical practice, as outlined in 
the introduction.  Serum PCSK9 levels were elevated by mean of 23% and median 
7% after treatment, but this did not reach statistical significance (Figure 70).   
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Alterations in PCSK9 could potentially alter LDL catabolism by regulating the 
availability of the LDL receptor.   However, no correlations were found between 
PCSK9 levels and LCL FCR or serum LDL-c levels (Figure 71). 
 
 
Figure 70 - Serum PCSK9 levels.   P value generated by Wilxocon matched-
pairs test. 
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Figure 71 - Spearman's correlation coefficient of serum PCSK9 with LDL-
cholesterol and fractional catabolic rate. 
 
 
3.4.7 HDL particle analysis 
High density lipoproteins were analysed for particle size in the same manner as 
LDL, as described earlier in this chapter.   No significant changes were seen in 
mean or peak particle size (Figure 72).   Mean particle size analysis revealed one 
outlier who demonstrated a large increase of around 25%.  Removing this outlier 
from the analysis (KAL011) lowered the p value to 0.027, but I was unable to 
identify any clinical or other laboratory reason to exclude them; I believe it is 
safest to assume that no difference in these parameters can be demonstrated by 
KALIBRA’s data. 
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Figure 72 - Peak (left) and mean (right) HDL particle diameter.   P value 
generated by paired t-tests. 
 
Particle analysis was used to determine what proportion of serum HDL was made 
up of each of 5 subparticles, graded on basis of density.   A trend was seen of 
HD2a being replaced by HDL2b; however, all the changes seen were of low 
magnitude, and only the fall in HDL2a was statistically significant.   These 
results are summarised in Table 24. 
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  Baseline  Treatment  Change (% of mass)   
  Mean 95% C.I. Mean 95% C.I. Mean p   
HDL2b 31.1 28.1 – 34.0 31.7 28.4 – 35.9 1.1 0.37 
 HDL2a 27.4 26.1 – 28.7 25.7 24.7 – 26.6 -1.7 0.005  ** 
HDL3a 25.2 24.2 – 26.1 24.7 23.2 – 26.2 -0.5 0.53 
 HDL3b 10.4 9.5 – 11.3 10.9 10.1 – 11.6 0.5 0.14 
 HDL3c 6.0 4.7 – 7.2 6.5 5.4 – 7.7 0.6 0.083 
  
Table 24 - Changes in proportion of serum HDL subparticles.  P values 
generated by paired t-tests. 
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3.5 Discussion 
3.5.1 Conclusions from outcome data 
The primary outcome measure of the KALIBRA study was the fractional catabolic 
rate of LDL, which fell by a median of 30% (or 0.16 pools/day) following 
tocilizumab therapy.   Individual changes in FCR varied widely.   The largest 
decrease was a fall of 80% from baseline.   The median baseline (i.e. in severe 
active RA) FCR of 0.53 pools/day is close to that measured in 
hypertriglycerideaemic patients by our own centre [PACKARD 2000].   Similarly, 
the median post-treatment FCR of 0.27 pools/day compares well with an 
expected “normal population” value of 0.3 pools/day, as observed in Packard et 
al.’s study (272).   In contrast, LDL production rates did not increase, but rather 
fell significantly from baseline.   This change, however, was too small to offset 
the dominant kinetic effect of reduced catabolism.   FCR correlated with CRP 
and ESR at baseline, but not CDAI.   A similar pattern of association was 
displayed when analysing the degree of change in FCR and inflammatory 
parameters.    
Reassuringly, serum cholesterol levels changed in a manner consistent with 
existing tocilizumab literature, with increases observed in TC, LDL-c and HDL-c 
but no change in the atherogenic index (the TC/HDL-c ratio), lending external 
validity to our results.   LDL cholesterol ester content (LDL-CE), as measured by 
pooled samples throughout the course of the week-long kinetic studies, 
increased from baseline in those subjects who had elevated CRP and ESR at 
baseline (and thus large falls in these reactants with tocilizumab therapy).   
Despite apparent correlations between the changes in LDL-CE and acute phase 
reactants, no association was seen with disease activity as quantified clinically 
by CDAI.   LDL-c as measured by betaquant seemed to behave in a similar 
manner but often without reaching statistical significance.   The LDL FCR was a 
strong determinant of LDL-c both before and after tocilizumab treatment.   In 
contrast, LDL production rate did not correlate significantly with LDL-c at any 
stage. 
Taken together, these findings allow some conclusions to be drawn.   Firstly, 
they imply that elevations in serum LDL-c following tocilizumab therapy are a 
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direct result of changes in the LDL fractional catabolic rate, a confirmation of 
our original hypothesis.   The magnitude of these changes suggests that this fall 
in FCR is more likely a “normalisation”, rather than a clear pathological or off-
target drug effect; this further leads to the likelihood that the reductions in 
serum cholesterol observed in severe, active RA are a result of increased 
catabolism, not reduced production. 
Secondly, the changes in LDL FCR seen in RA, and thus changes in serum LDL-c, 
are a specific result of alterations in hepatic IL-6 signalling, rather than 
reductions in inflammatory “disease activity” (i.e. synovitis).   This conclusion is 
further supported by the different lipidaemic effects that have been observed in 
past years between IL-6 blockade and anti-TNF despite the two therapies 
delivering broadly similar reductions in clinical disease activity, although 
admittedly no kinetic studies exist for anti-TNF therapy.   This leads me to 
suspect that the target tissue ultimately responsible for LDL-c changes is the 
liver.   Given that the liver is the only organ capable of directly excreting 
unwanted cholesterol from the body (in the form of bile salts), it would seem to 
be a reasonable target for any system aiming to drastically alter the catabolic 
rate of LDL.   However, the ubiquity of the gp130 component of the IL-6 
receptor on cell membranes means IL-6 is capable of transducing a signal in 
other tissues such as vascular endothelium, macrophages or indeed any other 
peripheral cells capable of taking up LDL particles; the kinetic assays employed 
in KALIBRA cannot differentiate between different sites of LDL breakdown.  
Inflammation driving increased uptake by such other cells makes evolutionary 
sense; in times of insult or stress, increased IL-6 would stimulate increased LDL 
consumption (not excretion) as a way of directing fuel and synthetic substrates 
to cells that have greatest need of them.   Whilst this mechanism might provide 
a survival advantage in an acute scenario (such as infection), it could prove 
maladaptive in the pathological state of chronic, high-grade inflammation that is 
RA.   Potential cellular mechanisms for underlying my observed kinetic changes 
are the subject of a later chapter in this thesis. 
I had the opportunity analyse a wide variety of secondary outcomes from the 
KALIBRA data.   Fewer changes in the composition of the other apoB-containing 
lipoproteins were observed; coupled with the lack of change in lipase activity, 
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this implies that tocilizumab’s effects are predominantly confined to LDL.   No 
significant changes were observed in LDL particle size or subfraction proportion. 
The reduction in serum Lp(a) is clinically relevant as this particle is recognised 
as pro-atherogenic, and thus our findings imply at least one other potentially 
atheroprotective function for IL-6 blockade.   This replicates the findings of the 
MEASURE (254) and ADACTA (253) trials.   In contrast to LDL-c and kinetic 
changes, no clear association was observed with inflammatory markers; this 
might suggest that a distinct mechanism or target tissue lies behind 
inflammatory manipulation of Lp(a).   KALIBRA was not designed or powered to 
explore changes in Lp(a), however, and further studies are required to 
determine the precise mechanisms behind this change. 
The increases in apoAI, apoAII and apoB reflect increased levels of the 
lipoproteins which contain them.   Coupled with the absence of change in LDL 
particle size, this indicates that LDL-c increases due to increased numbers of LDL 
particles in the circulation; again, this fits consistently with the concept of 
reduced particle catabolism (as opposed to another mechanism such as altered 
cholesterol flux between particles).   The biochemical and clinical significance 
of the changes seen in other apoproteins (particularly CII and CIII) and HDL are 
outwith the remit of this thesis but would potentially be a fertile area for future 
study. 
What do these findings mean for these patients’ cardiovascular risk?   In the 
absence of clinical cardiovascular endpoints, conclusions must be drawn 
cautiously.   The fact that our patients return from a hypercatabolic state to a 
roughly normal LDL FCR fits with largely a normalisation of function, rather than 
novel pathology.   This view is supported by the correlation of LDL FCR and LDL-c 
with acute phase reactants; i.e. lipid changes are in proportion to reversal of 
(pathological) elevated IL-6 signalling, a key feature of the high-grade 
inflammatory state of RA.   The unchanged atherogenic index, increase in HDL-c 
and reduction in Lp(a) are also reassuring, suggesting neutral or even 
cardioprotective changes.   An alternative possibility could be that increased LDL 
catabolism is a protective evolutionary adaptation to inflammation (and its 
subsequent increase in cardiovascular risk conferred by endothelial dysfunction, 
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platelet aggregation and other physiological changes) which attempts to reduce 
cardiovascular disease by safely sequestering LDL-c or excreting it from the 
body, and thus reducing the amount of serum LDL-c available for uptake into 
atheroma.   This position may be supported by our observation that CETP 
activity increases post-tociliuzmab; this would drive cholesterol ester from HDL 
to LDL, which can then bind to LDLr on hepatocytes and then be excreted.    
Accepting this view would, however, require us to believe that the significant 
increased CV risk seen in RA occurs in spite of, rather than because of, the 
profound cholesterol changes which define the lipid paradox.   Given that TC 
and LDL-c have been shown to alter to some extent even with drugs such as 
methotrexate and anti-TNF (which reduce CVD risk), I find this view difficult to 
accept. 
3.5.2 Comparison with Tofacitinib kinetics 
Only one other study has been published analysing lipid kinetics in RA.   Charles-
Schoeman et al. (273) recently performed kinetic studies on a cohort of 33 RA 
patients and 31 controls.   RA patients were assessed at baseline and following 6 
weeks of treatment with tofacitinib, a JAK inhibitor recently approved for use in 
treating RA in the USA which has been shown to increase HDL-c and LDL-c 
following 4-6 weeks of treatment.   LDL-associated apoB and HDL apoAI 
production and catabolic rates were measured using stable isotope leucine, 
given here in a 20-hour continuous infusion with blood samples taken at baseline 
and 16, 18 and 20 hours.   Cholesterol production and catabolic rates were 
measured using a 22-hour continuous infusion of 3,4-13C2 –labelled free 
cholesterol.   A three-compartment mathematical model was used to calculate 
kinetic parameters.   The study showed an increase in mean LDL-c of 15% 
(p=0.0002) and in mean HDL-c of 14% (p=0.0001), both of which represent 
normalisation to levels seen in the control group.   Similar changes were seen in 
serum apoAI and apoB.   In contrast to the KALIBRA cohort, RA patients at 
baseline had an LDL-associated apoB FCR which was not significantly different 
from healthy controls (1.61%/hour v 1.50%/hour, equivalent to 0.38 pools/day v 
0.36 pools/day, p=0.27) and did not significantly change with tofacitinib.   No 
significant changes were seen in HDL-associated apoAI production or catabolic 
rates.   However, baseline cholesterol ester FCR was greater in RA than in 
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controls, and fell towards “normal” levels after treatment.   The change in 
cholesterol ester FCR correlated inversely with the change in HDL-c (r=0.42, 
p=0.018) and in large HDL particle numbers as assessed by NMR (r=0.54, 
p=0.002).   Given the change in cholesterol ester metabolism without any change 
in apoAI or apoB catabolism, the authors conclude that RA patients have 
increased selective cholesterol ester uptake by scavenger receptor B1 in the 
liver; the subsequent reduction in HDL-c then leads to lower levels of LDL-c as 
there is less cholesterol ester in HDL for CETP to transfer to LDL particles 
(although it should be noted that the group found no change in CETP mass or 
activity). 
Why did the Charles-Schoeman study come to such a different conclusion 
regarding apoB catabolism from KALIBRA?   I believe there are some features of 
this study which restrict direct comparisons to KALIBRA’s findings.   Firstly, 
tofacitinib blocks the JAK/STAT signalling pathway; as mentioned previously, IL-
6 signals via activation of STAT3, and so tofacitinib will affect similar 
intracellular changes to tocilizumab.   However, the large number of cytokines 
which transduce signals using JAKs means that some of tofacitinib’s effects will 
be due to blockade of other cytokines, not just IL-6.   Secondly, the 
mathematical model used differs from our own, using a more recent model 
which is simplified and is not able to provide detailed information on non-LDL 
lipoproteins in the apoB delipidation cascade.   Thirdly, the baseline patient 
demographics are not clearly delineated and so the cohort may not be 
comparable to my own.    Entry criteria for disease severity consist of >4 tender 
and swollen joints, and ESR > 28mm/hour or CRP >7mg/L; baseline TJC and SJC 
are given (thought not out of what total count), but no other clinical data are 
presented at baseline or post-treatment.   Composite scores such as DAS28 or 
CDAI are not mentioned at any point.   It is also not stated how many, if any, 
patients were DMARD- or biologic-naive, limiting our judgement of how 
treatment resistant this group’s disease might have been.   Finally, and most 
concerningly, the study does report significant increases in apoB and apoAI 
following tofacitinib (rising to the levels seen in the control group) despite no 
change in their production or catabolic rates.   This does not seem biologically 
possible.   Potential explanations include: (a) underpowering of the study so that 
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it was unable to detect a genuine change in LDL FCR; or (b) wide margins of 
error in the laboratory techniques used to calculate reported values.   
3.5.3 KALIBRA – strengths and weaknesses 
KALIBRA had some notable strengths which should be documented in defence of 
our findings.   Many of my initial results, whilst not novel, are in accordance 
with what is already known about tocilizumab’s behaviour.   For example, 
increases in TC, LDL-c and HDL-c are well documented as detailed in the 
introduction.   The rapid reduction in acute phase reactants, with clinically 
relevant but more modest reductions in joint counts and clinical composite 
scores such as CDAI, is in keeping with the phase III trial literature and our own 
clinical experience.   Whilst all patients responded clinically to the drug, 
residual disease was present in most, with only one patient reaching 
ACR/Boolean remission – a finding perhaps not surprising given that all patients 
started from a baseline DAS28 of >5.1, and that several had previously failed at 
least one previous biologic drug.   Moreover, the demographics of the cohort are 
I believe quite representative of a typical RA population in the UK (78, 82), with 
the possible exception that only three of our patients were prescribed 
methotrexate.   These observations are reassuring for three reasons.   Firstly, 
they replicate the earlier findings of other groups, and lend credence to the 
validity of our novel findings.   Secondly, had some patients not responded to 
tocilizumab therapy, our observed average changes in inflammatory and lipid 
parameters would likely have been smaller and less likely to reach statistical 
significance.   Lastly, the cohort’s demographics, disease severity, drug history 
and magnitude of clinical responses reflect “real life” practice in tocilizumab 
prescribing, increasing the likelihood that our observed lipid changes accurately 
reflect those which occur in the typical clinic population.   KALIBRA’s results also 
demonstrate a reassuringly strong degree of internal consistency, with changes 
in lipids, apoproteins and lipoprotein kinetics all contributing to a consistent 
picture of inflammation-driven hypercatabolism which is reversible by 
tocilizumab. 
The relatively small cohort size of this study also brought some advantages.   It 
allowed each patient to be analysed in depth, with adequate numbers of blood 
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samples over an appropriate timespan and a wide variety of secondary outcome 
measures obtained.   The volume of data generated has been such that much 
remains to be analysed, such as the kinetics of VLDL1, VLDL2 and IDL, and 
changes in HDL-related parameters.   Nevertheless, the use of three separate 
Rheumatology outpatient departments in the Greater Glasgow area allowed me 
to draw on a reasonably sized pool of patients as I attempted to recruit the 
required number of subjects.   Additionally, the single-centre nature of the 
kinetic studies allowed all key assessments to be performed by the same 
individual.   For example, all clinical assessments including DAS28 and CDAI 
scoring were performed by me; one named research nurse in the Glasgow CRF 
performed phlebotomy; all sample processing was performed by the same small 
team of biochemists; and data analysis for mathematical modelling was 
performed by Professors Caslake and Packard.   By allowing different staff 
members to repeatedly practice the same techniques, and by reducing the risk 
of inter-operator variability, I suspect this pattern of working promoted 
consistency and efficiency in all stages of data collection and preparation, and 
improved the overall reliability of our outputs.   What’s more, I can personally 
testify that the familiarity and confidence engendered in our own skills and 
those of the rest of the team by this method of working encouraged good 
working relationships and a strong sense of teamwork within the unit.   As an 
increasingly busy research fellow, this was hugely important to my enjoyment of 
and enthusiasm for the project! 
Some criticisms could be aimed at the way the study was conducted.   The most 
apparent one is the small size of the cohort, with only 11 patients (short of our 
stated target of 15) completing the study.   In the end, our observed changes in 
FCR were sufficiently strong and consistent that even this small number of 
subjects allowed us to reach statistical significance for our primary outcome 
measure, and some of our secondary measures.   Nevertheless, I firmly believe 
that many of my analyses reflect genuine changes in biology but do not meet 
statistical significance because of having so few numbers, and issue which I will 
reflect further on later.   From the outset, it was recognised that recruitment 
would be the largest barrier to successfully completing the study, as is the case 
in all clinical trials and studies.   For the participants, the study was intense, 
with a 13-hour stay in hospital; only one low-calorie meal in a 21-hour period; 
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repeated venopuncture; and recurrent early starts (difficult in those with an 
inflammatory arthritis, whose pain and stiffness is typically worst on waking).   
Despite drawing on three centres for recruitment, our patient pool was limited 
by several factors.   In Glasgow, most physicians typically use tocilizumab as a 
second- or third-line biologic behind anti-TNF and possibly Rituximab.   To 
counter this, I actively identified patients who were booked to see a biologics 
specialist nurse for screening before commencing a biologic, and gave 
information on the study to any who would be eligible regardless of which 
biologic they were being considered for; if they were due to start anti-TNF but 
were a good candidate for KALIBRA, I discussed tocilizumab therapy with them 
and sought permission from their consultant Rheumatologist to enrol them into 
the study.   Another limiting factor was our desire to exclude patients with 
diabetes mellitus or who were taking statins, both scenarios which are extremely 
common in the west of Scotland.   At one point, around half the biologics 
patients that I had identified as potentially suitable for inclusion in KALIBRA 
were excluded solely because of either diabetes or statin use. 
A second potential criticism of the study is the lack of blinding.   Typically any 
study comparing two sets of results in human subjects benefits from blinding of 
either the subjects (to minimise the placebo effect of a treatment) or the 
assessors (to minimise bias in analysis and interpretation of results).   This was 
not felt to be practical for several reasons.   The “crossover” nature of the 
study, where values in the same participants are compared before and after 
treatment, was not amenable to blinding as by definition all patients began from 
a position of being “pre-treatment”.   Blinding of laboratory staff was also not 
feasible as the intensive nature of sample processing meant only one sample at a 
time could be handled, and the study number and stage of treatment of each 
sample could easily be determined by the time of month or year the sample was 
received at.   A “crossover” style study did help in that each patient acted as 
their own comparator, allowing paired statistical tests and removing the need 
for a separate healthy control group.   It could be argued that a control group 
would have been desirable (this was the method used by Charles-Schoeman et 
al.) but our laboratory sample processing capacity limited the number of 
participants we could enrol.   A group may have helped us to determine whether 
changes in lipids or kinetic rates were pathological changes (going away from 
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healthy population averages) or normalisation (returning towards healthy 
population averages).   However, the values we obtained for FCR were similar to 
those seen in the normal population and hypertriglycerideaemic patients in 
previous studies, as documented above, and so addition of a control group would 
have added little to our knowledge. 
 
3.5.4 Dilemmas 
3.5.4.1 Subject KAL007 as a statistical outlier 
Some of the analyses, especially correlation calculations, were affected by the 
presence of KAL007 as a clear statistical “outlier”.   In contrast to the other 
subjects, this patient had a large change in their acute phase response but 
relatively small changes in LDL-c and FCR.   Even using the non-parametric 
Spearman’s r (which uses ranking to adjust for extreme values), correlations in 
several domains did not reach statistical significance despite scatterplots 
seeming (to my eyes) to show a strong relationship.   Some of these r values then 
became statistically significant on exclusion of KAL007.   This problem is 
particularly acute in a small study such as this, where one patient makes up 9% 
of the cohort; inclusion or exclusion of only one patient can thus have 
particularly profound effects on average values.   Exclusion of patients in this 
manner is fraught with ethical difficulties.   It is a potential route to 
confirmation bias, as I could be accused of deliberately and selectively choosing 
to omit a reading which did not agree with my pre-determined conclusion; 
following the data on its own terms could arguably only be done by including the 
whole cohort.   Additionally, despite my own extensive discussions with and 
assessment of KAL007, and interrogations of their past medical notes, there was 
nothing in their clinical history or examination which would set them apart from 
the rest of the cohort.   The only possible finding of relevance I could determine 
was that KAL007 fell pregnant shortly after the conclusion of her second kinetic 
study.   However, she claimed to have been using barrier (not hormonal) 
contraception during the trial, and confirmed that she had menstruated after 
completing the kinetic study, making pregnancy during the sampling period 
unlikely.   The most likely explanation appears to be the fact that KAL007 was 
the only participant completing the study who was a premenopausal female.   It 
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is well recognised that LDL metabolism is drastically different pre- and post- 
menopause, with oestrogen capable of influencing LDLr expression amongst 
other effects.   KAL008 was also premenopausal, and it would have been most 
interesting to compare and contrast her results with KAL007’s had she not been 
forced to withdraw from the study.    
I discussed KAL007’s inclusion at length with Profs. Mcinnes, Sattar, Caslake and 
Packard throughout the analysis period.   We recognised that such quandaries 
are the result of “real world” data, which rarely fits neatly with the 
preconceived ideas of the researcher.   Indeed, a trial with 11 subjects which 
reached statistical significance in all outcomes would be suspected of biased 
data manipulation at best and outright fraud at worst.   My own view is that 
many of the correlations are biologically relevant and genuine despite not having 
a p <0.05.   If the statistical outlier KAL007 had not been enrolled in the study, 
or if data from a larger cohort were available, I suspect that, for example, the 
association between change in betaquant LDL-c and FCR would be more clear-
cut.   One could also argue that, as a woman in her 30s, KAL007 is a “clinical” 
outlier in a disease population which has a peak incidence in the 6th decade of 
life; as such, excluding her from the analysis would not be unreasonable if she is 
not representative of the majority of RA patients one would encounter in a 
clinic.   Overall, I believe that in these circumstances it is not sufficient to 
dismiss a result or association as “non-significant” by simply quoting a p-value in 
a table, something major clinical journals also recognise.   Accordingly, if there 
is doubt over the relevance of an association, I have displayed the values 
graphically, with and without KAL007.   This suppresses allegations of bias, and 
allows the reader to draw their own conclusions. 
3.5.4.2 LDL-CE versus Betaquant 
Two different measures of LDL-cholesterol are used in this analysis.   LDL-c by 
Betaquant, a standard technique for measuring serum LDL-c, was taken on day 1 
of each kinetic study, in the same venepuncture as CRP and ESR and on the same 
morning of clinical assessment.   An alternative measure is the cholesterol ester 
content of LDL particles as calculated by using pooled samples throughout the 5-
day kinetic study (during which serum lipids were not in steady-state).   LDL-CE 
is a reliable, directly-measured quantification of LDL-c, which carries minimal 
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statistical link to FCR.   The use of LDL-CE carries two main advantages over 
Betaquant.   Firstly, it can be viewed as a more reliable “average” value for a 
naturally fluctuating LDL-c, and may be preferable to the Betaquant sample 
which only gives a value at one timepoint.   Secondly, the Betaquant technique 
also includes IDL-cholesterol and Lp(a).   These latter two substances are 
unchanged and reduced, respectively, by tocilizumab therapy, in contrast to the 
general trend of increase for LDL-CE.   This probably explains why the Betaquant 
LDL-c does not correlate as cleanly with kinetic and inflammatory parameters, 
and reduces its utility as a mechanistic tool. 
The major drawback of LDL-CE for quantifying LDL-c is that it is not a technique 
which is easy or widely available, and never will be given the repeated blood 
sampling and intensive laboratory resources required.   Therefore, whilst it may 
reflect cholesterol biology more accurately than betaquant sampling, it does not 
reflect clinical practice or the LDL-c values the physician or scientist is likely to 
encounter in RA patients, and will not equate cholesterol values generated in 
most other studies or cohorts.   It is thus hazardous to directly compare these 
values to the findings of other groups who measure LDL-c by other means, such 
as Betaquant or the Freidwald equation.   For clarity, I have generally provided 
results for both measures of LDL-c side by side.    
3.5.4.3 Measuring disease activity 
Most studies, even those involving tocilizumab, use DAS28 as the first-choice 
composite measure of RA disease activity.   In contrast, I chose the clinical 
disease activity index (CDAI) as a way of quantifying synovitis.   CDAI consists 
only of tender and swollen joint counts, and patient and physician global 
assessment scores, and is a validated (274) measure of disease activity.   I did 
this because most other disease activity scores include acute phase reactants in 
their calculations, and can report misleadingly low levels of disease activity 
following IL-6 blockade due to supra-normalisation of the acute phase response 
even when persistent synovitis is apparent on clinical examination.   DAS28 is 
particularly susceptible to this phenomenon, as it includes the natural log of CRP 
or ESR; thus, small falls at low acute phase reactant levels will have a 
disproportionately large effect on the change in DAS28.   By way of illustration, 
a fall in CRP from 60mg/l to 25mlg/l (ln 4.1 to 3.2) has less impact on DAS28 
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than a fall from 10mg/l to 3mg/l (ln2.3 to 1.1).   CDAI does not include any 
biochemical component and I felt it was more useful as a surrogate for synovitic 
burden in the context of tocilizumab therapy.     
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4 Interleukin-6 and Foam Cell Formation In Vitro 
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4.1 Rationale 
Having demonstrated the effects of IL-6 blockade on LDL kinetics, I aimed to 
investigate the cellular mechanisms which may underlie these observations.   As 
outlined in the introduction to this thesis, IL-6’s biological functions are legion; 
it may demonstrate a variety of pro-inflammatory, and sometimes anti-
inflammatory, properties in vivo and in vitro.   More pertinently, IL-6 has also 
been directly implicated in lipid metabolism beyond the observations of 
decreased cholesterol in RA patients.  Serum IL-6 levels correlated inversely with 
TC and LDL-c in a cohort of postoperative patients (226) whilst exogenous IL-6 
reduces serum TC and alters VLDL subclasses in humans (227, 228).   TNF-α and 
bacterial lipopolysaccharide (LPS) can achieve similar results (229). 
Prior studies have examined the effects of IL-6 in vitro using a variety of cellular 
systems in an attempt to explain observed in vivo effects.   IL-6 has been shown 
to upregulate the LDL receptor (LDLr) in human HepG2 cells, a hepatocyte cell 
line (275), and decrease apoB excretion from these same cells (276).   IL-6 
induced expression of the scavenger receptors SR-A, CD36 and CD68 (but not 
LOX-1) in human aortic endothelial cells (277).   The same group also looked at 
macrophages generated from the THP-1 monocyte cell line and found IL-6 was 
capable of inducing expression of SR-A, but not SR-B, LOX or CD36, and 
facilitated cholesterol uptake and macrophage transformation into foam cells 
(278).    Frisdal’s group, in contrast, found IL-6 retarded foam cell formation by 
upregulating ABCA1 expression in THP-1 macrophages and human monocyte-
derived macrophages (HMDM) (279), though this seems to be contradicted by 
more recent findings of impaired cholesterol efflux in RA (280).   IL-6 has also 
been shown to increase production of intracellular cholesterol-regulating 
molecules, including HMGCoA reductase and SREBP in THP-1 macrophages (281).   
These findings are in contrast to studies in rodents, which have significantly 
different lipid physiology to primates.   Compared to humans, rodents normally 
demonstrate high HDL-c, low LDL-c and very little atherosclerosis (229).   Mouse 
models of atherogenesis are used quite frequently in cardiovascular research, 
but require genetic manipulation by LDLr or APO-E in conjunction with a high fat 
diet.   Rodents also seem to respond differently to IL-6.   Administration of 
exogenous IL-6 increased serum TC and TG (282), and whilst IL-6-driven foam 
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cell production has been observed in mouse cells, this is in the context of 
upregulating VLDLR, SR-A and CD36, not LDLr (283, 284).  
Macrophages are key cells in both the pathogenesis of rheumatoid arthritis and 
atherogenesis, and are the effector cells of the reticuloendothelial system which 
previous animal data have implicated in LDL hypercatabolism (as noted in 
Chapter 3).   I hypothesised that tocilizumab’s reduction in LDL catabolism is a 
result of reduced IL-6 signalling in macrophages, and their subsequent reduced 
uptake of LDL via scavenger receptors.   To investigate this possibility, I 
performed a series of experiments on macrophages in vitro.   Firstly, I aimed to 
confirm that IL-6 was capable of transducing a signal in the macrophage and 
changing its biology as a positive control.   Secondly, I measured the effects of 
IL-6 on macrophage lipid uptake and their transformation into foam cells.   
Thirdly, I investigated the effects of IL-6 on the expression of a variety of 
membrane-bound and intracellular proteins involved in cholesterol uptake, 
export and metabolism.   Finally, I attempted to replicate my observations in 
patients with RA, using blood samples taken from the KALIBRA patient cohort 
before and after tocilizumab therapy. 
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4.2 Methods 
4.2.1 THP-1 Macrophage Generation 
THP-1 cells are a monocyte cell line originally derived from a patient with 
monocytic leukaemia (285).   They have for many years been used as models of 
macrophages following differentiation with Vitamin D3 or phorbol 12-myristate 
13-acetate (PMA).   In an attempt to mirror the phenotype of primary human 
macrophages as closely as possible, two different THP-1 maturation protocols 
were used.   The “original” technique is well-established and has been 
extensively studied.   The “alternative” technique, as described by Daigneualt et 
al (286), may lead to generation of cells which more closely resemble primary 
human monocyte-derived macrophages [HMDM] in appearance and behaviour. 
4.2.2 “Original” THP-1 macrophage generation 
Proliferating THP-1 monocytes were maintained in 250ml vented flasks at 37oC 
incubation.   Cells were split and re-seeded twice a week at 2x106 cells in 25ml 
complete medium (RPMI 1640 (Invitrogen) supplemented with 10% foetal calf 
serum, 1% Penicillin/Streptomycin and 1% L-glutamine).   On the day of 
differentiation, cells were counted, resuspended at 2.5x105 cells/ml in complete 
RPMI supplemented with 50ng/ml PMA, and plated in a 24-well tissue culture 
plate at 1ml/well.   Cells were incubated at 37oC for 72 hours before 
stimulation. 
4.2.3 “Alternative” THP-1 macrophage generation 
THP-1 monocytes which were maintained in culture as above were counted and 
suspended at 2.5x105 cells/ml in complete RPMI supplemented with 5ng/ml PMA.   
These were then seeded at 1ml/well in a 24-well tissue culture plate and 
incubated at 37oC for 24 hours.   At this point medium was aspirated and 
replaced with fresh complete RPMI, and the cells were incubated for a further 5 
days before stimulation. 
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4.2.4 CD14 isolation 
Healthy human donor blood samples were obtained in the form of “buffy coats” 
(the fraction of a whole blood donation following gradient centrifugation that 
contains leukocytes and platelets) graciously provided by the Scottish National 
Blood Transfusion Service via the Western Infirmary, Glasgow.   From each 
donor, under sterile conditions buffy coat (typically 10-20ml) was diluted 1:1 in 
wash medium (500ml sterile PBS with 5ml Penicillin/Streptomycin).   This was 
then carefully layered with a dropper onto 4ml Histopaque in a 15ml centrifuge 
tube, to a total volume of 14ml, and spun at 2100rpm for 20 minutes.   From 
each tube, a dropper was used to remove the visible interphase of peripheral 
blood mononuclear cells lying immediately above the histopaque layer into a 
50ml centrifuge tube, and this was washed in 50ml wash medium at 1800rpm for 
10 minutes.   Cells were resuspended in 50ml wash medium, filtered through a 
70µm cell strainer into a fresh tube, and counted.  They were then spun at 
1500rpm at 4oC for 10 minutes and resuspended at 107 cells / 80µl in MACS 
buffer (500ml sterile PBS with 10ml foetal calf serum and 5ml 
Penicillin/Streptomycin) in a 15ml centifuge tube on ice.   CD14+ monocytes 
were then isolated from PBMCs using positive cell selection on an AutoMACS Pro 
(Miltenyi Biotech) according to the manufacturer’s instructions.    
4.2.5 Primary HMDM generation 
CD14+ monocytes, isolated from donor blood as above, were suspended in 10ml 
RPMI and counted.   They were then spun at 1,500RPM for 10 minutes and then 
resuspended at 2.5x105 cells/ml in complete RPMI supplemented with 50ng/ml 
M-CSF (Peprotech).   Cells were then seeded in 24 well plates at a 1ml/well.    
The medium was replaced with fresh complete RPMI + 50ng/ml M-CSF after 
three days, and cells were used after a total of 6 days differentiation. 
4.2.6 TNF production by macrophages 
Differentiated THP-1 macrophages or HMDMs in 24-well plates were “primed” by 
providing them with fresh complete RPMI supplemented with recombinant 
human IL-6 (Peprotech) at 1, 10 or 20ng/ml, recombinant soluble human IL6-
Receptor (Peprotech) at 100ng/ml, or combinations thereof.   After 24 hours 
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culture at 37oC, medium was aspirated and replaced with fresh complete RPMI 
supplemented with lipopolysaccharide (LPS, Sigma-Aldrich) at varying doses for a 
further 24 hours.   Supernatants were aspirated into 1.5ml microcentrifuge 
tubes, spun at 1,500 RPM for 5 minutes to remove any cells in suspension, and 
decanted into clean tubes.   Samples were stored at -20oC.   Prior to use, the 
samples were thawed at room temperature and vortexed.   Supernatants of cells 
exposed to LPS were diluted 1:10 with RPMI due to the high concentrations of 
TNF-α induced by LPS. 
4.2.7 TNF-α ELISA 
Supernatant TNF-α levels were measured by Human TNF- α CytoSet ELISA 
(Invitrogen).   A 96-well ELISA plate was coated overnight with 100µl/well of 
capture antibody diluted in phosphate buffered saline (PBS, Sigma Aldrich) to a 
concentration of 2µg/ml.   The next morning the plate was washed with 
PBS/0.1% Tween (Sigma-Aldrich) then blocked for one hour at room temperature 
with 200µL PBS/0.5% BSA (Sigma-Aldrich) per well.   After washing, TNF-α 
standards were prepared in complete RPMI and added at 100µl/well using serial 
dilutions to generate a seven-point standard curve, with the top standard at a 
concentration of 2,000pg/ml.   Supernatant samples were added at 100µl/well, 
and 50µl of detection antibody diluted to 0.32µg/ml in PBS/0.5% BSA was added 
to all wells.   The Plate was left on a rocker at room temperature for 2 hours, 
and washed three times with PBS/0.1% Tween.   A working Streptavidin-HRP 
solution was prepared by diluting stock solution 1/625 in PBS/0.5% BSA, and 
100µl was added to each well for 30 minutes on a rocker at room temperature.   
The plate was washed five times, and 100µl TMB substrate solution (R&D 
Systems) was added to each well for 5-10 minutes in the dark.   Reactions were 
stopped by adding 100µl Stop Solution (2N H2SO4).   TNF-α concentrations were 
determined according to absorbance at 450nm measured on a Dynex MRX TCii 
plate reader (Dynex Technologies, Chantilly VA, USA) with reference to the 
standard curve. 
4.2.8 Foam cell formation and visualisation 
THP-1 macrophages or HMDM were incubated for 24 hours at 37o with fresh 
complete RPMI alone, 10ng/ml recombinant human TNFα (Peprotech), 10ng/ml 
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IL6 or IL6 + 10µg/ml tocilizumab.   Where relevant, tocilizumab was added to 
wells 30 minutes before application of IL6.   Cells were then gently washed in 
PBS and incubated with varying concentrations of oxLDL (BTI Inc, Ward Mill USA) 
for a variety of durations, depending on the requirements of the experiment.   
Specific parameters are detailed where relevant in the results section.   
Adherent cells were fixed in their wells and stained with oil red O (Sigma 
Aldrich) to demonstrate lipid uptake. Two different staining protocols were used 
to allow cross validation of observations. 
The first technique was based on recommendations from the manufacturer of 
oxLDL.   A stock solution of 0.4% oil red O in was made by adding 200µg oil red O 
powder to 50ml of 100% isopropanol and filtering through a 0.2µm syringe filter.   
A working solution was made by diluting 60:40 with distilled water, and filtering; 
this was suitable for use for 4 hours, and was discarded afterwards.   Cells in the 
wells of the culture plate were washed twice with PBS, fixed with 250µl 3% 
paraformaldehyde for 5 minutes at room temperature, and washed twice again 
with PBS.   Cells were covered briefly with oil red O working solution then rinsed 
quickly twice with distilled water.   Cells were then visualised under light 
microscopy. 
The second technique was derived from an optimised staining protocol derived 
by Xu et al (287).   Stock and working solutions of oil red O were prepared as 
above.   Cells in the wells of the culture plate were fixed in 10% phosphate 
buffered formalin for 10 minutes, rinsed for 1 minute in PBS and rinsed for 15 
seconds in 60% isopropanol to facilitate staining.   Cells were then stained with 
oil red O working solution for 1 minute in darkness at 37oC.   The cells were 
destained by adding 60% isopropanol for 15 seconds, then washing three times 
with PBS for 3 minutes each.   Cells were then visualised under light microscopy. 
4.2.9 DiI-oxLDL uptake assay 
HMDMs were primed for 24 hours at 37o with fresh complete RPMI alone, 10ng/ml 
recombinant human TNFα (Peprotech), 10ng/ml IL6 or IL6 + 10µg/ml 
tocilizumab.   Where relevant, tocilizumab was added to wells 30 minutes before 
application of IL6.   Cells were then incubated for 4 hours with 100µg/ml DiI-
labelled oxLDL (Intracel, Frederick, USA) then washed 5 times with PBS.   300µl 
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100% isopropanol was added to each well and plates were placed on a rocker for 
15 minutes at room temperature.   Isopropanol was then aspirated and analysed 
on a BMG Fluostar Optima with excitation/emission values of 540/590nm.   Each 
sample was read at 3 different gain levels, and the values which were highest 
without going over the machine’s upper limit of detection were used.   All 
conditions were generated in duplicate for each donor with the mean of the 
duplicate values used for analysis. 
4.2.10 STAT3 phosphorylation 
Macrophages were detached from culture wells by adding 1ml of non-enzymatic 
cell dissociation solution (Sigma), incubating at 37oC for 20 minutes, and gently 
agitatating with a pipette.  Cells were resuspended in PBS at 5x105 cells/ml.  
2.5x105 cells in 0.5ml were added to FACS tubes containing: no stimulant; 
10ng/ml IL6; 100ng/ml sIL6R; IL6 + sIL6R; or IL6 + 10µg/ml tocilizumab (kindly 
provided by Center for Rheumatic Diseases, Glasgow Royal Infirmary, UK).  The 
cells were incubated a water bath at 37oC for 15 minutes.   At this point cells 
were washed in ice-cold PBS, fixed, permeablised and stained with 2.5µl pSTAT3 
intracellular antibody (BD Biosciences) in the dark for 30 minutes.  Cells were 
washed with Cellwash or PBS between each step before resuspending in 250µl 
PBS with 0.5% bovine serum albumin (BSA, Sigma-Aldrich).   Fluorescence was 
immediately measured using an AutoMacs Pro (Miltenyi, Cologne, Germany) and 
analysed on FlowJo V10 software. 
4.2.11 Flow cytometry antibody conjugation 
In preparation for flow cytometry staining, anti-human MARCO antibodies 
(Thermo Scientific, Rockford, IL, USA) were conjugated using the Lightning-Link 
PE Tandem Conjugation Kit (Innovia Biosciences, Cambridge, UK) according to 
the manufacturer’s instructions.   Briefly, 3µl of LL-modifier was added to 30µl 
of antibody in a 200µl microcentrifuge tube and mixed gently.   11µl of this mix 
was pipetted directly onto a liophylised mixture provided in a glass vial 
containing the PE ligand, mixed gently by pipetting, and left overnight at room 
temperature in the dark.   1µl of LL-quencher was added to each vial and left at 
4oC for thirty minutes before use. 
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4.2.12 Flow cytometry analysis of cell surface molecules 
THP-1 macrophages and HMDMs were cultured as previously described.   
Following 24 hours stimulation with 10ng/ml IL-6 or complete RPMI alone, 
supernatant was removed and cells were incubated at 37oC with 1ml non-
enzymatic Cell Dissociation Solution (Sigma) in each well for 45 minutes.   Non-
adherence was confirmed visually by light microscopy; adherent cells were 
loosened by gentle agitation using the pipette, and the suspension was 
transferred to a centrifuge tube.   Cells were counted, spun at 1,500RPM for 10 
minutes and resuspended in FACS buffer (PBS + 0.5% bovine serum albumin) at 
5x106 cells/ml.   For each experimental condition, 5x105 cells (ie. 100µl) were 
decanted into a FACS tube.   Cells were then incubated with 5µl Trustain Fc 
block (BioLegend, San Diego, USA) for 10 minutes at room temperature.   
Fluorescent antibody or isotype was added at 2.5µl per tube, and cells were 
incubated on ice for 15-20 minutes in the dark.   After washing twice with FACS 
buffer at 350g for 5 minutes, cells were resuspended in 500µl buffer.   
Fluorescence was immediately measured using an AutoMacs Pro (Miltenyi, 
Cologne, Germany) and analysed on FlowJo V10 software. 
4.2.13 RNA isolation from in vitro macrophages 
Primary human CD14+ monocytes were isolated and differentiated into 
macrophages as previously described.   For transcript analysis, cells were 
exposed for 24 hours to 10ng/ml IL-6 or RPMI alone, with two wells of 2.5x105 
cells each per condition. 
After 24 hours stimulation the cell supernatant was aspirated and cells lysed 
with 350µl QIAzol Lysis Reagent in the well.  This was aspirated, incubated at 
room temperature for 5 minutes to allow complete cell lysis, and stored at -20oC 
in a 1.5ml eppendorf tube; as two wells were combined for each condition from 
each donor, this resulted in each condition having RNA from a total of 5x105 cells 
in 700µl QIAzol ready for processing in a miRNeasy kit (Qiagen).   After thawing 
at room temperature, 140µl chloroform was added to each tube and centrifuged 
at 12,000g for 15 minutes.   200µl of the upper aqueous phase was carefully 
transferred to a new tube and 525µl of 100% ethanol added.   The sample was 
spun in an RNeasy Mini column at 8,000g for 15 seconds; 200µl buffer RWT was 
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added to the column and spun again at the same settings.   A DNase digest was 
then performed by making a master mix of 10µl DNase stock I solution and 70µl 
Buffer RDD for each sample, placing 80µl of this mix directly onto the spin 
column membrane, and leaving the column on the benchtop at room 
temperature for 15 minutes.   The digest was halted by adding 300µl buffer RWT 
and the column spun at 8,000g for 15s.   500µl buffer RPE was added and spun at 
8,000g for 15s; this was repeated with a further 500µl buffer RPE for 2 minutes.   
The RNA now held within the spin column was eluted by adding 30µl directly to 
the membrane and centrifuging at 8,000g for 1 minute.   This 30µl eluate was 
pipetted back onto the membrane and spun again using the same collection 
tube. 
4.2.14 cDNA synthesis 
Purity and concentration of RNA were measured by NanoDrop spectrophotometry 
(Thermo Scientific), and reverse transcription performed using AffinityScript 
Multi-Temperature cDNA synthesis kit (Aligent, California, USA) and the Veriti 
96-well thermal cycler (Applied Biosystems)   RNA from each sample was 
transferred into a 200µl PCR tube.   The required quantity of RNA was calculated 
so that 12 µl of the sample with the lowest concentration of RNA was used; for 
other samples, a lower volume of sample was thus be required to obtain the 
same quantity of RNA, and the volume was made up to 12 µl with RNase-free 
water (Life Technologies).   3µl of random primers was added to each tube and 
the reaction was incubated for 65oC for 5 minutes to denature the RNA, then left 
at room temperature for 10 minutes to allow primers to anneal.   A master mix 
was prepared on ice of: 
 2µl AffinityScript RT Buffer 
 0.8µl dNTP mix 
 0.5µl RNase Block Ribonuclease Inhibitor 
for each sample; 3.3µl of mix was added to each tube followed by1µl of 
AffinityScript Multiple Temperature RT.   The tubes were briefly centrifuged to 
eliminate air bubbles and then incubated at 25oC for 10 minutes to extend the 
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primers, then 42-55oC for one hour.  The reaction was terminated by incubating 
at 70oC for 15 minutes.  Samples were then placed on ice for immediate use, or 
stored at -20oC. 
4.2.15 RT-qPCR by SYBR 
Before extended gene analysis, samples were first assessed for suitability by real 
time PCR using SYBR Green reagents.   A 96-well PCR plate was loaded in 
triplicate with 2µl cDNA from each sample.  To each well was added: 
 10µl SYBR Select Master Mix (Life Technologies) 
 1µl forward and reverse primers for GAPDH or SOCS3 (Integrated DNA 
Technologies, Coralville, USA) 
 7µl RNase-free water (Life Technologies) 
For convenience and pipetting accuracy, these were prepared in a master mix 
beforehand.   The plate was spun at 350g for at least 10 seconds to ensure each 
reaction mix was at the bottom of the well.   Amplification was then quantified 
on a 7900HT Fast Real-Time PCR System (Life Technologies) as detailed below. 
4.2.16 RT-qPCR by TLDA 
Gene expression was quantified using TaqMan Low Density Array cards (Applied 
Biosystems).   The array is a 384 well microfluidic card, fed by one of eight 
loading ports.   Each well is pre-loaded with primers for a specified gene, and 
cards can be custom-designed according to the needs of the researcher.   In my 
case, cards were set up to accommodate four samples, allowing 32 genes to be 
analysed in triplicate for each sample.  Appendix H lists the genes included in 
this study, and the corresponding protein products and their roles. 
The card was removed from storage at 4oC and allowed to settle at room 
temperature for 15 minutes in the dark.   After defrosting cDNA on ice and 
gently vortexing, a master mix was made in a 1.5ml microcentrifuge tube of: 
 70µl cDNA  
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 30µl RNase-free water 
 100µl TaqMan Universal Master Mix II (Applied Biosystems) 
This mix was gently vortexed, spun briefly to eliminate air bubbles, and 
carefully added to the card.   The mix was equally divided between two loading 
reservoirs (i.e. 100µl into each port) to allow analysis of four samples per card as 
above.   The card was twice centrifuged at 1,200RPM for 1 minute at room 
temperature.   The card was then sealed to prevent samples leaking between 
wells.   Amplification was then quantified on a 7900HT Fast Real-Time PCR 
System (Life Technologies) by thermal cycling as follows: 50oC for 2 minutes; 
95oC for 10 minutes; then forty cycles of 97oC for 30 seconds; and 59.7oC for one 
minute.    
4.2.17 RT-qPCR analysis 
The comparative threshold (CT) method was used to quantify gene expression 
with RQ Manager  (Applied Biosystems).   The CT value indicates the PCR cycle, 
from 0 to 40, at which the amplified gene is deemed as being detected by 
reaching a defined threshold of fluorescence.  Mean CT values for all 32 genes in 
every sample from the three replicate values were calculated, including GAPDH 
as a control gene.   The ΔCT value (i.e. the expression of target gene relative to 
that of GAPDH) was then calculated as: 
  ΔCT =CT (target gene) – CT (GAPDH).    
The change in gene expression between stimulated and unstimulated cells for 
each donor was calculated as: 
ΔΔCT = ΔCT (stimulated sample) - ΔCT (unstimulated sample) 
Gene expression could then be expressed as fold change relative to unstimulated 
cells using the formula: 
Fold change = 2-ΔΔCT 
214 
 
 
 
For down-regulated genes, the negative inverse of the result was used to 
demonstrate a negative value. 
4.2.18 RNA isolation from KALIBRA blood samples 
Whole blood samples provided for the KALIBRA study were processed in the 
Centre for Vascular Biochemistry at the University of Glasgow, removing serum 
for lipoprotein analysis.   This left small volumes (around 2ml each) of blood 
from each patient rich in erythrocytes and leukocytes, which were stored at -
20oC.   Some of these samples, pre- and post-tocilizumab, were used to obtain 
RNA for gene expression analysis. 
Blood samples were thawed at room temperature, and transferred to PAXgene 
tubes (Qiagen).   Tubes were left at room temperature for 2 hours, then spun at 
3,000g for 10 minutes.   Supernatant was decanted, 4ml RNAse-free water was 
added, and the tubes were vortexed and spun at 3,000g for 10 minutes.   
Supernatant was removed, 350µl BR1 buffer was added, and tubes were 
vortexed.   Samples were pipette into a 1.5ml microcentrifuge tube, to which 
300µl BR2 buffer and 40µl proteinase K were added.   The tubes were vortexed 
for 5 seconds and incubated at 55oC for 10 minutes in a shaker-incubator at 
500RPM.   Lysate was transferred to a PAXgene shredder spin column in a 2ml 
microcentrifuge tube, and spun for 3 minutes at 8,000g.   The supernatant was 
transferred to a fresh 1.5ml microcentrifuge tube and 350µl 100% ethanol was 
added.   The tubes were vortexed and spun briefly.   700µl of this sample was 
pipette into a PAXgene RNA spin column in a 2ml processing tube, and spun for 1 
minute at 8,000g.   This process was repeated in the same spin column with any 
remaining sample.   350µl BR3 buffer was added to the spin column, which was 
spun for 1 minute at 8,000g.   A DNAse digest was then performed by adding a 
pre-prepared mix of 10µl DNase I stock solution and 70µl RDD buffer directly to 
the spin column membrane, and leaving at room temperature for 15 minutes.   
350µl BR3 buffer was then added and the tubes spun for 1 minute at 8,000g.   
This process was repeated twice with 500µl BR4 buffer, spinning for 3 minutes at 
the final stage.   The spin column was spun again for 1 minute at 8,000g in a 
clean 2ml processing tube, then transferred to a 1.5ml microcentrifuge tube.   
40µl BR5 buffer was pipette directly onto the spin column membrane, and this 
was spun for 1 minute at 8,000g; this step was performed twice.   The resulting 
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eluate was incubated in a shaker-incubator for 5 minutes at 65oC, then 
immediately placed on ice.   The resulting RNA was analysed for quantity and 
purity by NanoDrop spectrophotometry as described above. 
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4.3 Results  
4.3.1 TNFα assay 
In THP-1 macrophages generated by the “original” method, a dose-ranging assay 
showed a strong TNFα response following 24 hours of culture with 50ng/ml LPS, 
and a discernible elevation from baseline with 5ng/ml LPS (Figure 73).   In these 
cells, IL-6 alone did not provoke any secretion of TNFα at any dose.   Priming of 
cells with IL-6 with or without exogenous sIL-6R failed to augment LPS-driven 
TNFα production (Figure 74).   This conflicts with previously published data 
which showed IL-6 potentiating the ability of LPS to provoke TNFα production by 
THP-1 macrophages (288).   I repeated the experiment in macrophages 
generated by the “alternative” method, using lower levels of PMA and LPS in 
case this had overwhelmed the cells’ TNFα production capability.   Again, no 
increase in TNF production was seen with IL6 or sIL6R supplementation, though a 
slight reduction of TNF production was seen when stimulated with 1ng/ml LPS 
(Figure 74).    
 
 
Figure 73 – TNF-α production in THP-1 macrophages following culture for 24 
hours with ascending concentrations of LPS (ng/ml).    Mean of 2 repetitions 
with different cell generations ± SD.    
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Figure 74 - TNF production in THP-1 macrophages on culture with LPS with 
or without IL-6, as percentage of response seen with cells exposed to LPS 
alone.   (A) “Original” method of differentiation.   (B) “Alternative” method of 
differentiation.   Values presented as mean ± SD.  N = number of repetitions 
using different cell generations.   Black bar: LPS alone.   White bars: IL-6 
alone at 1, 10 or 20ng/ml.  Light grey bars: IL-6 + LPS.  Dark grey bars:  IL-6 + 
LPS + sIL6R (100ng/ml). 
 
In HMDM, a dose-ranging assay gave a similar dose-response curve as in THP-1 
macrophages, albeit with greater magnitude of production at each dose of LPS 
(Figure 75).   Priming with IL6 at all doses attenuated TNFα production following 
culture with 5ng/ml LPS but did not abrogate it completely (Figure 76), in 
keeping with previously published data (289). 
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Figure 75 - TNFα production in HMDM on culture for 2 hours ascending 
concentrations of LPS (ng/ml).   Donor n = 1 
 
 
Figure 76 – TNF-α production in HMDM on culture for 24 hours with LPS with 
or without IL-6, as percentage of response seen with cells exposed to LPS 
alone.   Mean±SD; analysed by t-test, donor n=6.  Black bar = LPS alone.   
White bars (not visible due to TNF-α production being below limit of 
detection): IL-6 alone at 1, 10 or 20ng/ml.    Grey bars: IL-6 + LPS + sIL-6R 
(100ng/ml).  
 
4.3.2 Foam cell formation quantified by Oil Red O staining 
I first attempted to replicate the results described in Hashizume et al. (278), 
where incubation of THP-1 macrophages with IL-6 increased foam cell formation.   
Initially however I carried out my own dose-ranging experiment to find out how 
much oxLDL was required to generate positive staining; 100µg/ml was used in 
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the above paper, which I was keen to reduce if possible given that oxLDL is (a) 
toxic to macrophages, and (b) expensive.   THP-1 macrophages generated using 
the “original" protocol were therefore activated with 50ng/ml LPS for 24 hours, 
then incubated for 48 hours with oxLDL at 1, 10 or 50µg/ml.    The intensity of 
staining increased incrementally with increasing concentration of oxLDL (Figure 
77), leading me to conclude that 50µg/ml was an appropriate concentration of 
oxLDL for foam cell generation.  
 
 
 
Figure 77 - Oil red O staining of THP-1 macrophage foam cells cultured for 
48 hours with oxLDL at (A) 1mcg/ml, (B) 10mcg/ml and (C) 50mcg/ml.  10x 
magnification   Images representative of two experiments. 
 
However, I noted that even cells with minimal oxLDL loading showed significant 
lipid staining, in contrast to previous literature.   To counter this I attempted to 
culture cells for the final 24 hours in serum-free medium, in case oil-red O 
staining simply reflected uptake of lipid from the foetal calf serum present in 
complete RPMI.   Unfortunately this led to significant amounts of cell death and 
loss of adherence to the well, and thus uninterpretable results.  In future, use of 
specifically designed serum free media would obviate this problem. 
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These experiments were repeated using the “alternative” method of THP-1 
macrophage generation as discussed above (286).   Results from these 
experiments were conflicting.   On one attempt, there was a subjective increase 
in frequency and intensity of oil red O staining following IL-6 priming, and this 
was ameliorated by pre-culture with tocilizumab (Figure 78).   However, 
attempts to replicate this were unsuccessful, with no observable difference 
between stimulated and unstimulated cells (Figure 78).   Once again, even cells 
cultured only in RPMI without exogenous cytokine or oxLDL supplementation 
stained heavily (Figure 79).     
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Figure 78 - Oil red O staining of THP-1 macrophage foam cells cultured for 
48 hours with 50 mcg/ml oxLDL and (A) RPMI alone (B) 10ng/ml IL-6 (C) IL-6 
+ 100ng/ml tocilizumab.  20x magnification.   Images representative of one 
experiment. 
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Figure 79 - Oil red O staining of THP-1 macrophage foam cells cultured for 
48 hours with (A) RPMI alone (B) 50mcg/ml oxLDL, (C) oxLDL + 10ng/ml IL-6 
(D) oxLDL + IL-6 + 100ng/ml tocilizumab.   Images obtained from the same 
experiment. 
 
4.3.3 Foam cell formation quantified by DiI-oxLDL 
DiI-labelled oxLDL was sequentially diluted in RPMI and directly analysed via 
fluorimetry, creating a standard curve (Figure 80) demonstrating its ability to 
generate increasing levels of fluorescence at increasing concentrations. 
 
 
Figure 80 - Fluorescence of DiI-oxLDL at increasing concentrations in a 96-
well plate.  Bars represent mean±SD of three wells for each condition in one 
experiment. 
 
Given the difficulties I encountered in replicating the findings of previous groups 
with oxLDL culture, dose-ranging studies were then carried out to ascertain the 
optimum concentration and duration of culture of THP-1 macrophages with DiI-
oxLDL.   Figure 81 shows the results of this experiment, with detectable 
fluorescence at culture concentrations of 10µg/ml oxLDL and above.   
Fluorescence was detectable from the earliest timepoint of 30 minutes of 
culture; this increased with longer periods of culture before plateauing (or at 
least having a slower rate of increase) beyond two hours.    Figure 82 shows 
these results in bar chart form for concentrations of 10µg/ml or 50µg/ml oxLDL.   
After one hour of culture in these conditions, whilst a discernable increase of 
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fluorescence from baseline was detected, there was still capacity for further 
increase of oxLDL uptake following cell stimulation.   Given the significant 
expense of purchasing DiI-labelled oxLDL, I decided to conduct all further 
experiments by culturing cells in 10µg/ml DiI-oxLDL for one hour before 
analysing. 
 
 
Figure 81 - Fluoresence of THP-1 macrophages following culture with DiI-
labelled oxLDL at varying times and concentrations.   Points represent 
mean±SD of three wells for each condition in one experiment. 
 
 
 
Figure 82 - Fluorescence of THP-1 macrophages following culture for 
varying times with (A) 10mgc/ml or (B) 50mcg/ml DiI-labelled oxLDL.   Points 
represent mean±SD of three wells for each condition in one experiment. 
Using these culture conditions, no significant differences were seen in oxLDL 
uptake following cell stimulation with IL-6 in either THP-1 macrophages or 
HMDMs from 5 healthy donors (Figure 83).   In an attempt to demonstrate the 
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reliability of my results I also included cells primed instead with 100ng GM-CSF.   
This was prompted by previous (unpublished) data obtained in our lab which 
suggested GM-CSF was capable of retarding oxLDL uptake into macrophages.   
However, in my experiments this effect was not observed.   I also repeated foam 
cell quantification using these culture condition and staining with oil red O as 
per Xu’s technique, as detailed in the methods section.   Again, no clear 
difference in staining was seen following IL-6 or tocilizumab exposure in THP-1 
macrophages (Figure 84) or HMDM (Figure 85). 
 
Figure 83 - Fluorescence of macrophages following culture with DiI-oxLDL, 
expressed as % of fluorescence of cells cultured with DiI-oxLDL and RPMI 
alone.   Bars represent mean ± 95% C.I. of three wells for each condition in 
three or five experiments. 
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Figure 84 – Oil red O staining of THP-1 macrophage foam cells. (A) 
unstained (B) unstimulated (C) IL-6 10ng/ml (D) IL-6 + Tocilizumab 100µg/ml.   
Images obtained from one experiment. 
 
 
Figure 85 - Oil red O staining of HMDM foam cells. (A) unstained (B) 
unstimulated (C) IL-6 10ng/ml (D) IL-6 + Tocilizumab 100µg/ml.   Images 
obtained from one experiment.  
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4.3.4 STAT3 phosphorylation 
The difficulties I encountered in demonstrating responses to IL-6 in different 
cells, especially THP-1 macrophages, raised the possibility that no active IL-6 
signalling was taking place in these cells.   To address this possibility, I 
quantified the presence of membrane-bound IL-6 receptor (IL-6R) on monocytes 
and macrophages, and the presence of intracellular phosphorylated STAT3 
(pSTAT3) after exposure of the cells to recombinant IL-6. 
Cell surface staining of THP-1 cells demonstrated the presence of membrane-
bound IL-6R on monocytes, but not on macrophages generated by either the 
“original” or “alternative” differentiation methods (Figure 86).   In accordance 
with this observation, IL-6 generated detectable increases in pSTAT3 in THP-1 
monocytes, but not macrophages (Figure 87), and this effect was blocked 
completely by pre-incubation of cells with tocilizumab (Figure 87). 
Flow cytometry did, however, demonstrate the presence of IL-6R on CD14+ 
monocytes and HMDM.   This experiment was performed with 3 donors for each 
cell type; Figure 88 shows representative FACS plots from one donor for each 
cell type.   Unfortunately, time pressures in the laboratory during my fellowship 
meant I was unable to demonstrate pSTAT3 signalling in human CD14+ 
monocytes or HMDM.   I deprioritised this because I had demonstrated both the 
presence of membrane-bound IL-6R and the effect of IL-6 administration on 
TNFα production on these cells.  
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Figure 86 - Cell surface staining for membrane-bound IL-6R in (A) THP-1 
monocytes, (B) "original" THP-1 macrophages and (C) "alternative" THP-1 
macrophages.   Red: unstained.   Blue: IL-6R.   Orange - isotype. 
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Figure 87 - Intracellular staining for phosphorylated STAT3 in (A) THP-1 
monocytes, (B) "original" THP-1 macrophages and (C) "alternative" THP-1 
macrophages.   Green: unstained.   Orange: unstimulated.   Blue: IL-6 
10ng/ml.   Red:  IL-6 10ng/ml plus tocilzumab 10µg/ml. 
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Figure 88 - Cell surface staining for membrane-bound IL-6R in (A) human 
primary CD14+ monocytes and (B) human monocyte-derived macrophages 
(HMDM).   Red: unstained.   Blue: IL-6R.   Orange: isotype. 
 
4.3.5 QPCR analysis of lipid-processing molecules in HMDM 
HMDM were generated using monocytes from a total of 13 healthy donors.   RNA 
was then harvested from HMDM following exposed to either complete RPMI or IL-
6 10ng/ml for 24 hours as detailed in the methods section.   SOCS3 expression 
was measured by SYBR qPCR as shown in Table 25.   Using SOCS3 upregulation as 
a marker for successful IL-6 signalling, the eight donors with the greatest fold 
increase in SOCS3 RNA were chosen for TLDA analysis.   The exception to this 
was donor #1, where there was a significant discrepancy in GAPDH expression 
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between unstimulated and stimulated cells, and which was therefore excluded.   
Unfortunately due to equipment error, the TLDA card failed to generate data for 
donors 9 or 10, and so full TLDA data was available for 6 donors. 
Donor Fold change  Donor Fold change 
1 4.00  8 2.85 * 
2 1.70  9 2.19 * 
3 3.16 *  10 1.51 * 
4 0.27  11 0.78 
5 1.44  12 11.25 * 
6 4.63 *  13 5.40 * 
7 5.20 *    
 
Table 25 - Fold change in SOCS3 RNA expression in HMDM from different 
donors following stimulation with 10ng/ml IL-6 compared to unstimulated 
cells  Samples chosen for TLDA analysis are identified by asterisk (*). 
 
TLDA analysis confirmed the increased expression of SOCS3 following IL-6 
stimulation in these donors, with mean fold change 4.23.   Of the cell surface 
molecules analysed at mRNA level, only the class A scavenger receptor MARCO 
(also known as macrophage receptor with collagenous structure) increased, 
demonstrating a mean fold change of 3.53 (Figure 89).   The biological 
significance of this finding was unclear, however, as several of the donors 
demonstrated CT values >30 both pre- and post stimulation with IL-6 (Table 26).   
This implies that even after a several-fold increase, the quantity of mRNA (and 
thus quantity of functional protein resulting from gene expression) could still be 
very low and unable to drive any significant change in cell phenotype.   
Additionally, the nature of qPCR is such that at very high CT values (and thus 
very low levels of RNA) the technique becomes inherently less reliable.      In 
contrast, expression of the scavenger receptor LOX-1 appeared to fall slightly 
(mean fold change 0.61 - Figure 89). 
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Figure 89 - Fold change in gene expression for lipid receptors in IL-6-exposed HMDM compared to unstimulated cells from 
same donor.  N of donors=6 
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Donor # MARCO CT  GAPDH CT  
 Unstimulated Stimulated Unstimulated Stimulated 
3 35.35 34.71 24.93 25.92 
6 32.02 30.77 22.25 22.34 
7 33.89 33.12 22.70 22.89 
8 34.62 34.03 22.50 22.51 
12 35.57 34.24 21.35 21.45 
13 35.30 31.89 23.11 22.93 
 
Table 26 - CT values for MARCO and GAPDH gene expression in HMDM 
cultured with 10ng/ml IL-6 (“Stimulated”) or RPMI alone (“unstimulated”) for 
24 hours. 
 
No clear change was seen in expression of cholesterol export proteins (Figure 90) 
or intracellular molecules known to have roles in lipid metabolism (Figure 91).   
Most intracellular proteins demonstrate one “outlier” which had a large fold 
increase in RNA production.   On interrogation of the data, these outlying values 
were all obtained from one donor (#3). 
 
 
 
Figure 90 - Fold change in gene expression for cholesterol export proteins in 
IL-6-exposed HMDM compared to unstimulated cells from same donor.  N of 
donors=6 
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Figure 91 - Fold change in gene expression for intracellular mediators of 
lipid metabolism in IL-6-exposed HMDM compared to unstimulated cells 
from same donor.  N of donors=6 
 
4.3.6 MARCO and LOX-1 protein quantification in HMDM 
I next sought to validate the findings of TLDA analysis by quantifying MARCO and 
LOX-1 expression at the protein level following macrophage stimulation with IL-
6.   HMDM were generated from 5 healthy donors, exposed to 10ng/ml IL-6 or 
RPMI for 24 hours, and stained for MARCO or LOX-1 by flow cytometry.   No 
change was found in mean fluorescence intensity of staining antibody for MARCO 
(Figure 92).   Mean fluorescence intensity of staining for LOX fell non-
significantly (Figure 92).   Figure 93 and Figure 94 show representative flow 
cytometry graphs for MARCO and LOX-1 respectively. 
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Figure 92 - Change in expression of LOX-1 and MARCO as determined by (a) 
mean fluorescence intensity of primary antibody minus that of isotype; (b) 
ratio of mean fluorescence intensity of primary antibody / isotype.   Analysis 
by Wilcoxon matched-pairs test. 
 
`235 
 
 
 
 
 
Figure 93 - Flow cytometric analysis of MARCO expression on HMDM from 
one donor. (A) FACS plot of selected cells. (B) MARCO present in detectable 
levels on cell surface. (C) MARCO expression increased on this donor 
following IL-6 stimulation. 
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Figure 94  - Flow cytometric analysis of LOX-1 expression on HMDM from 
one donor. (A) FACS plot of selected cells. (B) LOX-1 present in detectable 
levels on cell surface. (C) No change in LOX-1 expression on this donor 
following IL-6 stimulation. 
 
4.3.7 Gene expression in the KALIBRA cohort 
With the above data available, I was keen to try to replicate these findings in RA 
derived cells.   Monocytes present in RA blood have been shown to behave 
differently to those derived from healthy donors (Data from our centre currently 
being submitted for publication).   It is therefore possible that HMDM derived 
from RA monocytes could behave differently from non-RA cells in regards to lipid 
loading and gene expression, and indeed may show changes in phenotype 
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between active and treated RA.  It would therefore have been interesting to 
obtain CD14+ monocytes from RA patients before and after tocilizumab therapy, 
differentiate them into HMDM, and analyse their gene expression using my 
remaining TLDA plates.   Unfortunately, samples from the KALIBRA cohort had 
been stored in a manner not conducive to cell survival.   Instead, I attempted to 
observe genetic changes in the overall leukocyte population; this was the closest 
analogous technique I could conceive of to my previous in-vitro experiments. 
On thawing, it became apparent the samples were overtly haemolysed.   I 
initially attempted to obtain RNA from two samples using a miRNeasy kit as 
above.   However, during processing the samples developed large globules of 
precipitate which partly disappeared on vortexing.   Analysis by nanodrop 
showed extremely low concentrations of quantity RNA, compared to 
concentrations consistently >30ng/µl from HMDM.   Additionally, the quality of 
RNA was poor, precluding further analysis; this was particularly the case at the 
260/230 ratio, possibly reflecting contamination with EDTA as a result of the 
sampling process. 
 Sample 1 Sample 2 
260/280 1.20 1.17 
260/230 0.40 0.19 
Concentration (ng/µl) 4.7 3.1 
 
Table 27 - NanoDrop analysis of quantity and quality of RNA isolated from 
KALIBRA samples by miRNeasy kit. 
 
Subsequently, samples were analysed using PAXgene tubes.   This appeared to 
yield RNA at reasonable quality at around 40ng/µl.   However, when performing 
SYBC qPCR for GAPDH expression, CT values for five separate samples were 
uniformly greater than 34, and thus unlikely to yield reliable results.   At this 
point, I chose to abandon further analysis of the KALIBRA samples. 
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4.4 Discussion 
4.4.1 THP-1 macrophage biology 
Despite numerous attempts with different differentiation and culture conditions, 
I was unable to demonstrate any effect of IL-6 on the behaviour of THP-1 
macrophages.   This conflicts with previous literature, where other groups have 
claimed that IL-6 can potentiate TNF-α production (288), reduce uptake of 
acetylated LDL (290), increase uptake of oxLDL (278), and stimulate cholesterol 
export (279).   One manuscript showed that the chemokine CCR-1 was capable of 
inducing pSTAT3 on THP-1 macrophages, an effect ameliorated by anti-IL-6 
antibody (291), thus providing indirect evidence of IL-6R ligation leading to 
STAT3 phosphorylation in these cells.   This conclusion was confirmed very 
recently (292) by direct observation of IL-6 inducible pSTAT3 by Western blot in 
both THP-1 monocytes and macrophages, albeit using different differentiation 
techniques and a higher concentration of IL-6 (100ng/ml).   In sharp contrast to 
these findings, I did not find the IL-6 receptor present on the membrane of 
differentiated THP-1 macrophages.   This would explain why, in my experiments, 
exogenous IL-6 had no effect on STAT3 phosphorylation, TNF-α production or 
foam cell formation.   A possible explanation may lie in the wide variety of 
protocols for the culture and differentiation of these cells which have evolved 
over the last two decades, though a lack of experimental reproducibility would 
be especially disappointing given that a cell line (rather than randomly selected 
human donors) is being used.   In hindsight, I may have been able to 
demonstrate effects by the addition of exogenous soluble IL6-R to the cell 
culture, thus permitting STAT3 phosphorylation via trans-signalling.   However, 
this would not resolve the above conflicts with previous literature.    
It must be recognised that the THP-1 cell line acts as a macrophage model, not a 
replacement, for HMDM.   These cells lack the variation in response inherent in 
using cells from different human donors; a THP-1 experiment thus provides only 
a very narrow window on what in reality would be a wide spectrum of biological 
responses.   THP-1 cells, being derived from a leukaemia cell origin, also appear 
to be very metabolically active, as seen by their high levels of oil red O staining 
even when differentiated with low levels of PMA and in the absence of 
exogenous cytokine or oxLDL; this again contrasts with the much more subtle 
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staining of HMDM, and makes me more suspicious of their applicability to in vivo 
human biology.   Because of these considerations, if I were to obtain conflicting 
data from THP-1 macrophages and HMDM, I would feel the latter are most likely 
to represent human biology.  
4.4.2 HMDM and foam cell formation 
Subsequent in vitro experiments using primary cells generated important 
positive results regarding the role of IL-6 in human macrophage behaviour.   I 
demonstrated that the IL-6 receptor is present on human CD14+ monocytes and 
HMDM, and that IL-6 signalling can be detected in these cells by staining for 
pSTAT3 and by observing inhibition of LPS-induced TNF-α production (as 
documented in existing literature (289, 293)).   These foundation findings are 
reassuring, and make me more confident that subsequent results with these cells 
are robust.   Despite this, IL-6 did not demonstrate an ability to increase oxLDL 
uptake by HMDM, as measured by two separate research methods.   This 
conflicts with both my original hypothesis and the findings of other researchers 
as detailed above.   Previous unpublished work in our lab by another doctoral 
student also showed no increase in oil red O staining in HMDM exposed to IL-6; 
however, this researcher did find a significant reduction in lipid uptake following 
addition of GM-CSF, which I again failed to replicate.   I believe my results to be 
reliable as they were achieved after demonstrating successful IL-6 signalling and 
persisted despite a variety of culture conditions, but this clearly prompts 
speculation as to why my results clash with those of others.   Like the THP-1 
experiments, previous groups have used different techniques for HMDM 
differentiation that may affect final HMDM phenotype.   Liao (290) seeded the 
entire buffy coat onto polystyrene culture dishes, retained those cells adherent 
after 1 hour of culture, and differentiated them with RPMI supplemented with 
10% pooled human serum.   Frisdal (279) obtained PBMCs through an unclear 
method and differentiated them with M-CSF for 10 days.   Hashizume (278), 
whose paper was one of the first I read on this topic and which encouraged me 
to generate the main hypothesis of this chapter, only studied THP-1 
macrophages.   The protocol I used for HMDM generation is one that is used 
routinely in our lab for a variety of experiments evaluating the activation and 
behaviour of macrophages under inflammatory stimuli, usually in the context of 
RA.  In these parallel experiments they behave in a consistent manner albeit 
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recognising that individual donors offer variable magnitude and occasional 
qualitative responses. 
4.4.3 The limits of oil red O 
Another simple (but powerful) explanation for conflicting results may lie in the 
subjectivity of oil red O staining.   I found that the images generated by staining 
were highly dependent on factors such as: the intensity of light used on the 
microscope; the number of seconds the stain was applied for; the intensity of 
cell washing; and even the area of the well photographed.   Most importantly, 
small images suitable for a thesis or publication only show a tiny fraction of all 
the cells in a well.   In an “unblinded” experiment it would be very easy for the 
researcher to choose to photograph cells from a well which had taken up a little 
more or less stain. Some authors claim to have “measured” or “quantified” oil 
red O staining, but do not give detail as to how this was performed.   I therefore 
suggest that results of oil red O experiments should be interpreted cautiously.   
This is also the reason I was keen to replicate my findings using an alternative, 
quantitative technique, namely using fluorescently-labelled oxLDL. 
4.4.4 Scavenger receptors 
No consistent, significant changes were observed in expression of lipoprotein 
receptors, scavenger receptors or cholesterol export proteins in HMDM after IL-6 
exposure – again, in contrast to earlier studies.   The increase in production of 
MARCO following IL-6 stimulation found at the mRNA level is unlikely to be a 
relevant finding: it was not confirmed at the protein level by flow cytometry in 
most donors; it was detected at very high CT values, where the reliability of 
qPCR diminishes; and in any case it was clearly insufficient to exert phenotypic 
change as determined by foam cell formation.    
The disconnect between changes in gene expression at the mRNA and protein 
levels may also be because donors chosen for TAQMAN analysis were those who 
had demonstrated the greatest increases in SOCS3 expression after IL-6 
stimulation, and thus had more profound IL-6 signalling.   However, no such 
selection was performed for donors undergoing flow cytometry.   This leads on 
to another potential criticism of my experimental setup.   SOCS3 can be 
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regarded as an anti-IL-6 protein, as it binds to cytokine receptors or Janus 
kinases and acts as a regulator in a negative feedback loop to inhibit the 
intracellular effects of IL-6 signalling.  One could argue then that the cells with 
greater SOCS3 expression were in fact those who would be least likely to show 
phenotypic changes typical of an inflammatory state, as these cells were those 
where continuing IL-6 signalling was most successfully inhibited.   If I had 
analysed cells from donors with no elevation in SOCS3 mRNA, would more 
relevant changes in expression of other genes have been observed?  
Nevertheless, SOCS3 is well recognised as a downstream marker of IL-6R ligation.   
Perhaps a more effective approach would have been for me to accompany all 
the above phenotypic experiments with concomitant pSTAT3 quantification by 
flow cytometry on cells from every donor, only continuing further 
experimentation on donors with demonstrable increases in pSTAT3 after IL-6 
exposure.   Whilst planning my experiments originally I thought this would be 
unnecessary and labour-intensive; however, in retrospect, and with appropriate 
experiment planning, it may have been both feasible and worthwhile.   If I were 
to revisit these experiments, I would also attempt alternative culture conditions 
including higher concentrations of IL-6 (20ng/ml as in Laio, 50ng/ml as in Frisdal 
et al, or 100ng/ml as in Kiedar et al) and explore the effects of supplementation 
with IL-6R to encourage trans-signalling.   Given the relatively high CT values 
seen in some of my results, qPCR experiments may also benefit from having 
increased numbers of cells, and so more available mRNA, for each condition. 
4.4.5 Extrapolation and replication in RA patients 
Frustratingly, no data could be gleaned from stored samples from the KALIBRA 
cohort, as such an experiment had not been planned at KALIBRA’s inception and 
so samples were not stored in such a way as to preserve viable leukocytes.   As 
my in vitro work was an attempt to mimic the behaviour of macrophages in the 
reticuloendothelial system, or arterial wall, reproducing my experimental 
methods in vivo is challenging.   One could assess gene expression in circulating 
CD14+ monocytes before and after tocilizumab therapy, though it would seem 
that tissue macrophages are more likely to take up oxLDL than undifferentiated 
monocytes.   It is theoretically possible that RA monocytes post-tocilizumab may 
be sufficiently altered in vivo as to persistently display altered phenotype even 
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after differentiation into macrophages, though I have no reason to believe this is 
the case.   Then again, in the RA patient, IL-6 would be present before, during 
and after differentiation of monocytes; this was one factor I did not control for 
in vitro, as I added IL-6 only after cells had fully matured into macrophages. 
In summary, in contrast to the findings of previous researchers, I found that 
culture with IL-6 has no effect on foam cell formation or expression of scavenger 
receptors in either THP-1 macrophages or HMDM.   Based on these findings, at 
least in my experimental systems I cannot support the notion that tocilizumab  
alters LDL catabolism as a result of reduced IL-6 signalling in macrophages in the 
atheromatous plaque or the reticuloendothelial system.  I recognise however the 
limitations in the analysis I have performed in vitro and in future experiments 
would wish to re-examine this hypothesis with refined methodologies. 
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5 Final Discussion and future study 
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5.1 Summary of conclusions 
Herein I draw together some final conclusions based on my observations 
described thus far. 
Patients with severe active RA display hypercatabolism of LDL, which can be 
reduced to a value approximating normal values following tocilizumab 
treatment.   This reduction in LDL fractional catabolic rate is largely responsible 
for the increase in LDL-cholesterol seen following tocilizumab.    
Changes in LDL catabolic rate, and LDL-cholesterol, associate tightly with 
changes in acute phase response, but not CDAI.   This raises the possibility that 
hepatic IL-6 signalling, rather than the burden of synovitis, is the prime driver of 
reduced LDL in RA.  These may be related, but there are complexities to the 
relationship that bear further observation, and that challenge overly simplistic 
interpretations of current inflammation – lipid level – clinical response 
paradigms. 
In the MEASURE study, changes in NMR lipid profile previously described after 12 
weeks of tocilizumab therapy – namely, increased large LDL particles, unchanged 
small LDL particles and increased small HDL particles – are maintained at 52 
weeks, and have been replicated in the placebo group of the study after they 
switched to open-label tocilizumab.   These changes are driven by inflammation 
(as measured by CRP and ESR). 
The “normalisation” of LDL catabolism and the pattern of lipoprotein changes 
observed in these studies suggest that IL-6 blockade may be cardioprotective in 
patients with RA despite elevations in serum LDL-c. 
The novel NMR-based biomarker GlycA is highly reliant on IL-6 signalling and, 
commensurate with this, behaves in a manner similar to CRP.   GlycA was unable 
to predict clinical response in those exposed to tocilizumab, and provided little 
extra information on clinical response over and above decisions built on the use 
of CRP or ESR. 
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Elevations in serum LDL-c do not appear to be due to abrogation of IL-6 
signalling on macrophages and reduction in subsequent lipid uptake and foam 
cell formation.   However, the absence of IL-6-related effects on foam cell 
formation or scavenger receptor expression on macrophages stand in contrast to 
previous studies, and require further attempts at replication.    
5.2 Application to clinical practice 
One of the driving factors behind investigating the role of IL-6 blockade in RA 
dyslipidaemia was the possibility that this treatment could increase the CVD risk 
of an already higher-risk population by increasing LDL-c levels. This has led to 
reluctance on the part of some clinicians to prescribe tocilizumab, especially in 
those with a history of hyperlipidaemia or pre-existing cardiovascular disease.   
The work in this thesis has generated several strands of evidence to ameliorate 
some of these concerns, particularly the following observations following IL-6 
blockade, namely: elevations of large, rather than small, LDL particles on NMR; 
reduced levels of the proatherogenic Lp(a); normalisation of LDL fractional 
catabolic rate; reduction, not elevation, in the production rate of LDL (though 
this is not reflected in serum cholesterol levels as it is overcome by the reduced 
catabolic rate that leads to a net increase in LDL-c); stability of the total 
cholesterol / HDL-c ratio; increased levels of HDL-c and small HDL particles – 
though the significance of these changes in predicting CVD risk is not as certain 
as once thought, and a matter of considerable debate. 
These findings can be added to existing evidence of IL-6 contributing to CVD risk 
from Mendelian randomisation based approaches, and epidemiological data 
showing high-sensitivity CRP as a predictor of cardiovascular disease in the non-
RA population.   Taken together, I propose that these results should support 
clinicians to be more accepting of use of IL-6 blockade as a therapeutic tool in 
RA patients who are at high risk of cardiovascular disease.   Additionally, if we 
as clinicians are able to reassure our patients that our medications are safe (or 
even reduce CVD risk) this may well increase patients’ compliance with their 
therapy and thus improve clinical outcomes.   Nevertheless, this is a conclusion 
which can be implied only indirectly from these mechanistic studies.   Trials 
using hard cardiovascular clinical outcomes are required, and such studies are 
relatively lacking at present but are ongoing.  Until their endpoints are achieved 
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(or not as the case may be), our mechanism based approaches provide 
temporary relief and information to drive prescribing.    
The profound changes in lipid metabolism outlined here should also act to 
remind clinicians of the increased CVD risk that RA patients carry, and prompt us 
to conduct CVD risk assessment before and after treatment.   In addition to tight 
disease control, control of conventional risk factors remains critical.   For 
example, both RCTs and cohort studies have demonstrated that RA patients 
derive similar reductions in serum LDL-c to non-RA subjects from commencing 
statin therapy (294, 295).   In a separate population-based longitudinal study, 
cessation of statin therapy in RA patients was associated with a 60% increase in 
cardiovascular death, also in a manner similar to that observed in the non-RA 
population (296).    
On a personal note, I believe that the clinical significance of the questions which 
prompted these studies, and the results gained from them, should also prompt 
clinicians to encourage enrolment of our patients into clinical trials or biologics 
registries as a way of improving the care we provide.   My experience of KALIBRA 
was that, at the end of the study, the feedback I received from participants 
about their experience was almost universally positive.   This was despite a fairly 
arduous protocol which demanded significant amounts of time and effort from 
participants.   Common themes of feedback included being able to “give 
something back” to the health service that has assisted them so far; the 
perception that they were receiving closer attention and more personalised and 
precise care as study participants (helped in part, no doubt, by being provided 
with the business card and mobile phone number of a rheumatology registrar); a 
sense of “getting some control back” over their disease, and taking an positive, 
pro-active role in their own treatment; and the knowledge that their effort 
would improve treatment for future patients with RA – which generally still 
included themselves, given the chronic nature of the disease . 
5.3 Avenues for future study 
Whilst the results in this thesis have progressed our understanding of the lipid 
paradox in RA, much of this complex area of biology remains unclear.   I suggest 
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there are a number of ways in which this research could be successfully taken 
forward in the future. 
NMR analysis, as performed in MEASURE, offers an opportunity for detailed 
analysis of lipid profiles.   NMR data, with some clinical data, is currently 
available for the OPTION study, a large phase III RCT of 623 RA patients 
randomised to tocilizumab 8mg/kg, tocilizumab 4mg/kg, or placebo for 24 
weeks.   This would offer the chance to replicate the findings of MEASURE in a 
larger cohort.   Similar analysis may also be available on other RA cohorts, 
including TaSER.   TaSER provides a change to compare and contrast lipid 
profiles with the tocilizumab cohorts, as its patients had lower average disease 
activity, much shorter duration of disease, were almost exclusively treatment 
naive at enrolment, and were treated largely with conventional DMARDS.   The 
nature of the “treat-to-target” strategy in TaSER also differentiates this from 
the less aggressive treatment protocols of OPTION and MEASURE, and reflects 
modern best practice in early RA.   NMR would therefore be useful both from a 
mechanistic perspective (helping us untangle which lipid changes are reflective 
of “disease control” generally rather than IL-6 blockade specifically) but also in 
terms of informing clinicians on the effects of the current gold-standard 
treatment for early RA.   Lipid changes in TaSER could also be examined for their 
relationships with the detailed clinical assessments available for all patients at 
each timepoint.   As TaSER contains ultrasound and radiographic changes as 
endpoints, we can also evaluate GlycA’s performance in predicting disease 
progression and radiological response, and compare its utility as a biomarker 
with that of CRP and ESR. 
As alluded to above, assessment of cardiovascular outcomes in patients receiving 
tocilizumab therapy remains a priority.   In Glasgow we have increasing numbers 
of patients using tocilizumab but at present no way of accessing data from them 
on a city-wide basis.   In any case, it is unlikely that we would be able to have 
enough patients on the drug to generate a cohort large enough to successfully 
examine CVD event rates, though using surrogates such as CIMT or presence of 
plaque or coronary artery calcification may be easier.   Even here, however, 
reliable outcomes are far from guaranteed; assessment of arterial stiffness by 
quantification of pulse wave velocity was a secondary outcome of MEASURE, but 
technical difficulties precluded a successful analysis.[MCINNES2013]   Two, 
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perhaps more profitable, avenues are currently available.   The first is the 
British Society for Rheumatology Biologic Registers (BSRBR), a series of 
prospective cohorts to which patients commencing biologic drugs are recruited 
from across the UK.   The RA register has been interrogated previously for 
cardiovascular outcomes following anti-TNF therapy (as discussed in chapter 1) 
and may provide a fertile source of investigation for patients receiving 
tocilizumab.   The second involves accessing national health databases for 
information on RA patients with cardiovascular outcomes.   The service for 
accessing secondary care patient data in Scotland is provided by the Farr 
Institute Scotland.   This allows access to anonymised clinical data through a 
secure system known as a “Safe Haven”, one of which is hosted by NHS GGC.   
Hosted data includes the Scottish Morbidity Record, a combination of national 
datasets derived from inpatient and outpatient hospital consultations since 1997.   
A similar system for general practice, known as SPIRE (Scottish Primary Care 
Information Resource) is currently under development.   Either of these routes 
may conceivably be used to assess CVD events associated with tocilizumab, with 
or without accessory data on lipid levels. 
Beyond KALIBRA, only one other published study has evaluated LDL kinetics in RA 
patients (273).   Performing a similar study on alternative therapies for RA (e.g. 
anti-TNF, or conventional DMARDS) may shed light on the different mechanisms 
underlying lipid changes in specific therapies.   However, as should be apparent 
from chapter 3 of this thesis, kinetic studies are difficult to perform, and a fresh 
kinetic study on other RA therapeutics seems less appealing because (a) LDL 
changes are much less pronounced, and so statistically significant data will be 
harder to obtain, and (b) both methotrexate and anti-TNF agents have proven 
CVD benefits, and so less clinical concern over potential elevations in LDL-c.   I 
do, however, have access to the remainder of the kinetic data from KALIBRA 
which has not been looked at in detail, specifically the kinetics of VLDL and IDL, 
and some data on the behaviour of HDL.   Analysis of this data may shed further 
light on the mechanisms underscoring altered LDL metabolism.   In addition, the 
presence of the only pre-menopausal female participant in KALIBRA as an 
apparent outlier in regards to the relationship between lipid changes and disease 
control raises the intriguing possibility that this subset of patients may exhibit 
significantly different lipidaemic responses to IL-6 inhibition.   This in turn may 
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have implications for cardiovascular risk, and indeed for prescribing decisions in 
these patients.   As we enter the era of “personalised medicine”, evaluating this 
phenomenon could be critical for ensuring the most appropriate treatment for 
each patient. 
As discussed extensively in chapter 4, I am uncertain of how robust my findings 
regarding macrophage lipid uptake are.   Further attempts at replication, 
perhaps using alternative methods of macrophage generation, would seem 
reasonable.   One technique that I was unable to properly perform was the 
examination of gene expression in monocytes or HMDM isolated from RA patients 
pre- and post-tocilizumab.   Given the possibility of the liver being a target 
organ in IL-6 induced dyslipidaemia, similar work on gene expression could also 
be performed on hepatocytes (for example the hep-G2 cell line) as has been 
done in one published manuscript previously.   The above techniques require cell 
culture with an accompanying number of variables; a less precise, but more 
straightforward, alternative would be to perform a whole-blood transcriptomic 
analysis using a technique such as the PAXGene tube.   This technique causes 
leukocyte lysis and RNA stabilisation at the point of phlebotomy, potentially 
allowing for more robust transcriptome data at the cost of reduced information 
on the specific cell lineages being affected.   PAXGene samples may be used in a 
“hypothesis-generating” manner through microarray analysis (e.g. Affimetrix), 
but also permit hypothesis testing by analysing pre-chosen genes of interest as in 
my experiments on TLDA plates. 
 Undertaking this PhD has been an enormous challenge, but a very rewarding 
one, and I consider it a privilege to have been a clinical research fellow in a time 
of such exciting discovery in our discipline.   I sincerely hope that my findings 
are not just of academic interest to researchers in the field, but become 
relevant to both patients and physicians as together we strive to improve all 
aspects of our patient care.   I firmly believe that the experience I have gained 
over these years in trial design, data analysis, and translational research are 
valuable ones which will shape me as I go forward in my career as a 
rheumatologist, and that my collaborations with other clinicians and scientists 
will equip me to perform such research more effectively in the future. 
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Appendix A – Abbreviations 
ACR  American College of Rheumatology 
ACPA  Anti-Citrullinated Protein Antibody 
AUC  Area under the curve  
CCP  Cyclic citrullinated peptide 
CDAI  Clinical Disease Activity Index 
CETP  Cholesterol Ester Transfer Protein 
CRP  C-reactive protein 
DAS28  28 joint Disease Activity Score 
DMARD Disease Modifying Anti-Rheumatic Drug 
ESR  Erythrocyte sedimentation rate 
EULAR  European League Against Rheumatism 
FBC  Full blood count 
GM-CSF Granulocyte-macrophage colony stimulating factor 
HCQ  Hydroxychloroquine 
HDL  High-density lipoprotein 
HDL-c  High-density lipoprotein cholesterol 
HMDM  Human monocyte-derived macrophages 
HPL  Hepatic lipase 
IL-6  Interleukin 6 
LCAT  Lecithin-cholesterol acetyltransferase 
LDL  Low-density lipoprotein 
LDL-c  Low-density lipoprotein cholesterol 
LDL-CE Low-density lipoprotein cholesterol ester 
LFT  Liver function tests 
LPL  Lipoprotein lipase 
MTX  Methotrexate 
NHSGGC NHS Greater Glasgow and Clyde 
OA  Osteoarthritis 
ORO  Oil-red O stain 
oxLDL  Oxidised low-density lipoprotein 
PBMC  Peripheral blood mononuclear cells 
PCSK9  Proprotein convertase subtilisin/kexin type 9 
RA  Rheumatoid arthritis 
RF  Rheumatoid factor 
ROC  Receiver-Operating Characteristics 
RPMI  Roswell Park Memorial Institute medium 
SSZ  Sulfasalazine 
SDAI  Simplified Disease Activity Index  
SNP  Single nucleotide polymorphism 
TNF-α  Tumour Necrosis Factor-α 
U&E  Urea and electrolytes 
ULN  Upper limit of normal 
VLDL  Very low-density lipoprotein
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Appendix C – KALIBRA recruitment poster 
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Appendix D – KALIBRA patient information leaflet 
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Appendix E – KALIBRA patient consent form 
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Appendix F – Kinetic overview of apoB-
containing lipoproteins 
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Appendix G – LDL kinetic graph of subject 
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Appendix H – Genes studied in TLDA analysis 
Gene Symbol Protein Symbol Protein name 
Lipoprotein and scavenger receptors 
LDLR LDLr Low-density lipoprotein receptor 
VLDLR VLDLr Very low-density lipoprotein receptor 
LRP1 LRP-1 LDL-receptor related protein 1 
LRP2 LRP-2 LDL-receptor related protein 2 
LRPAP1 LRPAP LRP-associated protein 
SCARA1 
 
SR-A1 (MSR1) 
 
Scavenger receptor A1  
(Macrophage scavenger receptor) 
SCARA2 
 
MARCO 
 
Macrophage receptor with collagenous 
structure 
SCARA3 SR-A3 Scavenger receptor A3 
COLEC12 SR-A4 Scavenger receptor A4 
SCARA5 SR-A5 Scavenger receptor A5 
SCARB1 SR-B1 Scavenger receptor B1 
SCARB2 SR-B2 Scavenger receptor B2 
SCARB3 CD36 Cluster of differentiation 36 
OLR1 LOX-1 Lectin-type oxidised LDL receptor 1 
CD68 CD68 Cluster of differentiation 68 
Cholesterol efflux proteins 
ABCA1 ABCA1 ATP-binding cassette A1 
ABCA2 ABCA2 ATP-binding cassette A2 
ABCA7 ABCA7 ATP-binding cassette A7 
ABCG1 ABCG1 ATP-binding cassette G1 
Intracellular proteins 
NR1H3 LXRα Liver X receptor α 
NR1H2 LXRβ Liver X receptor β 
FOXO1 FoxO1 Forkhead box O1 
FOXO3a FoxO3a Forkhead box 03a 
FOXO4 FoxO4 Forkhead box 04 
PPARA PPARα Peroxisome proliferation activating receptor α 
PPARD PPARδ Peroxisome proliferation activating receptor δ 
PPARG PPARγ Peroxisome proliferation activating receptor β 
SREBF1 SREBP1 Sterol regulatory element binding protein 1 
SREBF2 SREBP2 Sterol regulatory element binding protein 2 
SCAP SCAP SREBP cleavage activation protein 
HMGCR HMGCOaR HMG-coenzyme A reductase 
SOCS3 SOCS Suppressor of cytokine signalling 3 
GAPDH GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
 
